


WEST Search History

DATE: Monday, August 30, 2004

Hide?	Set Name	Query	Hit Count
<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ</i>			
<input type="checkbox"/>	L15	L14 AND D-amino acid	132
<input type="checkbox"/>	L14	(amyloid-beta OR beta-amyloid OR abeta)	2989
<input type="checkbox"/>	L13	L12 AND D-amino acid	25
<input type="checkbox"/>	L12	L11 AND amyloid AND beta	207
<input type="checkbox"/>	L11	514/2.CCLS.	6232
<input type="checkbox"/>	L10	L9 AND D-amino acid	10
<input type="checkbox"/>	L9	L8 AND amyloid AND beta	33
<input type="checkbox"/>	L8	L6 AND beta-amyloid	33
<input type="checkbox"/>	L7	L6 AND abeta	5
<input type="checkbox"/>	L6	424/184.1,185.1,193.1.CCLS.	3828
<input type="checkbox"/>	L5	Schenk.IN.	2887
<input type="checkbox"/>	L4	Schenk-D.IN.	7
<input type="checkbox"/>	L3	Schenk-Dale.IN.	3
<input type="checkbox"/>	L2	Schenk-D-B.IN.	17
<input type="checkbox"/>	L1	(Schenk-Dale-B.IN.)	32

END OF SEARCH HISTORY



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books
 Search PubMed for beta-amyloid AND D-amino acid Go Clear
 Limits Preview/Index History Clipboard Details

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Display Summary Show: 500 Sort Send to Text
 Items 1-4 of 4 One page.

1: Brenneman DE, Spong CY, Hauser JM, Abebe D, Pinhasov A, Golian T, Gozes I. Related Articles, Links

Protective peptides that are orally active and mechanistically nonchiral.
 J Pharmacol Exp Ther. 2004 Jun;309(3):1190-7. Epub 2004 Mar 08.
 PMID: 15007105 [PubMed - indexed for MEDLINE]

2: Formaggio F, Bettio A, Moretto V, Crisma M, Toniolo C, Broxterman QR. Related Articles, Links

Disruption of the beta-sheet structure of a protected pentapeptide, related to the beta-amyloid sequence 17-21, induced by a single, helicogenic C(alpha)-tetrasubstituted alpha-amino acid.
 J Pept Sci. 2003 Jul;9(7):461-6.
 PMID: 12916643 [PubMed - indexed for MEDLINE]

3: Chalifour RJ, McLaughlin RW, Lavoie L, Morissette C, Tremblay N, Boule M, Sarazin P, Stea D, Lacombe D, Tremblay P, Gervais F. Related Articles, Links

Stereoselective interactions of peptide inhibitors with the beta-amyloid peptide.
 J Biol Chem. 2003 Sep 12;278(37):34874-81. Epub 2003 Jul 02.
 PMID: 12840031 [PubMed - indexed for MEDLINE]

4: Blanchard BJ, Konopka G, Russell M, Ingram VM. Related Articles, Links

Mechanism and prevention of neurotoxicity caused by beta-amyloid peptides: relation to Alzheimer's disease.
 Brain Res. 1997 Nov 21;776(1-2):40-50.
 PMID: 9439794 [PubMed - indexed for MEDLINE]


[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Jul 27 2004 06:47:37



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books
 Search **PubMed** for **Alzheimers AND D-amino acid** **Go** **Clear**
 Limits Preview/Index History Clipboard Details

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Display **Summary** Show: **500** **Sort** **Send to** **Text**
 Items 1-5 of 5 One page.

☐ **1:** Wiesehan K, Buder K, Linke RP, Patt S, Stoldt M, Unger E, Schmitt B, Bucci E, Willbold D. Related Articles, Links

Selection of D-amino-acid peptides that bind to Alzheimer's disease amyloid peptide abeta1-42 by mirror image phage display.
 Chembiochem. 2003 Aug 4;4(8):748-53.
 PMID: 12898626 [PubMed - indexed for MEDLINE]

☐ **2:** Blanchard BJ, Konopka G, Russell M, Ingram VM. Related Articles, Links

Mechanism and prevention of neurotoxicity caused by beta-amyloid peptides: relation to Alzheimer's disease.
 Brain Res. 1997 Nov 21;776(1-2):40-50.
 PMID: 9439794 [PubMed - indexed for MEDLINE]

☐ **3:** Soto C, Kindy MS, Baumann M, Frangione B. Related Articles, Links

Inhibition of Alzheimer's amyloidosis by peptides that prevent beta-sheet conformation.
 Biochem Biophys Res Commun. 1996 Sep 24;226(3):672-80.
 PMID: 8831674 [PubMed - indexed for MEDLINE]

☐ **4:** Fisher GH, Petrucelli L, Gardner C, Emory C, Frey WH 2nd, Amaducci L, Sorbi S, Sorrentino G, Borghi M, D'Aniello A. Related Articles, Links

Free D-amino acids in human cerebrospinal fluid of Alzheimer disease, multiple sclerosis, and healthy control subjects.
 Mol Chem Neuropathol. 1994 Oct-Dec;23(2-3):115-24.
 PMID: 7702702 [PubMed - indexed for MEDLINE]

☐ **5:** Fisher GH, D'Aniello A, Vetere A, Padula L, Cusano GP, Man EH. Related Articles, Links

Free D-aspartate and D-alanine in normal and Alzheimer brain.
 Brain Res Bull. 1991 Jun;26(6):983-5.
 PMID: 1933416 [PubMed - indexed for MEDLINE]

Display **Summary** Show: **500** **Sort** **Send to** **Text**


[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Jul 27 2004 06:47:37



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books
Search **PubMed** for **amyloid precursor protein AND D-amino acid** **Go** **Clear**
Limits Preview/Index History Clipboard Details

About Entrez

No items found.

Text Version

Entrez PubMed

Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services

Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources

Order Documents
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Jul 27 2004 06:47:37

Welcome to STN International! Enter x:x
***** Welcome to STN International *****
***** STN Columbus *****

FILE 'HOME' ENTERED AT 12:10:17 ON 30 AUG 2004

=> file BIOSCIENCE

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

FILE 'ADISCTI' ENTERED AT 12:10:27 ON 30 AUG 2004

COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 12:10:27 ON 30 AUG 2004

COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 12:10:27 ON 30 AUG 2004

COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'AGRICOLA' ENTERED AT 12:10:27 ON 30 AUG 2004

FILE 'AQUALINE' ENTERED AT 12:10:27 ON 30 AUG 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'ANABSTR' ENTERED AT 12:10:27 ON 30 AUG 2004

COPYRIGHT (c) 2004 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'ANTE' ENTERED AT 12:10:27 ON 30 AUG 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'AQUASCI' ENTERED AT 12:10:27 ON 30 AUG 2004

COPYRIGHT 2004 FAO (On behalf of the ASFA Advisory Board). All rights reserved.

FILE 'BIOBUSINESS' ENTERED AT 12:10:27 ON 30 AUG 2004

Copyright (c) 1998 The Thomson Corporation.

FILE 'BIOCOMMERCE' ENTERED AT 12:10:27 ON 30 AUG 2004

COPYRIGHT (C) 2004 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All r:

FILE 'BIOENG' ENTERED AT 12:10:27 ON 30 AUG 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'BIOSIS' ENTERED AT 12:10:27 ON 30 AUG 2004

Copyright (c) 2004 The Thomson Corporation.

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 12:10:27 ON 30 AUG 2004

COPYRIGHT (C) 2004 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION

FILE 'BIOTECHNO' ENTERED AT 12:10:27 ON 30 AUG 2004

COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CABA' ENTERED AT 12:10:27 ON 30 AUG 2004

COPYRIGHT (C) 2004 CAB INTERNATIONAL (CABI)

FILE 'CANCERLIT' ENTERED AT 12:10:27 ON 30 AUG 2004

FILE 'CAPLUS' ENTERED AT 12:10:27 ON 30 AUG 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEABA-VTB' ENTERED AT 12:10:27 ON 30 AUG 2004

COPYRIGHT (c) 2004 DECHEMA eV

FILE 'CEN' ENTERED AT 12:10:27 ON 30 AUG 2004

COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 12:10:27 ON 30 AUG 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'CONFSCI' ENTERED AT 12:10:27 ON 30 AUG 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'CROPU' ENTERED AT 12:10:27 ON 30 AUG 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DISSABS' ENTERED AT 12:10:27 ON 30 AUG 2004
COPYRIGHT (C) 2004 ProQuest Information and Learning Company; All Rights Reserved

FILE 'DDFB' ACCESS NOT AUTHORIZED

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 12:10:27 ON 30 AUG 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DRUGB' ENTERED AT 12:10:27 ON 30 AUG 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DRUGMONOG2' ENTERED AT 12:10:27 ON 30 AUG 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'IMSDRUGNEWS' ENTERED AT 12:10:27 ON 30 AUG 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 12:10:27 ON 30 AUG 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'IMSRESEARCH' ENTERED AT 12:10:27 ON 30 AUG 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'EMBAL' ENTERED AT 12:10:27 ON 30 AUG 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'EMBASE' ENTERED AT 12:10:27 ON 30 AUG 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 12:10:27 ON 30 AUG 2004
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'FEDRIP' ENTERED AT 12:10:27 ON 30 AUG 2004

FILE 'FOMAD' ENTERED AT 12:10:27 ON 30 AUG 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FOREGE' ENTERED AT 12:10:27 ON 30 AUG 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FROSTI' ENTERED AT 12:10:27 ON 30 AUG 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FSTA' ENTERED AT 12:10:27 ON 30 AUG 2004
COPYRIGHT (C) 2004 International Food Information Service

FILE 'GENBANK' ENTERED AT 12:10:27 ON 30 AUG 2004

FILE 'HEALSAFE' ENTERED AT 12:10:27 ON 30 AUG 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 12:10:27 ON 30 AUG 2004
COPYRIGHT (C) 2004 IFI CLAIMS(R) Patent Services (IFI)

FILE 'IMSPRODUCT' ENTERED AT 12:10:27 ON 30 AUG 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'JICST-EPLUS' ENTERED AT 12:10:27 ON 30 AUG 2004
COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'KOSMET' ENTERED AT 12:10:27 ON 30 AUG 2004
COPYRIGHT (C) 2004 International Federation of the Societies of Cosmetics Chemists

FILE 'LIFESCI' ENTERED AT 12:10:27 ON 30 AUG 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 12:10:27 ON 30 AUG 2004
COPYRIGHT (c) 2004 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'MEDLINE' ENTERED AT 12:10:27 ON 30 AUG 2004

FILE 'NIOSHTIC' ENTERED AT 12:10:27 ON 30 AUG 2004
COPYRIGHT (C) 2004 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NTIS' ENTERED AT 12:10:27 ON 30 AUG 2004
Compiled and distributed by the NTIS, U.S. Department of Commerce.
It contains copyrighted material.
All rights reserved. (2004)

FILE 'NUTRACEUT' ENTERED AT 12:10:27 ON 30 AUG 2004
Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'OCEAN' ENTERED AT 12:10:27 ON 30 AUG 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'PASCAL' ENTERED AT 12:10:27 ON 30 AUG 2004
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2004 INIST-CNRS. All rights reserved.

FILE 'PCTGEN' ENTERED AT 12:10:27 ON 30 AUG 2004
COPYRIGHT (C) 2004 WIPO

FILE 'PHAR' ENTERED AT 12:10:27 ON 30 AUG 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHARMAML' ENTERED AT 12:10:27 ON 30 AUG 2004
Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PHIC' ENTERED AT 12:10:27 ON 30 AUG 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHIN' ENTERED AT 12:10:27 ON 30 AUG 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PROMT' ENTERED AT 12:10:27 ON 30 AUG 2004
COPYRIGHT (C) 2004 Gale Group. All rights reserved.

FILE 'PROUSDDR' ENTERED AT 12:10:27 ON 30 AUG 2004
COPYRIGHT (C) 2004 Prous Science

FILE 'RDISCLOSURE' ENTERED AT 12:10:27 ON 30 AUG 2004
COPYRIGHT (C) 2004 Kenneth Mason Publications Ltd.

FILE 'SCISEARCH' ENTERED AT 12:10:27 ON 30 AUG 2004
Copyright (c) 2004 The Thomson Corporation.

FILE 'SYNTHLINE' ENTERED AT 12:10:27 ON 30 AUG 2004
COPYRIGHT (C) 2004 Prous Science

FILE 'TOXCENTER' ENTERED AT 12:10:27 ON 30 AUG 2004
COPYRIGHT (C) 2004 ACS

FILE 'USPATFULL' ENTERED AT 12:10:27 ON 30 AUG 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 12:10:27 ON 30 AUG 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'VETB' ENTERED AT 12:10:27 ON 30 AUG 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'VETU' ENTERED AT 12:10:27 ON 30 AUG 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WATER' ENTERED AT 12:10:27 ON 30 AUG 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'WPIDS' ENTERED AT 12:10:27 ON 30 AUG 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WPIFV' ENTERED AT 12:10:27 ON 30 AUG 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

=> S D-amino acid
15 FILES SEARCHED...
25 FILES SEARCHED...
41 FILES SEARCHED...
59 FILES SEARCHED...
67 FILES SEARCHED...

L1 35501 D-AMINO ACID

=> S Alzheimers OR beta-amyloid OR amyloid-beta OR amyloid precursor protein
13 FILES SEARCHED...
19 FILES SEARCHED...
25 FILES SEARCHED...
33 FILES SEARCHED...
47 FILES SEARCHED...
63 FILES SEARCHED...

L2 160285 ALZHEIMERS OR BETA-AMYLOID OR AMYLOID-BETA OR AMYLOID PRECURSOR
PROTEIN

=> S L1 AND L2
50 FILES SEARCHED...

L3 685 L1 AND L2

=> DUP REM L3

DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, BIOCOMMERCE, DGENE,
DRUGMONOG2, IMSRESEARCH, FEDRIP, FOREGE, GENBANK, IMSPRODUCT, KOSMET,
MEDICONF, NUTRACEUT, PCTGEN, PHAR, PHARMAML, PROUSDDR, RDISCLOSURE, SYNTHLINE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L3

L4 564 DUP REM L3 (121 DUPLICATES REMOVED)

=> S L4 AND beta-amyloid
20 FILES SEARCHED...
37 FILES SEARCHED...
61 FILES SEARCHED...

L5 367 L4 AND BETA-AMYLOID

=> D L5 1-367

L5 ANSWER 1 OF 367 ADISINSIGHT COPYRIGHT (C) 2004 Adis Data Information BV
on STN

ACCESSION NUMBER: 2004:204 ADISINSIGHT
SOURCE: Adis R&D Insight
DOCUMENT NO: 020334
CHANGE DATE: Jun 25, 2004
GENERIC NAME: Research programme: neuroprotective therapies - Allon
Therapeutics
SYNONYM: ADN-9; AL209; AL309; SAL; SALLRSIPA
MOLECULAR FORMULA: Unspecified
STRUCTURE:

STRUCTURE DIAGRAM IS NOT AVAILABLE

EPHMA ATC CODE: N7X All other CNS drugs
WHO ATC CODE: N07X Other Nervous System Drugs
HIGHEST DEV. PHASE: Preclinical

COMPANY INFORMATION

ORIGINATOR: Allon Therapeutics (United States)
PARENT: Allon Therapeutics

WORD COUNT: 596

L5 ANSWER 2 OF 367 ADISINSIGHT COPYRIGHT (C) 2004 Adis Data Information BV
on STN

ACCESSION NUMBER: 2001:589 ADISINSIGHT
SOURCE: Adis R&D Insight
DOCUMENT NO: 015723
CHANGE DATE: Jan 22, 2003
GENERIC NAME: Research programme: huntingtin decoy peptides -
Massachusetts Institute of Technology
SYNONYM: Huntingtin decoy peptides research programme -
Massachusetts Institute of Technology
MOLECULAR FORMULA: Unspecified
STRUCTURE:

EPHMRA ATC CODE: N7X All other CNS drugs
WHO ATC CODE: N07X Other Nervous System Drugs
HIGHEST DEV. PHASE: No Development Reported

COMPANY INFORMATION

ORIGINATOR: Nonindustrial source (United States)
PARENT: Nonindustrial source

WORD COUNT: 142

L5 ANSWER 3 OF 367 ADISINSIGHT COPYRIGHT (C) 2004 Adis Data Information BV
on STN

ACCESSION NUMBER: 2001:586 ADISINSIGHT

SOURCE: Adis R&D Insight

DOCUMENT NO: 015715

CHANGE DATE: Jun 24, 2003

GENERIC NAME: ***Research programme: beta-amyloid decoy peptides -***
*** Massachusetts Institute of Technology***

SYNONYM: ***Beta amyloid decoy peptides research programme -***
*** Massachusetts Institute of Technology***

MOLECULAR FORMULA: Unspecified

STRUCTURE:

STRUCTURE DIAGRAM IS NOT AVAILABLE

EPHMRA ATC CODE: N7D9 All other anti-Alzheimer products; N7X All other
CNS drugs

WHO ATC CODE: N06D-X Other anti-dementia drugs; N07X Other Nervous
System Drugs

HIGHEST DEV. PHASE: No Development Reported

COMPANY INFORMATION

ORIGINATOR: Massachusetts Institute of Technology (United States)

PARENT: Massachusetts Institute of Technology

OTHER: Amgen

WORD COUNT: 283

L5 ANSWER 4 OF 367 ADISINSIGHT COPYRIGHT (C) 2004 Adis Data Information BV
on STN

ACCESSION NUMBER: 2000:1811 ADISINSIGHT

SOURCE: Adis R&D Insight

DOCUMENT NO: 014948

CHANGE DATE: Jul 28, 2004

GENERIC NAME: AL 108

SYNONYM: ADNP-8; AL108; NAP; NAPVSIPO

CHEMICAL NAME: L-Asparaginy-L-alanyl-L-prolyl-L-valyl-L-seryl-L-
isoleucyl-L-prolyl-L-glutamine

MOLECULAR FORMULA: C36 H60 N10 O12

STRUCTURE:

STRUCTURE DIAGRAM IS NOT AVAILABLE

EPHMRA ATC CODE: N7D9 All other anti-Alzheimer products; N7X All other
CNS drugs

WHO ATC CODE: N06D-X Other anti-dementia drugs; N07X Other Nervous
System Drugs

HIGHEST DEV. PHASE: Preclinical

COMPANY INFORMATION

ORIGINATOR: Hadassah Medical Organization (Israel); Tel Aviv
University (Israel); Allon Therapeutics (United States);
National Institutes of Health (United States)

PARENT: Allon Therapeutics; Hebrew University of Jerusalem;
National Institutes of Health (USA); Tel Aviv University

WORD COUNT: 1048

L5 ANSWER 5 OF 367 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
STN

AN 2004:163974 BIOSIS

DN PREV200400167893

TI Modulators of ***beta*** - ***amyloid*** peptide aggregation
comprising ***D*** - ***amino*** ***acids***

AU Findeis, Mark A. [Inventor, Reprint Author]; Gefter, Malcolm L.
[Inventor]; Musso, Gary [Inventor]; Signer, Ethan R. [Inventor];

[Inventor]; Lee, Jung-Ja [Inventor]; Kelley, Michael [Inventor]; Komar-Panicucci, Sonja [Inventor]; Arico-Muendel, Christopher C. [Inventor]; Phillips, Kathryn [Inventor]; Hayward, Neil J. [Inventor]
 CS ASSIGNEE: Praecis Pharmaceuticals, Incorporated, Waltham, MA, USA
 PI US 6689752 February 10, 2004
 SO Official Gazette of the United States Patent and Trademark Office Patents, (Feb 10 2004) Vol. 1279, No. 2. <http://www.uspto.gov/web/menu/patdata.html>
 . e-file.
 ISSN: 0098-1133 (ISSN print).
 DT Patent
 LA English
 ED Entered STN: 24 Mar 2004
 Last Updated on STN: 24 Mar 2004

L5 ANSWER 6 OF 367 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
 AN 2003:490981 BIOSIS
 DN PREV200300493335
 TI Stereoselective interactions of peptide inhibitors with the ***beta***
 - ***amyloid*** peptide.
 AU Chalifour, Robert J.; McLaughlin, Richard W.; Lavoie, Louis; Morissette, Celine; Tremblay, Nadine; Boule, Marie; Sarazin, Philippe; Stea, Dino; Lacombe, Diane; Tremblay, Patrick; Gervais, Francine [Reprint Author]
 CS Neurochem Inc., 7220, Frederick-Banting, Suite 100, Saint-Laurent, PQ, H4S 2A1, Canada
 abstracts@neurochem.com
 SO Journal of Biological Chemistry, (September 12 2003) Vol. 278, No. 37, pp. 34874-34881. print.
 CODEN: JBCHA3. ISSN: 0021-9258.
 DT Article
 LA English
 ED Entered STN: 22 Oct 2003
 Last Updated on STN: 22 Oct 2003

L5 ANSWER 7 OF 367 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
 AN 2003:477543 BIOSIS
 DN PREV200300477543
 TI Disruption of the beta-sheet structure of a protected pentapeptide, related to the ***beta*** - ***amyloid*** sequence 17-21, induced by a single, helicogenic Calpha-tetrasubstituted alpha-amino acid.
 AU Formaggio, Fernando [Reprint Author]; Bettio, Andrea; Moretto, Vittorio; Crisma, Marco; Toniolo, Claudio; Broxterman, Quirinus B.
 CS Department of Organic Chemistry, University of Padova, Via Marzolo I, 35131, Padova, Italy
 fernando.formaggio@unipd.it
 SO Journal of Peptide Science, (July 2003) Vol. 9, No. 7, pp. 461-466. print.
 ISSN: 1075-2617 (ISSN print).
 DT Article
 LA English
 ED Entered STN: 15 Oct 2003
 Last Updated on STN: 15 Oct 2003

L5 ANSWER 8 OF 367 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
 AN 2003:436021 BIOSIS
 DN PREV200300436021
 TI Modulators of mu-amyloid peptide aggregation.
 AU Findeis, Mark A. [Inventor, Reprint Author]; Phillips, Kathryn [Inventor]; Olson, Gary L. [Inventor]; Self, Christopher [Inventor]
 CS Boston, MA, USA
 ASSIGNEE: Praecis Pharmaceuticals Inc.
 PI US 6610658 August 26, 2003
 SO Official Gazette of the United States Patent and Trademark Office Patents, (Aug 26 2003) Vol. 1273, No. 4. <http://www.uspto.gov/web/menu/patdata.html>
 . e-file.
 ISSN: 0098-1133 (ISSN print).
 DT Patent
 LA English
 ED Entered STN: 17 Sep 2003
 Last Updated on STN: 17 Sep 2003

L5 ANSWER 9 OF 367 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
 AN 2003:326954 BIOSIS

TI REGULATION OF SERINE RACEMASE AND D - SERINE PRODUCTION BY INFLAMMATORY
 MEDIATORS AND HORMONES.
 AU Wu, S. Z. [Reprint Author]; Bodles, A. M.; Porter, M. M.; Barger, S. W.
 [Reprint Author]
 CS Anatomy and neurobiology, Geriatrics, U. Arkansas Med.Sci, Little Rock,
 AR, USA
 SO Society for Neuroscience Abstract Viewer and Itinerary Planner, (2002)
 Vol. 2002, pp. Abstract No. 784.15. <http://sfn.scholarone.com.cd-rom>.
 Meeting Info.: 32nd Annual Meeting of the Society for Neuroscience.
 Orlando, Florida, USA. November 02-07, 2002. Society for Neuroscience.
 DT Conference; (Meeting)
 Conference; (Meeting Poster)
 Conference; Abstract; (Meeting Abstract)
 LA English
 ED Entered STN: 16 Jul 2003
 Last Updated on STN: 16 Jul 2003

L5 ANSWER 10 OF 367 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
 STN
 AN 2001:572898 BIOSIS
 DN PREV200100572898
 TI Modulators of ***beta*** - ***amyloid*** peptide aggregation
 comprising ***D*** - ***amino*** ***acids***
 AU Findeis, Mark A. [Inventor]; Gefter, Malcolm L. [Inventor]; Musso, Gary
 [Inventor]; Signer, Ethan R. [Inventor]; Wakefield, James [Inventor];
 Molineaux, Susan [Inventor]; Chin, Joseph [Inventor]; Lee, Jung-Ja
 [Inventor]; Kelley, Michael [Inventor]; Komar-Panicucci, Sonja [Inventor];
 Arico-Muendel, Christopher C. [Inventor]; Phillips, Kathryn [Inventor];
 Hayward, Neil J. [Inventor]
 CS ASSIGNEE: Praecis Pharmaceuticals, Inc., Waltham, MA, USA
 PI US 6303567 October 16, 2001
 SO Official Gazette of the United States Patent and Trademark Office Patents,
 (Oct. 16, 2001) Vol. 1251, No. 3. e-file.
 CODEN: OGUPE7. ISSN: 0098-1133.
 DT Patent
 LA English
 ED Entered STN: 12 Dec 2001
 Last Updated on STN: 25 Feb 2002

L5 ANSWER 11 OF 367 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
 STN
 AN 2001:479082 BIOSIS
 DN PREV200100479082
 TI Modulators of ***beta*** - ***amyloid*** peptide aggregation
 comprising ***D*** - ***amino*** ***acids***
 AU Findeis, Mark A. [Inventor]; Gefter, Malcolm L. [Inventor]; Musso, Gary
 [Inventor]; Signer, Ethan R. [Inventor]; Wakefield, James [Inventor];
 Reprint author; Molineaux, Susan [Inventor]; Chin, Joseph [Inventor];
 Lee, Jung-Ja [Inventor]; Kelley, Michael [Inventor]; Komar-Panicucci,
 Sonja [Inventor]; Arico-Muendel, Christopher C. [Inventor]; Phillips,
 Kathryn [Inventor]; Hayward, Neil J. [Inventor]
 CS Brookline, MA, USA
 ASSIGNEE: Praecis Pharmaceuticals, Inc., Waltham, MA, USA
 PI US 6277826 August 21, 2001
 SO Official Gazette of the United States Patent and Trademark Office Patents,
 (Aug. 21, 2001) Vol. 1249, No. 3. e-file.
 CODEN: OGUPE7. ISSN: 0098-1133.
 DT Patent
 LA English
 ED Entered STN: 10 Oct 2001
 Last Updated on STN: 23 Feb 2002

L5 ANSWER 12 OF 367 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
 STN
 AN 2000:292029 BIOSIS
 DN PREV200000292029
 TI Modulators of ***beta*** - ***amyloid*** peptide aggregation
 comprising ***D*** - ***amino*** ***acids***
 AU Findeis, Mark A. [Inventor, Reprint author]; Gefter, Malcolm L.
 [Inventor]; Musso, Gary [Inventor]; Signer, Ethan R. [Inventor];
 Wakefield, James [Inventor]; Molineaux, Susan [Inventor]; Chin, Joseph
 [Inventor]; Lee, Jung-J [Inventor]; Kelley, Michael [Inventor];
 Komar-Panicucci, Sonj [Inventor]; Arico-Muendel, Christopher C.
 [Inventor]; Phillips, Kathryn [Inventor]; Hayward, Neil J. [Inventor]
 CS North Grafton, MA, USA

PI US 5985242 November 16, 1999
 SO Official Gazette of the United States Patent and Trademark Office Patents,
 (Nov. 16, 1999) Vol. 1228, No. 3. e-file.
 CODEN: OGUPE7. ISSN: 0098-1133.
 DT Patent
 LA English
 ED Entered STN: 6 Jul 2000
 Last Updated on STN: 7 Jan 2002

L5 ANSWER 13 OF 367 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
 STN
 AN 1998:80765 BIOSIS
 DN PREV199800080765
 TI Mechanism and prevention of neurotoxicity caused by ***beta*** -
 amyloid peptides: Relation to Alzheimer's disease.
 AU Blanchard, Barbara J.; Konopka, Genevieve; Russell, Margaret; Ingram,
 Vernon M. [Reprint author]
 CS Dep. Biol., Massachusetts Inst. Technol., Cambridge, MA 02139, USA
 SO Brain Research, (Nov. 21, 1997) Vol. 776, No. 1-2, pp. 40-50. print.
 CODEN: BRREAP. ISSN: 0006-8993.
 DT Article
 LA English
 ED Entered STN: 24 Feb 1998
 Last Updated on STN: 24 Feb 1998

L5 ANSWER 14 OF 367 BIOTECHDS COPYRIGHT 2004 THOMSON DERWENT/ISI on STN
 AN 2004-14623 BIOTECHDS
 TI Identifying an agent that alters processing of ***beta*** -
 amyloid precursor (APP) protein by contacting the agent with an
 animal host cell that expresses APP and an APP processing enzyme and
 detecting altered APP processing;
 beta - ***amyloid*** ***precursor*** ***protein***
 process alteration and transgenic animal for use in disease therapy
 AU HAGEN F S; LANNFELT L; GELLERFORS P
 PA BIOARCTIC NEUROSCIENCE AB; ICOGEN CORP
 PI WO 2004041213 21 May 2004
 AI WO 2003-US35294 4 Nov 2003
 PRAI US 2002-424031 4 Nov 2002; US 2002-424031 4 Nov 2002
 DT Patent
 LA English
 OS WPI: 2004-400523 [37]

L5 ANSWER 15 OF 367 BIOTECHDS COPYRIGHT 2004 THOMSON DERWENT/ISI on STN
 AN 2004-09510 BIOTECHDS
 TI Treating viral disease such as HIV, herpes simplex virus, varicella
 zoster virus, poliomyelitis virus, cytomegalovirus, in subjects, involves
 administering amyloidogenic peptide modulator compound to the subject;
 for use in gene therapy and drug screening
 AU ISRAEL D I; MIRZABEKOV T; WOJTIOWICZ W M; SODROSKI J
 PA PRAECIS PHARM INC
 PI WO 2003105677 24 Dec 2003
 AI WO 2003-US19365 18 Jun 2003
 PRAI US 2002-394390 8 Jul 2002; US 2002-390040 18 Jun 2002
 DT Patent
 LA English
 OS WPI: 2004-169032 [16]

L5 ANSWER 16 OF 367 BIOTECHDS COPYRIGHT 2004 THOMSON DERWENT/ISI on STN
 AN 2003-14872 BIOTECHDS
 TI New Activity Dependent Neurotrophic Factor I complex polypeptide, useful
 for reducing neuronal cell death, treating oxidative stress in a patient,
 or improving learning and/or memory in a subject with e.g. Alzheimer's
 disease;
 protein and antibody useful for disease therapy and diagnosis
 AU BRENNEMAN D E; CASTELLON R; SPONG C Y; HAUSER J M; GOZES I
 PA UNIV RAMOT AT TEL AVIV LTD; US DEPT HEALTH and HUMAN SERVICES
 PI WO 2003022226 20 Mar 2003
 AI WO 2002-US29146 12 Sep 2002
 PRAI US 2002-371961 10 Apr 2002; US 2001-322760 12 Sep 2001
 DT Patent
 LA English
 OS WPI: 2003-354501 [33]

L5 ANSWER 17 OF 367 BIOTECHDS COPYRIGHT 2004 THOMSON DERWENT/ISI on STN
 AN 2003-08134 BIOTECHDS

beta - ***amyloid*** peptide, useful in diagnosis, prevention and treatment of Alzheimer's disease;

beta - ***amyloid*** peptide useful for Alzheimer disease therapy and diagnosis

AU WILLBOLD D; WIESEHAN K
PA IMB INST MOLEKULARE BIOTECHNOLOGIE EV
PI WO 2002081505 17 Oct 2002
AI WO 2002-EP3862 8 Apr 2002
PRAI DE 2001-1017281 6 Apr 2001; DE 2001-1017281 6 Apr 2001
DT Patent
LA German
OS WPI: 2003-103321 [09]

L5 ANSWER 18 OF 367 BIOTECHDS COPYRIGHT 2004 THOMSON DERWENT/ISI on STN
AN 2003-02087 BIOTECHDS
TI Novel therapeutic agent useful for treating an amyloidogenic disorder, e.g. Alzheimer's disease, comprises an immunoglobulin heavy chain constant region linked to a peptide capable of binding amyloidogenic protein;

vector-mediated gene transfer, expression in host cell for recombinant protein production and disease therapy

AU GEFTER M L; ISRAEL D I; JOYAL J L; GOSSELIN M
PA PRAECIS PHARM INC
PI WO 2002042462 30 May 2002
AI WO 2001-US44581 27 Nov 2001
PRAI US 2000-257186 20 Dec 2000; US 2000-253302 27 Nov 2000
DT Patent
LA English
OS WPI: 2002-636427 [68]

L5 ANSWER 19 OF 367 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN
AN 2003:37010600 BIOTECHNO

TI Selection of ***D*** - ***amino*** - ***acid*** peptides that bind to Alzheimer's disease amyloid peptide A.beta..sub.1.sub.-.sub.4.sub.2 by mirror image phage display
AU Wiesehan K.; Buder K.; Linke R.P.; Patt S.; Stoldt M.; Unger E.; Schmitt B.; Bucci E.; Willbold D.
CS Dr. D. Willbold, Forschungszentrum Julich, IBI-2, 52425 Julich, Germany. E-mail: dieter.willbold@uni-duesseldorf.de
SO ChemBioChem, (04 AUG 2003), 4/8 (748-753), 29 reference(s)
CODEN: CBCHFX ISSN: 1439-4227
DT Journal; Article
CY Germany, Federal Republic of
LA English
SL English

L5 ANSWER 20 OF 367 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2004:454464 CAPLUS
DN 141:64409
TI Protective peptides that are orally active and mechanistically nonchiral
AU Brenneman, Douglas E.; Spong, Catherine Y.; Hauser, Janet M.; Abebe, Daniel; Pinhasov, Albert; Golian, Tania; Gozes, Illana
CS Section on Developmental and Molecular Pharmacology, Laboratory of Developmental Neurobiology, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA
SO Journal of Pharmacology and Experimental Therapeutics (2004), 309(3), 1190-1197

CODEN: JPETAB; ISSN: 0022-3565
PB American Society for Pharmacology and Experimental Therapeutics
DT Journal
LA English

RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 21 OF 367 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:496984 CAPLUS
DN 140:72737
TI Identification and characterization of a specific ligand for the Alzheimer ***amyloid*** -. ***beta*** -.peptide (A.beta.)
AU Wiesehan, Katja
CS Institut fuer Biologische Informationsverarbeitung, Forschungszentrum Juelich, Germany
SO Berichte des Forschungszentrums Juelich (2003), Juel-4024, i-vii, 1-143
CODEN: FJBEE5; ISSN: 0944-2952
DT Report

RE.CNT 158 THERE ARE 158 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 22 OF 367 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:190130 CAPLUS
TI Designed helical peptides as gamma-secreatase inhibitors
AU Das, Chittaranjan; Wolfe, Michael S.; Tsai, Jui-Yi; Diehl, Thekla S.
CS Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard
Medical school, Boston, MA, 02115, USA
SO Abstracts of Papers, 223rd ACS National Meeting, Orlando, FL, United
States, April 7-11, 2002 (2002), MEDI-011 Publisher: American Chemical
Society, Washington, D. C.
CODEN: 69CKQP
DT Conference; Meeting Abstract
LA English

L5 ANSWER 23 OF 367 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:628174 CAPLUS
DN 133:221242
TI Modulators of ***beta*** - ***amyloid*** peptide aggregation
comprising ***D*** - ***amino*** ***acids***
IN Findeis, Mark A.; Phillips, Kathryn; Olson, Gary L.; Self, Christopher
PA Praecis Pharmaceuticals Incorporated, USA
SO PCT Int. Appl., 87 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000052048	A1	20000908	WO 2000-US5574	20000303
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1161449	A1	20011212	EP 2000-916028	20000303
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 2000008738	A	20011226	BR 2000-8738	20000303
	JP 2002543043	T2	20021217	JP 2000-602272	20000303
	US 6610658	B1	20030826	US 2000-519019	20000303
	NZ 514414	A	20040227	NZ 2000-514414	20000303
	ZA 2001007913	A	20020926	ZA 2001-7913	20010926
	US 2003236197	A1	20031225	US 2003-395290	20030324
PRAI	US 1999-122736P	P	19990304		
	US 2000-519019	A1	20000303		
	WO 2000-US5574	W	20000303		

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 24 OF 367 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:163613 CAPLUS
DN 128:217639
TI Preparation of ***D*** - ***amino*** ***acid*** peptides as
modulators of . ***beta*** - ***amyloid*** peptide aggregation
IN Findeis, Mark A.; Geffter, Malcolm L.; Musso, Gary; Signer, Ethan R.;
Wakefield, James; Molineaux, Susan; Chin, Joseph; Lee, Jung-Ja; Kelley,
Michael; Komar-Panicucci, Sonja; Arico-Muendel, Christopher C.; Phillips,
Kathryn; Hayward, Neil J.
PA Praecis Pharmaceuticals Incorporated, USA
SO PCT Int. Appl., 92 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 7

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9808868	A1	19980305	WO 1997-US15166	19970827
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC,				

RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN,
 YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,
 GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,
 GN, ML, MR, NE, SN, TD, TG

US 6303567	B1	20011016	US 1996-703675	19960827
AU 9742387	A1	19980319	AU 1997-42387	19970827
AU 741199	B2	20011122		
EP 929574	A1	19990721	EP 1997-940663	19970827
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2001500852	T2	20010123	JP 1998-511914	19970827
AU 759036	B2	20030403	AU 2000-35389	20000519
AU 769915	B2	20040212	AU 2002-15539	20020211
PRAI US 1996-703675	A	19960827		
US 1997-897342	A	19970721		
US 1995-404831	A2	19950314		
US 1995-475579	A2	19950607		
US 1995-548998	B2	19951027		
AU 1996-52524	A3	19960314		
US 1996-616081	B2	19960314		
AU 1997-42387	A3	19970827		
WO 1997-US15166	W	19970827		

OS MARPAT 128:217639
 RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 25 OF 367 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1997:490012 CAPLUS
 TI Effects of racemization on the aggregational properties of the
 amyloid . ***beta*** -peptide in Alzheimer's disease
 AU Yang, Jing; Hong, Anita; Zagorski, Michael
 CS Department Chemistry, Case Western Reserve University, Cleveland, OH,
 44106, USA
 SO Book of Abstracts, 214th ACS National Meeting, Las Vegas, NV, September
 7-11 (1997), MEDI-255 Publisher: American Chemical Society, Washington, D.
 C.
 DT CODEN: 64RNAO
 LA Conference; Meeting Abstract
 English

L5 ANSWER 26 OF 367 CIN COPYRIGHT 2004 ACS on STN
 AN 31(18):20204N CIN
 TI Patents
 SO Biotechnol. News, 12 Apr 2002 (20020412), 22(9), p. 12. ISSN: 0273-3226;
 CODEN: BINWEY.
 LA English

L5 ANSWER 27 OF 367 CIN COPYRIGHT 2004 ACS on STN
 AN 31(8):8178Z CIN
 TI Patents
 SO Biotechnol. News, 1 Feb 2002 (20020201), 22(3), p. 12. ISSN: 0273-3226;
 CODEN: BINWEY.
 LA English

L5 ANSWER 28 OF 367 DISSABS COPYRIGHT (C) 2004 ProQuest Information and
 Learning Company; All Rights Reserved on STN
 AN 2001:43543 DISSABS Order Number: AAI9999583
 TI Synthesis and evaluation of difluoro ketone peptidomimetic inhibitors to
 investigate the intramembranous cleavage of ***amyloid***
 precursor ***protein*** and notch
 AU Moore, Chad Leroy [Ph.D.]; Wolfe, Michael S. [adviser]
 CS The University of Tennessee Center for the Health Sciences (0783)
 SO Dissertation Abstracts International, (2001) Vol. 61, No. 12B, p. 6483.
 Order No.: AAI9999583. 169 pages.
 ISBN: 0-493-08021-X.
 DT Dissertation
 FS DAI
 LA English

L5 ANSWER 29 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN ABP99468 Peptide DGENE
 TI New ***D*** - ***amino*** ***acid*** peptide specific for
 beta - ***amyloid*** peptide, useful in diagnosis, prevention
 and treatment of Alzheimer's disease -

PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.
 PI WO 2002081505 A2 20021017 28p
 AI WO 2002-EP3862 20020408
 PRAI DE 2001-10117281 20010406
 DT Patent
 LA German
 OS 2003-103321 [09]
 DESC ***Beta*** - ***amyloid*** binding D-form peptide 55.

L5 ANSWER 30 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN ABP99467 Peptide DGENE
 TI New ***D*** - ***amino*** ***acid*** peptide specific for
 beta - ***amyloid*** peptide, useful in diagnosis, prevention
 and treatment of Alzheimer's disease -
 IN Willbold D; Wiesehan K
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.
 PI WO 2002081505 A2 20021017 28p
 AI WO 2002-EP3862 20020408
 PRAI DE 2001-10117281 20010406
 DT Patent
 LA German
 OS 2003-103321 [09]
 DESC ***Beta*** - ***amyloid*** binding D-form peptide 54.

L5 ANSWER 31 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN ABP99466 Peptide DGENE
 TI New ***D*** - ***amino*** ***acid*** peptide specific for
 beta - ***amyloid*** peptide, useful in diagnosis, prevention.
 and treatment of Alzheimer's disease -
 IN Willbold D; Wiesehan K
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.
 PI WO 2002081505 A2 20021017 28p
 AI WO 2002-EP3862 20020408
 PRAI DE 2001-10117281 20010406
 DT Patent
 LA German
 OS 2003-103321 [09]
 DESC ***Beta*** - ***amyloid*** binding D-form peptide 53.

L5 ANSWER 32 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN ABP99465 Peptide DGENE
 TI New ***D*** - ***amino*** ***acid*** peptide specific for
 beta - ***amyloid*** peptide, useful in diagnosis, prevention
 and treatment of Alzheimer's disease -
 IN Willbold D; Wiesehan K
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.
 PI WO 2002081505 A2 20021017 28p
 AI WO 2002-EP3862 20020408
 PRAI DE 2001-10117281 20010406
 DT Patent
 LA German
 OS 2003-103321 [09]
 DESC ***Beta*** - ***amyloid*** binding D-form peptide 52.

L5 ANSWER 33 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN ABP99464 Peptide DGENE
 TI New ***D*** - ***amino*** ***acid*** peptide specific for
 beta - ***amyloid*** peptide, useful in diagnosis, prevention
 and treatment of Alzheimer's disease -
 IN Willbold D; Wiesehan K
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.
 PI WO 2002081505 A2 20021017 28p
 AI WO 2002-EP3862 20020408
 PRAI DE 2001-10117281 20010406
 DT Patent
 LA German
 OS 2003-103321 [09]
 DESC ***Beta*** - ***amyloid*** binding D-form peptide 51.

L5 ANSWER 34 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN ABP99463 Peptide DGENE
 TI New ***D*** - ***amino*** ***acid*** peptide specific for
 beta - ***amyloid*** peptide, useful in diagnosis, prevention
 and treatment of Alzheimer's disease -
 IN Willbold D; Wiesehan K

PI WO 2002081505 A2 20021017 28p
 AI WO 2002-EP3862 20020408
 PRAI DE 2001-10117281 20010406
 DT Patent
 LA German
 OS 2003-103321 [09]
 DESC ***Beta*** - ***amyloid*** binding D-form peptide 50.

L5 ANSWER 35 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN ABP99462 Peptide DGENE
 TI New ***D*** - ***amino*** ***acid*** peptide specific for
 beta - ***amyloid*** peptide, useful in diagnosis, prevention
 and treatment of Alzheimer's disease -
 IN Willbold D; Wiesehan K
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.
 PI WO 2002081505 A2 20021017 28p
 AI WO 2002-EP3862 20020408
 PRAI DE 2001-10117281 20010406
 DT Patent
 LA German
 OS 2003-103321 [09]
 DESC ***Beta*** - ***amyloid*** binding D-form peptide 49.

L5 ANSWER 36 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN ABP99461 Peptide DGENE
 TI New ***D*** - ***amino*** ***acid*** peptide specific for
 beta - ***amyloid*** peptide, useful in diagnosis, prevention
 and treatment of Alzheimer's disease -
 IN Willbold D; Wiesehan K
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.
 PI WO 2002081505 A2 20021017 28p
 AI WO 2002-EP3862 20020408
 PRAI DE 2001-10117281 20010406
 DT Patent
 LA German
 OS 2003-103321 [09]
 DESC ***Beta*** - ***amyloid*** binding D-form peptide 48.

L5 ANSWER 37 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN ABP99460 Peptide DGENE
 TI New ***D*** - ***amino*** ***acid*** peptide specific for
 beta - ***amyloid*** peptide, useful in diagnosis, prevention
 and treatment of Alzheimer's disease -
 IN Willbold D; Wiesehan K
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.
 PI WO 2002081505 A2 20021017 28p
 AI WO 2002-EP3862 20020408
 PRAI DE 2001-10117281 20010406
 DT Patent
 LA German
 OS 2003-103321 [09]
 DESC ***Beta*** - ***amyloid*** binding D-form peptide 47.

L5 ANSWER 38 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN ABP99459 Peptide DGENE
 TI New ***D*** - ***amino*** ***acid*** peptide specific for
 beta - ***amyloid*** peptide, useful in diagnosis, prevention
 and treatment of Alzheimer's disease -
 IN Willbold D; Wiesehan K
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.
 PI WO 2002081505 A2 20021017 28p
 AI WO 2002-EP3862 20020408
 PRAI DE 2001-10117281 20010406
 DT Patent
 LA German
 OS 2003-103321 [09]
 DESC ***Beta*** - ***amyloid*** binding D-form peptide 46.

L5 ANSWER 39 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN ABP99458 Peptide DGENE
 TI New ***D*** - ***amino*** ***acid*** peptide specific for
 beta - ***amyloid*** peptide, useful in diagnosis, prevention
 and treatment of Alzheimer's disease -
 IN Willbold D; Wiesehan K
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.

AI WO 2002-EP3862 20020408
 PRAI DE 2001-10117281 20010406
 DT Patent
 LA German
 OS 2003-103321 [09]
 DESC ***Beta*** - ***amyloid*** binding D-form peptide 45.

L5 ANSWER 40 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN ABP99457 Peptide DGENE
 TI New ***D*** - ***amino*** ***acid*** peptide specific for
 beta - ***amyloid*** peptide, useful in diagnosis, prevention
 and treatment of Alzheimer's disease -
 IN Willbold D; Wiesehan K
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.
 PI WO 2002081505 A2 20021017 28p
 AI WO 2002-EP3862 20020408
 PRAI DE 2001-10117281 20010406
 DT Patent
 LA German
 OS 2003-103321 [09]
 DESC ***Beta*** - ***amyloid*** binding D-form peptide 44.

L5 ANSWER 41 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN ABP99456 Peptide DGENE
 TI New ***D*** - ***amino*** ***acid*** peptide specific for
 beta - ***amyloid*** peptide, useful in diagnosis, prevention
 and treatment of Alzheimer's disease -
 IN Willbold D; Wiesehan K
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.
 PI WO 2002081505 A2 20021017 28p
 AI WO 2002-EP3862 20020408
 PRAI DE 2001-10117281 20010406
 DT Patent
 LA German
 OS 2003-103321 [09]
 DESC ***Beta*** - ***amyloid*** binding D-form peptide 43.

L5 ANSWER 42 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN ABP99455 Peptide DGENE
 TI New ***D*** - ***amino*** ***acid*** peptide specific for
 beta - ***amyloid*** peptide, useful in diagnosis, prevention
 and treatment of Alzheimer's disease -
 IN Willbold D; Wiesehan K
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.
 PI WO 2002081505 A2 20021017 28p
 AI WO 2002-EP3862 20020408
 PRAI DE 2001-10117281 20010406
 DT Patent
 LA German
 OS 2003-103321 [09]
 DESC ***Beta*** - ***amyloid*** binding D-form peptide 42.

L5 ANSWER 43 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN ABP99454 Peptide DGENE
 TI New ***D*** - ***amino*** ***acid*** peptide specific for
 beta - ***amyloid*** peptide, useful in diagnosis, prevention
 and treatment of Alzheimer's disease -
 IN Willbold D; Wiesehan K
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.
 PI WO 2002081505 A2 20021017 28p
 AI WO 2002-EP3862 20020408
 PRAI DE 2001-10117281 20010406
 DT Patent
 LA German
 OS 2003-103321 [09]
 DESC ***Beta*** - ***amyloid*** binding D-form peptide 41.

L5 ANSWER 44 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN ABP99453 Peptide DGENE
 TI New ***D*** - ***amino*** ***acid*** peptide specific for
 beta - ***amyloid*** peptide, useful in diagnosis, prevention
 and treatment of Alzheimer's disease -
 IN Willbold D; Wiesehan K
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.
 PI WO 2002081505 A2 20021017 28p

PRAI DE 2001-10117281 20010406
 DT Patent
 LA German
 OS 2003-103321 [09]
 DESC ***Beta*** - ***amyloid*** binding D-form peptide 40.

L5 ANSWER 45 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN ABP99452 Peptide DGENE
 TI New ***D*** - ***amino*** ***acid*** peptide specific for
 beta - ***amyloid*** peptide, useful in diagnosis, prevention
 and treatment of Alzheimer's disease -
 IN Willbold D; Wiesehan K
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.
 PI WO 2002081505 A2 20021017 28p
 AI WO 2002-EP3862 20020408
 PRAI DE 2001-10117281 20010406
 DT Patent
 LA German
 OS 2003-103321 [09]
 DESC ***Beta*** - ***amyloid*** binding D-form peptide 39.

L5 ANSWER 46 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN ABP99451 Peptide DGENE
 TI New ***D*** - ***amino*** ***acid*** peptide specific for
 beta - ***amyloid*** peptide, useful in diagnosis, prevention
 and treatment of Alzheimer's disease -
 IN Willbold D; Wiesehan K
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.
 PI WO 2002081505 A2 20021017 28p
 AI WO 2002-EP3862 20020408
 PRAI DE 2001-10117281 20010406
 DT Patent
 LA German
 OS 2003-103321 [09]
 DESC ***Beta*** - ***amyloid*** binding D-form peptide 38.

L5 ANSWER 47 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN ABP99450 Peptide DGENE
 TI New ***D*** - ***amino*** ***acid*** peptide specific for
 beta - ***amyloid*** peptide, useful in diagnosis, prevention
 and treatment of Alzheimer's disease -
 IN Willbold D; Wiesehan K
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.
 PI WO 2002081505 A2 20021017 28p
 AI WO 2002-EP3862 20020408
 PRAI DE 2001-10117281 20010406
 DT Patent
 LA German
 OS 2003-103321 [09]
 DESC ***Beta*** - ***amyloid*** binding D-form peptide 37.

L5 ANSWER 48 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN ABP99449 Peptide DGENE
 TI New ***D*** - ***amino*** ***acid*** peptide specific for
 beta - ***amyloid*** peptide, useful in diagnosis, prevention
 and treatment of Alzheimer's disease -
 IN Willbold D; Wiesehan K
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.
 PI WO 2002081505 A2 20021017 28p
 AI WO 2002-EP3862 20020408
 PRAI DE 2001-10117281 20010406
 DT Patent
 LA German
 OS 2003-103321 [09]
 DESC ***Beta*** - ***amyloid*** binding D-form peptide 36.

L5 ANSWER 49 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN ABP99448 Peptide DGENE
 TI New ***D*** - ***amino*** ***acid*** peptide specific for
 beta - ***amyloid*** peptide, useful in diagnosis, prevention
 and treatment of Alzheimer's disease -
 IN Willbold D; Wiesehan K
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.
 PI WO 2002081505 A2 20021017 28p
 AI WO 2002-EP3862 20020408

DT Patent
LA German
OS 2003-103321 [09]
DESC ***Beta*** - ***amyloid*** binding D-form peptide 35.

L5 ANSWER 50 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ABP99447 Peptide DGENE
TI New ***D*** - ***amino*** ***acid*** peptide specific for
beta - ***amyloid*** peptide, useful in diagnosis, prevention
and treatment of Alzheimer's disease -
IN Willbold D; Wiesehan K
PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.
PI WO 2002081505 A2 20021017 28p
AI WO 2002-EP3862 20020408
PRAI DE 2001-10117281 20010406
DT Patent
LA German
OS 2003-103321 [09]
DESC ***Beta*** - ***amyloid*** binding D-form peptide 34.

L5 ANSWER 51 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ABP99446 Peptide DGENE
TI New ***D*** - ***amino*** ***acid*** peptide specific for
beta - ***amyloid*** peptide, useful in diagnosis, prevention
and treatment of Alzheimer's disease -
IN Willbold D; Wiesehan K
PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.
PI WO 2002081505 A2 20021017 28p
AI WO 2002-EP3862 20020408
PRAI DE 2001-10117281 20010406
DT Patent
LA German
OS 2003-103321 [09]
DESC ***Beta*** - ***amyloid*** binding D-form peptide 33.

L5 ANSWER 52 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ABP99445 Peptide DGENE
TI New ***D*** - ***amino*** ***acid*** peptide specific for
beta - ***amyloid*** peptide, useful in diagnosis, prevention
and treatment of Alzheimer's disease -
IN Willbold D; Wiesehan K
PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.
PI WO 2002081505 A2 20021017 28p
AI WO 2002-EP3862 20020408
PRAI DE 2001-10117281 20010406
DT Patent
LA German
OS 2003-103321 [09]
DESC ***Beta*** - ***amyloid*** binding D-form peptide 32.

L5 ANSWER 53 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ABP99444 Peptide DGENE
TI New ***D*** - ***amino*** ***acid*** peptide specific for
beta - ***amyloid*** peptide, useful in diagnosis, prevention
and treatment of Alzheimer's disease -
IN Willbold D; Wiesehan K
PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.
PI WO 2002081505 A2 20021017 28p
AI WO 2002-EP3862 20020408
PRAI DE 2001-10117281 20010406
DT Patent
LA German
OS 2003-103321 [09]
DESC ***Beta*** - ***amyloid*** binding D-form peptide 31.

L5 ANSWER 54 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ABP99443 Peptide DGENE
TI New ***D*** - ***amino*** ***acid*** peptide specific for
beta - ***amyloid*** peptide, useful in diagnosis, prevention
and treatment of Alzheimer's disease -
IN Willbold D; Wiesehan K
PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.
PI WO 2002081505 A2 20021017 28p
AI WO 2002-EP3862 20020408
PRAI DE 2001-10117281 20010406

LA German
 OS 2003-103321 [09]
 DESC ***Beta*** - ***amyloid*** binding D-form peptide 30.

L5 ANSWER 55 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN ABP99442 Peptide DGENE
 TI New ***D*** - ***amino*** ***acid*** peptide specific for
 beta - ***amyloid*** peptide, useful in diagnosis, prevention
 and treatment of Alzheimer's disease -
 IN Willbold D; Wiesehan K
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.
 PI WO 2002081505 A2 20021017 28p
 AI WO 2002-EP3862 20020408
 PRAI DE 2001-10117281 20010406
 DT Patent
 LA German
 OS 2003-103321 [09]
 DESC ***Beta*** - ***amyloid*** binding D-form peptide 29.

L5 ANSWER 56 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN ABP99441 Peptide DGENE
 TI New ***D*** - ***amino*** ***acid*** peptide specific for
 beta - ***amyloid*** peptide, useful in diagnosis, prevention
 and treatment of Alzheimer's disease -
 IN Willbold D; Wiesehan K
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.
 PI WO 2002081505 A2 20021017 28p
 AI WO 2002-EP3862 20020408
 PRAI DE 2001-10117281 20010406
 DT Patent
 LA German
 OS 2003-103321 [09]
 DESC ***Beta*** - ***amyloid*** binding D-form peptide 28.

L5 ANSWER 57 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN ABP99440 Peptide DGENE
 TI New ***D*** - ***amino*** ***acid*** peptide specific for
 beta - ***amyloid*** peptide, useful in diagnosis, prevention
 and treatment of Alzheimer's disease -
 IN Willbold D; Wiesehan K
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.
 PI WO 2002081505 A2 20021017 28p
 AI WO 2002-EP3862 20020408
 PRAI DE 2001-10117281 20010406
 DT Patent
 LA German
 OS 2003-103321 [09]
 DESC ***Beta*** - ***amyloid*** binding D-form peptide 27.

L5 ANSWER 58 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN ABP99439 Peptide DGENE
 TI New ***D*** - ***amino*** ***acid*** peptide specific for
 beta - ***amyloid*** peptide, useful in diagnosis, prevention
 and treatment of Alzheimer's disease -
 IN Willbold D; Wiesehan K
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.
 PI WO 2002081505 A2 20021017 28p
 AI WO 2002-EP3862 20020408
 PRAI DE 2001-10117281 20010406
 DT Patent
 LA German
 OS 2003-103321 [09]
 DESC ***Beta*** - ***amyloid*** binding D-form peptide 26.

L5 ANSWER 59 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN ABP99438 Peptide DGENE
 TI New ***D*** - ***amino*** ***acid*** peptide specific for
 beta - ***amyloid*** peptide, useful in diagnosis, prevention
 and treatment of Alzheimer's disease -
 IN Willbold D; Wiesehan K
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.
 PI WO 2002081505 A2 20021017 28p
 AI WO 2002-EP3862 20020408
 PRAI DE 2001-10117281 20010406
 DT Patent

OS 2003-103321 [09]
DESC ***Beta*** - ***amyloid*** binding D-form peptide 25.

L5 ANSWER 60 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ABP99437 Peptide DGENE
TI New ***D*** - ***amino*** ***acid*** peptide specific for
beta - ***amyloid*** peptide, useful in diagnosis, prevention
and treatment of Alzheimer's disease -
IN Willbold D; Wiesehan K
PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.
PI WO 2002081505 A2 20021017 28p
AI WO 2002-EP3862 20020408
PRAI DE 2001-10117281 20010406
DT Patent
LA German
OS 2003-103321 [09]
DESC ***Beta*** - ***amyloid*** binding D-form peptide 24.

L5 ANSWER 61 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ABP99436 Peptide DGENE
TI New ***D*** - ***amino*** ***acid*** peptide specific for
beta - ***amyloid*** peptide, useful in diagnosis, prevention
and treatment of Alzheimer's disease -
IN Willbold D; Wiesehan K
PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.
PI WO 2002081505 A2 20021017 28p
AI WO 2002-EP3862 20020408
PRAI DE 2001-10117281 20010406
DT Patent
LA German
OS 2003-103321 [09]
DESC ***Beta*** - ***amyloid*** binding D-form peptide 23.

L5 ANSWER 62 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ABP99435 Peptide DGENE
TI New ***D*** - ***amino*** ***acid*** peptide specific for
beta - ***amyloid*** peptide, useful in diagnosis, prevention
and treatment of Alzheimer's disease -
IN Willbold D; Wiesehan K
PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.
PI WO 2002081505 A2 20021017 28p
AI WO 2002-EP3862 20020408
PRAI DE 2001-10117281 20010406
DT Patent
LA German
OS 2003-103321 [09]
DESC ***Beta*** - ***amyloid*** binding D-form peptide 22.

L5 ANSWER 63 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ABP99434 Peptide DGENE
TI New ***D*** - ***amino*** ***acid*** peptide specific for
beta - ***amyloid*** peptide, useful in diagnosis, prevention
and treatment of Alzheimer's disease -
IN Willbold D; Wiesehan K
PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.
PI WO 2002081505 A2 20021017 28p
AI WO 2002-EP3862 20020408
PRAI DE 2001-10117281 20010406
DT Patent
LA German
OS 2003-103321 [09]
DESC ***Beta*** - ***amyloid*** binding D-form peptide 21.

L5 ANSWER 64 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ABP99433 Peptide DGENE
TI New ***D*** - ***amino*** ***acid*** peptide specific for
beta - ***amyloid*** peptide, useful in diagnosis, prevention
and treatment of Alzheimer's disease -
IN Willbold D; Wiesehan K
PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.
PI WO 2002081505 A2 20021017 28p
AI WO 2002-EP3862 20020408
PRAI DE 2001-10117281 20010406
DT Patent
LA German

DESC ***Beta*** - ***amyloid*** binding D-form peptide 20.

L5 ANSWER 65 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ABP99432 Peptide DGENE
TI New ***D*** - ***amino*** ***acid*** peptide specific for
beta - ***amyloid*** peptide, useful in diagnosis, prevention
and treatment of Alzheimer's disease -
IN Willbold D; Wiesehan K
PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.
PI WO 2002081505 A2 20021017 28p
AI WO 2002-EP3862 20020408
PRAI DE 2001-10117281 20010406
DT Patent
LA German
OS 2003-103321 [09]
DESC ***Beta*** - ***amyloid*** binding D-form peptide 19.

L5 ANSWER 66 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ABP99431 Peptide DGENE
TI New ***D*** - ***amino*** ***acid*** peptide specific for
beta - ***amyloid*** peptide, useful in diagnosis, prevention
and treatment of Alzheimer's disease -
IN Willbold D; Wiesehan K
PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.
PI WO 2002081505 A2 20021017 28p
AI WO 2002-EP3862 20020408
PRAI DE 2001-10117281 20010406
DT Patent
LA German
OS 2003-103321 [09]
DESC ***Beta*** - ***amyloid*** binding D-form peptide 18.

L5 ANSWER 67 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ABP99430 Peptide DGENE
TI New ***D*** - ***amino*** ***acid*** peptide specific for
beta - ***amyloid*** peptide, useful in diagnosis, prevention
and treatment of Alzheimer's disease -
IN Willbold D; Wiesehan K
PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.
PI WO 2002081505 A2 20021017 28p
AI WO 2002-EP3862 20020408
PRAI DE 2001-10117281 20010406
DT Patent
LA German
OS 2003-103321 [09]
DESC ***Beta*** - ***amyloid*** binding D-form peptide 17.

L5 ANSWER 68 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ABP99429 Peptide DGENE
TI New ***D*** - ***amino*** ***acid*** peptide specific for
beta - ***amyloid*** peptide, useful in diagnosis, prevention
and treatment of Alzheimer's disease -
IN Willbold D; Wiesehan K
PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.
PI WO 2002081505 A2 20021017 28p
AI WO 2002-EP3862 20020408
PRAI DE 2001-10117281 20010406
DT Patent
LA German
OS 2003-103321 [09]
DESC ***Beta*** - ***amyloid*** binding D-form peptide 16.

L5 ANSWER 69 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ABP99428 Peptide DGENE
TI New ***D*** - ***amino*** ***acid*** peptide specific for
beta - ***amyloid*** peptide, useful in diagnosis, prevention
and treatment of Alzheimer's disease -
IN Willbold D; Wiesehan K
PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.
PI WO 2002081505 A2 20021017 28p
AI WO 2002-EP3862 20020408
PRAI DE 2001-10117281 20010406
DT Patent
LA German
OS 2003-103321 [09]

L5 ANSWER 70 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN ABP99427 Peptide DGENE
 TI New ***D*** - ***amino*** ***acid*** peptide specific for
 beta - ***amyloid*** peptide, useful in diagnosis, prevention
 and treatment of Alzheimer's disease -
 IN Willbold D; Wiesehan K
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.
 PI WO 2002081505 A2 20021017 28p
 AI WO 2002-EP3862 20020408
 PRAI DE 2001-10117281 20010406
 DT Patent
 LA German
 OS 2003-103321 [09]
 DESC ***Beta*** - ***amyloid*** binding D-form peptide 14.

L5 ANSWER 71 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN ABP99426 Peptide DGENE
 TI New ***D*** - ***amino*** ***acid*** peptide specific for
 beta - ***amyloid*** peptide, useful in diagnosis, prevention
 and treatment of Alzheimer's disease -
 IN Willbold D; Wiesehan K
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.
 PI WO 2002081505 A2 20021017 28p
 AI WO 2002-EP3862 20020408
 PRAI DE 2001-10117281 20010406
 DT Patent
 LA German
 OS 2003-103321 [09]
 DESC ***Beta*** - ***amyloid*** binding D-form peptide 13.

L5 ANSWER 72 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN ABP99425 Peptide DGENE
 TI New ***D*** - ***amino*** ***acid*** peptide specific for
 beta - ***amyloid*** peptide, useful in diagnosis, prevention
 and treatment of Alzheimer's disease -
 IN Willbold D; Wiesehan K
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.
 PI WO 2002081505 A2 20021017 28p
 AI WO 2002-EP3862 20020408
 PRAI DE 2001-10117281 20010406
 DT Patent
 LA German
 OS 2003-103321 [09]
 DESC ***Beta*** - ***amyloid*** binding L-form peptide 1.

L5 ANSWER 73 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN ABP99424 Peptide DGENE
 TI New ***D*** - ***amino*** ***acid*** peptide specific for
 beta - ***amyloid*** peptide, useful in diagnosis, prevention
 and treatment of Alzheimer's disease -
 IN Willbold D; Wiesehan K
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.
 PI WO 2002081505 A2 20021017 28p
 AI WO 2002-EP3862 20020408
 PRAI DE 2001-10117281 20010406
 DT Patent
 LA German
 OS 2003-103321 [09]
 DESC ***Beta*** - ***amyloid*** binding D-form peptide 12.

L5 ANSWER 74 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN ABP99423 Peptide DGENE
 TI New ***D*** - ***amino*** ***acid*** peptide specific for
 beta - ***amyloid*** peptide, useful in diagnosis, prevention
 and treatment of Alzheimer's disease -
 IN Willbold D; Wiesehan K
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.
 PI WO 2002081505 A2 20021017 28p
 AI WO 2002-EP3862 20020408
 PRAI DE 2001-10117281 20010406
 DT Patent
 LA German
 OS 2003-103321 [09]
 DESC ***Beta*** - ***amyloid*** binding D-form peptide 11.

L5 ANSWER 75 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN ABP99422 Peptide DGENE
 TI New ***D*** - ***amino*** ***acid*** peptide specific for
 beta - ***amyloid*** peptide, useful in diagnosis, prevention
 and treatment of Alzheimer's disease -
 IN Willbold D; Wiesehan K
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.
 PI WO 2002081505 A2 20021017 28p
 AI WO 2002-EP3862 20020408
 PRAI DE 2001-10117281 20010406
 DT Patent
 LA German
 OS 2003-103321 [09]
 DESC ***Beta*** - ***amyloid*** binding D-form peptide 10.

L5 ANSWER 76 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN ABP99421 Peptide DGENE
 TI New ***D*** - ***amino*** ***acid*** peptide specific for
 beta - ***amyloid*** peptide, useful in diagnosis, prevention
 and treatment of Alzheimer's disease -
 IN Willbold D; Wiesehan K
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.
 PI WO 2002081505 A2 20021017 28p
 AI WO 2002-EP3862 20020408
 PRAI DE 2001-10117281 20010406
 DT Patent
 LA German
 OS 2003-103321 [09]
 DESC ***Beta*** - ***amyloid*** binding D-form peptide 9.

L5 ANSWER 77 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN ABP99420 Peptide DGENE
 TI New ***D*** - ***amino*** ***acid*** peptide specific for
 beta - ***amyloid*** peptide, useful in diagnosis, prevention
 and treatment of Alzheimer's disease -
 IN Willbold D; Wiesehan K
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.
 PI WO 2002081505 A2 20021017 28p
 AI WO 2002-EP3862 20020408
 PRAI DE 2001-10117281 20010406
 DT Patent
 LA German
 OS 2003-103321 [09]
 DESC ***Beta*** - ***amyloid*** binding D-form peptide 8.

L5 ANSWER 78 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN ABP99419 Peptide DGENE
 TI New ***D*** - ***amino*** ***acid*** peptide specific for
 beta - ***amyloid*** peptide, useful in diagnosis, prevention
 and treatment of Alzheimer's disease -
 IN Willbold D; Wiesehan K
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.
 PI WO 2002081505 A2 20021017 28p
 AI WO 2002-EP3862 20020408
 PRAI DE 2001-10117281 20010406
 DT Patent
 LA German
 OS 2003-103321 [09]
 DESC ***Beta*** - ***amyloid*** binding D-form peptide 7.

L5 ANSWER 79 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN ABP99418 Peptide DGENE
 TI New ***D*** - ***amino*** ***acid*** peptide specific for
 beta - ***amyloid*** peptide, useful in diagnosis, prevention
 and treatment of Alzheimer's disease -
 IN Willbold D; Wiesehan K
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.
 PI WO 2002081505 A2 20021017 28p
 AI WO 2002-EP3862 20020408
 PRAI DE 2001-10117281 20010406
 DT Patent
 LA German
 OS 2003-103321 [09]
 DESC ***Beta*** - ***amyloid*** binding D-form peptide 6.

AN ABP99417 Peptide DGENE
 TI New ***D*** - ***amino*** ***acid*** peptide specific for
 beta - ***amyloid*** peptide, useful in diagnosis, prevention
 and treatment of Alzheimer's disease -
 IN Willbold D; Wiesehan K
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.
 PI WO 2002081505 A2 20021017 28p
 AI WO 2002-EP3862 20020408
 PRAI DE 2001-10117281 20010406
 DT Patent
 LA German
 OS 2003-103321 [09]
 DESC ***Beta*** - ***amyloid*** binding D-form peptide 5.

L5 ANSWER 81 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN ABP99416 Peptide DGENE
 TI New ***D*** - ***amino*** ***acid*** peptide specific for
 beta - ***amyloid*** peptide, useful in diagnosis, prevention
 and treatment of Alzheimer's disease -
 IN Willbold D; Wiesehan K
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.
 PI WO 2002081505 A2 20021017 28p
 AI WO 2002-EP3862 20020408
 PRAI DE 2001-10117281 20010406
 DT Patent
 LA German
 OS 2003-103321 [09]
 DESC ***Beta*** - ***amyloid*** binding D-form peptide 4.

L5 ANSWER 82 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN ABP99415 Peptide DGENE
 TI New ***D*** - ***amino*** ***acid*** peptide specific for
 beta - ***amyloid*** peptide, useful in diagnosis, prevention
 and treatment of Alzheimer's disease -
 IN Willbold D; Wiesehan K
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.
 PI WO 2002081505 A2 20021017 28p
 AI WO 2002-EP3862 20020408
 PRAI DE 2001-10117281 20010406
 DT Patent
 LA German
 OS 2003-103321 [09]
 DESC ***Beta*** - ***amyloid*** binding D-form peptide 3.

L5 ANSWER 83 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN ABP99414 Peptide DGENE
 TI New ***D*** - ***amino*** ***acid*** peptide specific for
 beta - ***amyloid*** peptide, useful in diagnosis, prevention
 and treatment of Alzheimer's disease -
 IN Willbold D; Wiesehan K
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.
 PI WO 2002081505 A2 20021017 28p
 AI WO 2002-EP3862 20020408
 PRAI DE 2001-10117281 20010406
 DT Patent
 LA German
 OS 2003-103321 [09]
 DESC ***Beta*** - ***amyloid*** binding D-form peptide 2.

L5 ANSWER 84 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN ABP99413 Peptide DGENE
 TI New ***D*** - ***amino*** ***acid*** peptide specific for
 beta - ***amyloid*** peptide, useful in diagnosis, prevention
 and treatment of Alzheimer's disease -
 IN Willbold D; Wiesehan K
 PA (IMBM-N) IMB INST MOLEKULARE BIOTECHNOLOGIE EV.
 PI WO 2002081505 A2 20021017 28p
 AI WO 2002-EP3862 20020408
 PRAI DE 2001-10117281 20010406
 DT Patent
 LA German
 OS 2003-103321 [09]
 DESC ***Beta*** - ***amyloid*** binding D-form peptide 1.

L5 ANSWER 85 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN

TI Modulator compound for treating disorders associated with
 beta-amyloidosis e.g. Alzheimer's disease, comprises a ***beta*** -
 amyloid peptide containing ***D*** - ***amino***
 acids -

IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;
 Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips
 K; Hayward N J

PA (PRAE-N) PRAECIS PHARM INC.
 PI US 6277826 B1 20010821 41p
 AI US 1999-356931 19990719
 PRAI US 1997-920162 19970827
 US 1996-703675 19960827

DT Patent
 LA English
 OS 2001-637856 [73]
 DESC Peptide #3 for analysis of ***beta*** ***amyloid*** modulators
 comprising D-residues.

L5 ANSWER 86 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAE12548 peptide DGENE
 TI Modulator compound for treating disorders associated with
 beta-amyloidosis e.g. Alzheimer's disease, comprises a ***beta*** -
 amyloid peptide containing ***D*** - ***amino***
 acids -

IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;
 Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips
 K; Hayward N J

PA (PRAE-N) PRAECIS PHARM INC.
 PI US 6277826 B1 20010821 41p
 AI US 1999-356931 19990719
 PRAI US 1997-920162 19970827
 US 1996-703675 19960827

DT Patent
 LA English
 OS 2001-637856 [73]
 DESC Peptide #2 for analysis of ***beta*** ***amyloid*** modulators
 comprising D-residues.

L5 ANSWER 87 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAE12547 peptide DGENE
 TI Modulator compound for treating disorders associated with
 beta-amyloidosis e.g. Alzheimer's disease, comprises a ***beta*** -
 amyloid peptide containing ***D*** - ***amino***
 acids -

IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;
 Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips
 K; Hayward N J

PA (PRAE-N) PRAECIS PHARM INC.
 PI US 6277826 B1 20010821 41p
 AI US 1999-356931 19990719
 PRAI US 1997-920162 19970827
 US 1996-703675 19960827

DT Patent
 LA English
 OS 2001-637856 [73]
 DESC Peptide #1 for analysis of ***beta*** ***amyloid*** modulators
 comprising D-residues.

L5 ANSWER 88 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAE12546 peptide DGENE
 TI Modulator compound for treating disorders associated with
 beta-amyloidosis e.g. Alzheimer's disease, comprises a ***beta*** -
 amyloid peptide containing ***D*** - ***amino***
 acids -

IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;
 Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips
 K; Hayward N J

PA (PRAE-N) PRAECIS PHARM INC.
 PI US 6277826 B1 20010821 41p
 AI US 1999-356931 19990719
 PRAI US 1997-920162 19970827
 US 1996-703675 19960827

DT Patent
 LA English
 OS 2001-637856 [73]

L5 ANSWER 89 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAE12539 peptide DGENE
 TI Modulator compound for treating disorders associated with
 beta-amyloidosis e.g. Alzheimer's disease, comprises a ***beta*** -
 amyloid peptide containing ***D*** - ***amino***
 acids
 IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;
 Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips
 K; Hayward N J
 PA (PRAE-N) PRAECIS PHARM INC.
 PI US 6277826 B1 20010821 41p
 AI US 1999-356931 19990719
 PRAI US 1997-920162 19970827
 US 1996-703675 19960827
 DT Patent
 LA English
 OS 2001-637856 [73]
 DESC APP70 abeta peptide (residues 17-20) inverso isomer mutant (F19iodo Y).

L5 ANSWER 90 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAE12538 peptide DGENE
 TI Modulator compound for treating disorders associated with
 beta-amyloidosis e.g. Alzheimer's disease, comprises a ***beta*** -
 amyloid peptide containing ***D*** - ***amino***
 acids
 IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;
 Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips
 K; Hayward N J
 PA (PRAE-N) PRAECIS PHARM INC.
 PI US 6277826 B1 20010821 41p
 AI US 1999-356931 19990719
 PRAI US 1997-920162 19970827
 US 1996-703675 19960827
 DT Patent
 LA English
 OS 2001-637856 [73]
 DESC APP70 abeta peptide (residues 17-21) inverso isomer mutant (F19Y).

L5 ANSWER 91 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAE12537 peptide DGENE
 TI Modulator compound for treating disorders associated with
 beta-amyloidosis e.g. Alzheimer's disease, comprises a ***beta*** -
 amyloid peptide containing ***D*** - ***amino***
 acids
 IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;
 Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips
 K; Hayward N J
 PA (PRAE-N) PRAECIS PHARM INC.
 PI US 6277826 B1 20010821 41p
 AI US 1999-356931 19990719
 PRAI US 1997-920162 19970827
 US 1996-703675 19960827
 DT Patent
 LA English
 OS 2001-637856 [73]
 DESC APP70 abeta peptide.

L5 ANSWER 92 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAE12536 peptide DGENE
 TI Modulator compound for treating disorders associated with
 beta-amyloidosis e.g. Alzheimer's disease, comprises a ***beta*** -
 amyloid peptide containing ***D*** - ***amino***
 acids
 IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;
 Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips
 K; Hayward N J
 PA (PRAE-N) PRAECIS PHARM INC.
 PI US 6277826 B1 20010821 41p
 AI US 1999-356931 19990719
 PRAI US 1997-920162 19970827
 US 1996-703675 19960827
 DT Patent
 LA English
 OS 2001-637856 [73]

L5 ANSWER 93 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAE12535 peptide DGENE
 TI Modulator compound for treating disorders associated with
 beta-amyloidosis e.g. Alzheimer's disease, comprises a ***beta*** -
 amyloid peptide containing ***D*** - ***amino***
 acids
 IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;
 Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips
 K; Hayward N J
 PA (PRAE-N) PRAECIS PHARM INC.
 PI US 6277826 B1 20010821 41p
 AI US 1999-356931 19990719
 PRAI US 1997-920162 19970827
 US 1996-703675 19960827
 DT Patent
 LA English
 OS 2001-637856 [73]
 DESC APP70 abeta peptide (residues 17-21) inverso isomer mutant (F19Y; F20Y).

L5 ANSWER 94 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAE12534 peptide DGENE
 TI Modulator compound for treating disorders associated with
 beta-amyloidosis e.g. Alzheimer's disease, comprises a ***beta*** -
 amyloid peptide containing ***D*** - ***amino***
 acids
 IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;
 Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips
 K; Hayward N J
 PA (PRAE-N) PRAECIS PHARM INC.
 PI US 6277826 B1 20010821 41p
 AI US 1999-356931 19990719
 PRAI US 1997-920162 19970827
 US 1996-703675 19960827
 DT Patent
 LA English
 OS 2001-637856 [73]
 DESC APP70 abeta peptide (residues 17-21) inverso isomer mutant (A21V).

L5 ANSWER 95 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAE12533 peptide DGENE
 TI Modulator compound for treating disorders associated with
 beta-amyloidosis e.g. Alzheimer's disease, comprises a ***beta*** -
 amyloid peptide containing ***D*** - ***amino***
 acids
 IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;
 Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips
 K; Hayward N J
 PA (PRAE-N) PRAECIS PHARM INC.
 PI US 6277826 B1 20010821 41p
 AI US 1999-356931 19990719
 PRAI US 1997-920162 19970827
 US 1996-703675 19960827
 DT Patent
 LA English
 OS 2001-637856 [73]
 DESC APP70 abeta peptide (residues 17-21) inverso isomer mutant (A21F).

L5 ANSWER 96 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAE12532 peptide DGENE
 TI Modulator compound for treating disorders associated with
 beta-amyloidosis e.g. Alzheimer's disease, comprises a ***beta*** -
 amyloid peptide containing ***D*** - ***amino***
 acids
 IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;
 Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips
 K; Hayward N J
 PA (PRAE-N) PRAECIS PHARM INC.
 PI US 6277826 B1 20010821 41p
 AI US 1999-356931 19990719
 PRAI US 1997-920162 19970827
 US 1996-703675 19960827
 DT Patent
 LA English
 OS 2001-637856 [73]

L5 ANSWER 97 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAE12531 peptide DGENE
 TI Modulator compound for treating disorders associated with
 beta-amyloidosis e.g. Alzheimer's disease, comprises a ***beta*** -
 amyloid peptide containing ***D*** - ***amino***
 acids
 IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;
 Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips
 K; Hayward N J
 PA (PRAE-N) PRAECIS PHARM INC.
 PI US 6277826 B1 20010821 41p
 AI US 1999-356931 19990719
 PRAI US 1997-920162 19970827
 US 1996-703675 19960827
 DT Patent
 LA English
 OS 2001-637856 [73]
 DESC APP70 abeta peptide (residues 17-21) inverso isomer mutant (V18F; A21F).

L5 ANSWER 98 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAE12530 peptide DGENE
 TI Modulator compound for treating disorders associated with
 beta-amyloidosis e.g. Alzheimer's disease, comprises a ***beta*** -
 amyloid peptide containing ***D*** - ***amino***
 acids
 IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;
 Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips
 K; Hayward N J
 PA (PRAE-N) PRAECIS PHARM INC.
 PI US 6277826 B1 20010821 41p
 AI US 1999-356931 19990719
 PRAI US 1997-920162 19970827
 US 1996-703675 19960827
 DT Patent
 LA English
 OS 2001-637856 [73]
 DESC APP70 abeta peptide (residues 17-21) inverso isomer mutant.

L5 ANSWER 99 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAE12529 peptide DGENE
 TI Modulator compound for treating disorders associated with
 beta-amyloidosis e.g. Alzheimer's disease, comprises a ***beta*** -
 amyloid peptide containing ***D*** - ***amino***
 acids
 IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;
 Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips
 K; Hayward N J
 PA (PRAE-N) PRAECIS PHARM INC.
 PI US 6277826 B1 20010821 41p
 AI US 1999-356931 19990719
 PRAI US 1997-920162 19970827
 US 1996-703675 19960827
 DT Patent
 LA English
 OS 2001-637856 [73]
 DESC APP 770 Abeta peptide (residues 18-21) retro inverso isomer.

L5 ANSWER 100 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAE12528 peptide DGENE
 TI Modulator compound for treating disorders associated with
 beta-amyloidosis e.g. Alzheimer's disease, comprises a ***beta*** -
 amyloid peptide containing ***D*** - ***amino***
 acids
 IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;
 Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips
 K; Hayward N J
 PA (PRAE-N) PRAECIS PHARM INC.
 PI US 6277826 B1 20010821 41p
 AI US 1999-356931 19990719
 PRAI US 1997-920162 19970827
 US 1996-703675 19960827
 DT Patent
 LA English
 OS 2001-637856 [73]

L5 ANSWER 101 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAE12527 peptide DGENE
 TI Modulator compound for treating disorders associated with
 beta-amyloidosis e.g. Alzheimer's disease, comprises a ***beta***
 amyloid peptide containing ***D*** - ***amino***
 acids
 IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;
 Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips
 K; Hayward N J
 PA (PRAE-N) PRAECIS PHARM INC.
 PI US 6277826 B1 20010821 41p
 AI US 1999-356931 19990719
 PRAI US 1997-920162 19970827
 US 1996-703675 19960827
 DT Patent
 LA English
 OS 2001-637856 [73]
 DESC APP70 abeta peptide (residues 17-21) inverso isomer mutant (F20iodo Y).

L5 ANSWER 102 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAE12526 peptide DGENE
 TI Modulator compound for treating disorders associated with
 beta-amyloidosis e.g. Alzheimer's disease, comprises a ***beta***
 amyloid peptide containing ***D*** - ***amino***
 acids
 IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;
 Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips
 K; Hayward N J
 PA (PRAE-N) PRAECIS PHARM INC.
 PI US 6277826 B1 20010821 41p
 AI US 1999-356931 19990719
 PRAI US 1997-920162 19970827
 US 1996-703675 19960827
 DT Patent
 LA English
 OS 2001-637856 [73]
 DESC APP70 abeta peptide (residues 17-21) inverso isomer mutant (F20Y).

L5 ANSWER 103 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAE12525 peptide DGENE
 TI Modulator compound for treating disorders associated with
 beta-amyloidosis e.g. Alzheimer's disease, comprises a ***beta***
 amyloid peptide containing ***D*** - ***amino***
 acids
 IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;
 Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips
 K; Hayward N J
 PA (PRAE-N) PRAECIS PHARM INC.
 PI US 6277826 B1 20010821 41p
 AI US 1999-356931 19990719
 PRAI US 1997-920162 19970827
 US 1996-703675 19960827
 DT Patent
 LA English
 OS 2001-637856 [73]
 DESC APP70 abeta peptide (residues 17-21) inverso isomer mutant (F19iodo Y).

L5 ANSWER 104 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAE12524 peptide DGENE
 TI Modulator compound for treating disorders associated with
 beta-amyloidosis e.g. Alzheimer's disease, comprises a ***beta***
 amyloid peptide containing ***D*** - ***amino***
 acids
 IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;
 Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips
 K; Hayward N J
 PA (PRAE-N) PRAECIS PHARM INC.
 PI US 6277826 B1 20010821 41p
 AI US 1999-356931 19990719
 PRAI US 1997-920162 19970827
 US 1996-703675 19960827
 DT Patent
 LA English
 OS 2001-637856 [73]

L5 ANSWER 105 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAE12523 peptide DGENE
 TI Modulator compound for treating disorders associated with
 beta-amyloidosis e.g. Alzheimer's disease, comprises a ***beta*** -
 amyloid peptide containing ***D*** - ***amino***
 acids
 IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;
 Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips
 K; Hayward N J
 PA (PRAE-N) PRAECIS PHARM INC.
 PI US 6277826 B1 20010821 41p
 AI US 1999-356931 19990719
 PRAI US 1997-920162 19970827
 US 1996-703675 19960827
 DT Patent
 LA English
 OS 2001-637856 [73]
 DESC APP70 abeta peptide (residues 17-21) inverso isomer mutant (L17A; A21L).

L5 ANSWER 106 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAE12522 peptide DGENE
 TI Modulator compound for treating disorders associated with
 beta-amyloidosis e.g. Alzheimer's disease, comprises a ***beta*** -
 amyloid peptide containing ***D*** - ***amino***
 acids
 IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;
 Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips
 K; Hayward N J
 PA (PRAE-N) PRAECIS PHARM INC.
 PI US 6277826 B1 20010821 41p
 AI US 1999-356931 19990719
 PRAI US 1997-920162 19970827
 US 1996-703675 19960827
 DT Patent
 LA English
 OS 2001-637856 [73]
 DESC APP 770 Abeta peptide (residues 17-21) inverso isomer.

L5 ANSWER 107 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAE12521 peptide DGENE
 TI Modulator compound for treating disorders associated with
 beta-amyloidosis e.g. Alzheimer's disease, comprises a ***beta*** -
 amyloid peptide containing ***D*** - ***amino***
 acids
 IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;
 Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips
 K; Hayward N J
 PA (PRAE-N) PRAECIS PHARM INC.
 PI US 6277826 B1 20010821 41p
 AI US 1999-356931 19990719
 PRAI US 1997-920162 19970827
 US 1996-703675 19960827
 DT Patent
 LA English
 OS 2001-637856 [73]
 DESC APP70 abeta peptide (residues 17-20) inverso isomer mutant (F20A).

L5 ANSWER 108 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAE12520 peptide DGENE
 TI Modulator compound for treating disorders associated with
 beta-amyloidosis e.g. Alzheimer's disease, comprises a ***beta*** -
 amyloid peptide containing ***D*** - ***amino***
 acids
 IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;
 Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips
 K; Hayward N J
 PA (PRAE-N) PRAECIS PHARM INC.
 PI US 6277826 B1 20010821 41p
 AI US 1999-356931 19990719
 PRAI US 1997-920162 19970827
 US 1996-703675 19960827
 DT Patent
 LA English
 OS 2001-637856 [73]

L5 ANSWER 109 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAE12519 peptide DGENE
 TI Modulator compound for treating disorders associated with
 beta-amyloidosis e.g. Alzheimer's disease, comprises a ***beta*** -
 amyloid peptide containing ***D*** - ***amino***
 acids
 IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;
 Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips
 K; Hayward N J
 PA (PRAE-N) PRAECIS PHARM INC.
 PI US 6277826 B1 20010821 41p
 AI US 1999-356931 19990719
 PRAI US 1997-920162 19970827
 US 1996-703675 19960827
 DT Patent
 LA English
 OS 2001-637856 [73]
 DESC APP70 abeta peptide (residues 17-20) inverso isomer mutant (F19Y).

L5 ANSWER 110 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAE12518 peptide DGENE
 TI Modulator compound for treating disorders associated with
 beta-amyloidosis e.g. Alzheimer's disease, comprises a ***beta*** -
 amyloid peptide containing ***D*** - ***amino***
 acids
 IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;
 Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips
 K; Hayward N J
 PA (PRAE-N) PRAECIS PHARM INC.
 PI US 6277826 B1 20010821 41p
 AI US 1999-356931 19990719
 PRAI US 1997-920162 19970827
 US 1996-703675 19960827
 DT Patent
 LA English
 OS 2001-637856 [73]
 DESC APP 770 Abeta peptide (residues 17-20) inverso isomer #2.

L5 ANSWER 111 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAE12517 peptide DGENE
 TI Modulator compound for treating disorders associated with
 beta-amyloidosis e.g. Alzheimer's disease, comprises a ***beta*** -
 amyloid peptide containing ***D*** - ***amino***
 acids
 IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;
 Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips
 K; Hayward N J
 PA (PRAE-N) PRAECIS PHARM INC.
 PI US 6277826 B1 20010821 41p
 AI US 1999-356931 19990719
 PRAI US 1997-920162 19970827
 US 1996-703675 19960827
 DT Patent
 LA English
 OS 2001-637856 [73]
 DESC APP 770 Abeta peptide (residues 17-20) inverso isomer #1.

L5 ANSWER 112 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAE12515 peptide DGENE
 TI Modulator compound for treating disorders associated with
 beta-amyloidosis e.g. Alzheimer's disease, comprises a ***beta*** -
 amyloid peptide containing ***D*** - ***amino***
 acids
 IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;
 Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips
 K; Hayward N J
 PA (PRAE-N) PRAECIS PHARM INC.
 PI US 6277826 B1 20010821 41p
 AI US 1999-356931 19990719
 PRAI US 1997-920162 19970827
 US 1996-703675 19960827
 DT Patent
 LA English
 OS 2001-637856 [73]

Abeta peptide (residues 17-20).

L5 ANSWER 113 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAE12514 peptide DGENE
TI Modulator compound for treating disorders associated with
beta-amyloidosis e.g. Alzheimer's disease, comprises a ***beta*** -
amyloid peptide containing ***D*** - ***amino***
acids
IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;
Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips
K; Hayward N J
PA (PRAE-N) PRAECIS PHARM INC.
PI US 6277826 B1 20010821 41p
AI US 1999-356931 19990719
PRAI US 1997-920162 19970827
US 1996-703675 19960827
DT Patent
LA English
OS 2001-637856 [73]
DESC APP 770 Abeta peptide retro inverso isomer mutant (A21F).

L5 ANSWER 114 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAE12513 peptide DGENE
TI Modulator compound for treating disorders associated with
beta-amyloidosis e.g. Alzheimer's disease, comprises a ***beta*** -
amyloid peptide containing ***D*** - ***amino***
acids
IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;
Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips
K; Hayward N J
PA (PRAE-N) PRAECIS PHARM INC.
PI US 6277826 B1 20010821 41p
AI US 1999-356931 19990719
PRAI US 1997-920162 19970827
US 1996-703675 19960827
DT Patent
LA English
OS 2001-637856 [73]
DESC APP 770 Abeta peptide retro inverso isomer mutant (A21L).

L5 ANSWER 115 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAE12512 peptide DGENE
TI Modulator compound for treating disorders associated with
beta-amyloidosis e.g. Alzheimer's disease, comprises a ***beta*** -
amyloid peptide containing ***D*** - ***amino***
acids
IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;
Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips
K; Hayward N J
PA (PRAE-N) PRAECIS PHARM INC.
PI US 6277826 B1 20010821 41p
AI US 1999-356931 19990719
PRAI US 1997-920162 19970827
US 1996-703675 19960827
DT Patent
LA English
OS 2001-637856 [73]
DESC APP 770 Abeta peptide retro inverso isomer mutant (V18L).

L5 ANSWER 116 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAE12511 peptide DGENE
TI Modulator compound for treating disorders associated with
beta-amyloidosis e.g. Alzheimer's disease, comprises a ***beta*** -
amyloid peptide containing ***D*** - ***amino***
acids
IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;
Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips
K; Hayward N J
PA (PRAE-N) PRAECIS PHARM INC.
PI US 6277826 B1 20010821 41p
AI US 1999-356931 19990719
PRAI US 1997-920162 19970827
US 1996-703675 19960827
DT Patent
LA English

DESC APP 770 Abeta peptide (residues 17-21) retro inverso isomer.

L5 ANSWER 117 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAE12510 peptide DGENE
TI Modulator compound for treating disorders associated with
beta-amyloidosis e.g. Alzheimer's disease, comprises a ***beta*** -
amyloid peptide containing ***D*** - ***amino***
acids -

IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;
Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips
K; Hayward N J
(PRAE-N) PRAECIS PHARM INC.
PI US 6277826 B1 20010821 41p
AI US 1999-356931 19990719
PRAI US 1997-920162 19970827
US 1996-703675 19960827
OT Patent
LA English
OS 2001-637856 [73]
DESC ***Beta*** - ***amyloid*** ***precursor*** ***protein***
Abeta peptide (residues 17-21).

L5 ANSWER 118 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAE12509 peptide DGENE
TI Modulator compound for treating disorders associated with
beta-amyloidosis e.g. Alzheimer's disease, comprises a ***beta*** -
amyloid peptide containing ***D*** - ***amino***
acids -

IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;
Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips
K; Hayward N J
(PRAE-N) PRAECIS PHARM INC.
PI US 6277826 B1 20010821 41p
AI US 1999-356931 19990719
PRAI US 1997-920162 19970827
US 1996-703675 19960827
OT Patent
LA English
OS 2001-637856 [73]
DESC ***Beta*** - ***amyloid*** ***precursor*** ***protein***
(APP-770) fragment.

L5 ANSWER 119 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAE12508 peptide DGENE
TI Modulator compound for treating disorders associated with
beta-amyloidosis e.g. Alzheimer's disease, comprises a ***beta*** -
amyloid peptide containing ***D*** - ***amino***
acids -

IN Findeis M A; Gefter M L; Musso G; Signer E R; Wakefield J; Molineaux S;
Chin J; Lee J; Kelley M; Komar-Panicucci S; Arico-Muendel C C; Phillips
K; Hayward N J
(PRAE-N) PRAECIS PHARM INC.
PI US 6277826 B1 20010821 41p
AI US 1999-356931 19990719
PRAI US 1997-920162 19970827
US 1996-703675 19960827
OT Patent
LA English
OS 2001-637856 [73]
DESC ***Beta*** - ***amyloid*** peptide (AP) of ***beta*** -
amyloid ***precursor*** ***protein*** (APP-770).

L5 ANSWER 120 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB62806 peptide DGENE
TI Chemical compound/composition for e.g. treating neurodegenerative
diseases, comprises peptide comprising Nalpha substituted alpha- ***D***
- ***amino*** - ***acid*** residues which inhibit the aggregation of
other proteins/peptides into beta-sheet -

IN Stott K
PA (STOT-I) STOTT K.
PI WO 2001007474 A1 20010201 76p
AI WO 2000-GB2923 20000728
PRAI GB 1999-17725 19990728
OT Patent
LA English

DESC Peptide X version 2 used to inhibit ***beta*** - ***amyloid*** peptide aggregation.

L5 ANSWER 121 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB62805 peptide DGENE
TI Chemical compound/composition for e.g. treating neurodegenerative diseases, comprises peptide comprising Nalpha substituted alpha- ***D*** - ***amino*** - ***acid*** residues which inhibit the aggregation of other proteins/peptides into beta-sheet -

IN Stott K
PA (STOT-I) STOTT K.
PI WO 2001007474 A1 20010201 76p
AI WO 2000-GB2923 20000728
PRAI GB 1999-17725 19990728
DT Patent
LA English
OS 2001-168537 [17]
DESC ***Beta*** - ***amyloid*** peptide related amino acid sequence.

L5 ANSWER 122 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB62804 peptide DGENE
TI Chemical compound/composition for e.g. treating neurodegenerative diseases, comprises peptide comprising Nalpha substituted alpha- ***D*** - ***amino*** - ***acid*** residues which inhibit the aggregation of other proteins/peptides into beta-sheet -

IN Stott K
PA (STOT-I) STOTT K.
PI WO 2001007474 A1 20010201 76p
AI WO 2000-GB2923 20000728
PRAI GB 1999-17725 19990728
DT Patent
LA English
OS 2001-168537 [17]
DESC Peptide X used to inhibit ***beta*** - ***amyloid*** peptide aggregation.

L5 ANSWER 123 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB62803 peptide DGENE
TI Chemical compound/composition for e.g. treating neurodegenerative diseases, comprises peptide comprising Nalpha substituted alpha- ***D*** - ***amino*** - ***acid*** residues which inhibit the aggregation of other proteins/peptides into beta-sheet -

IN Stott K
PA (STOT-I) STOTT K.
PI WO 2001007474 A1 20010201 76p
AI WO 2000-GB2923 20000728
PRAI GB 1999-17725 19990728
DT Patent
LA English
OS 2001-168537 [17]
DESC Residues 16-20 of ***beta*** - ***amyloid*** peptide.

L5 ANSWER 124 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAY56104 peptide DGENE
TI Compound comprising a peptidic structure, an amino-terminal modifying group and a carboxy-terminal modifying group, useful for treating Alzheimer's disease -

IN Wakefield J; Molineaux S; Signer E R; Kelley M; Komar-Panicucci S; Musso G; Phillips K; Hayward N J; Gefter M L; Findeis M A; Lee J; Arico-Muendel C C; Chin J
PA (PRAE-N) PRAECIS PHARM INC.
PI US 5985242 A 19991116 40p
AI US 1997-920162 19970827
PRAI US 1995-548998 19951027
US 1996-616081 19960314
US 1996-703675 19960827
US 1997-897342 19970721
DT Patent
LA English
OS 2000-022266 [02]
DESC Peptide SEQ ID NO:31.

L5 ANSWER 125 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAY56103 peptide DGENE
TI Compound comprising a peptidic structure, an amino-terminal modifying

Alzheimer's disease -
 IN Wakefield J; Molineaux S; Signer E R; Kelley M; Komar-Panicucci S; Musso G; Phillips K; Hayward N J; Gefter M L; Findeis M A; Lee J; Arico-Muendel C C; Chin J
 PA (PRAE-N) PRAECIS PHARM INC.
 PI US 5985242 A 19991116 40p
 AI US 1997-920162 19970827
 PRAI US 1995-548998 19951027
 US 1996-616081 19960314
 US 1996-703675 19960827
 US 1997-897342 19970721
 DT Patent
 LA English
 OS 2000-022266 [02]
 DESC ***Beta*** ***amyloid*** ***precursor*** ***protein***
 APP-770 peptide sequence from 672.

L5 ANSWER 126 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAY56102 peptide DGENE
 TI Compound comprising a peptidic structure, an amino-terminal modifying group and a carboxy-terminal modifying group, useful for treating Alzheimer's disease -
 IN Wakefield J; Molineaux S; Signer E R; Kelley M; Komar-Panicucci S; Musso G; Phillips K; Hayward N J; Gefter M L; Findeis M A; Lee J; Arico-Muendel C C; Chin J
 PA (PRAE-N) PRAECIS PHARM INC.
 PI US 5985242 A 19991116 40p
 AI US 1997-920162 19970827
 PRAI US 1995-548998 19951027
 US 1996-616081 19960314
 US 1996-703675 19960827
 US 1997-897342 19970721
 DT Patent
 LA English
 OS 2000-022266 [02]
 DESC Natural ***beta*** ***amyloid*** peptide 43 amino acid sequence.

L5 ANSWER 127 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAY56101 peptide DGENE
 TI Compound comprising a peptidic structure, an amino-terminal modifying group and a carboxy-terminal modifying group, useful for treating Alzheimer's disease -
 IN Wakefield J; Molineaux S; Signer E R; Kelley M; Komar-Panicucci S; Musso G; Phillips K; Hayward N J; Gefter M L; Findeis M A; Lee J; Arico-Muendel C C; Chin J
 PA (PRAE-N) PRAECIS PHARM INC.
 PI US 5985242 A 19991116 40p
 AI US 1997-920162 19970827
 PRAI US 1995-548998 19951027
 US 1996-616081 19960314
 US 1996-703675 19960827
 US 1997-897342 19970721
 DT Patent
 LA English
 OS 2000-022266 [02]
 DESC Natural ***beta*** ***amyloid*** peptide aggregation modulating compound #8.

L5 ANSWER 128 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAY50000 peptide DGENE
 TI Compound comprising a peptidic structure, an amino-terminal modifying group and a carboxy-terminal modifying group, useful for treating Alzheimer's disease -
 IN Wakefield J; Molineaux S; Signer E R; Kelley M; Komar-Panicucci S; Musso G; Phillips K; Hayward N J; Gefter M L; Findeis M A; Lee J; Arico-Muendel C C; Chin J
 PA (PRAE-N) PRAECIS PHARM INC.
 PI US 5985242 A 19991116 40p
 AI US 1997-920162 19970827
 PRAI US 1995-548998 19951027
 US 1996-616081 19960314
 US 1996-703675 19960827
 US 1997-897342 19970721
 DT Patent
 LA English

DESC Natural ***beta*** ***amyloid*** peptide aggregation modulating compound #7.

L5 ANSWER 129 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAY49999 peptide DGENE
TI Compound comprising a peptidic structure, an amino-terminal modifying group and a carboxy-terminal modifying group, useful for treating Alzheimer's disease -
IN Wakefield J; Molineaux S; Signer E R; Kelley M; Komar-Panicucci S; Musso G; Phillips K; Hayward N J; Gefter M L; Findeis M A; Lee J; Arico-Muendel C C; Chin J
PA (PRAE-N) PRAECIS PHARM INC.
PI US 5985242 A 19991116 40p
AI US 1997-920162 19970827
PRAI US 1995-548998 19951027
US 1996-616081 19960314
US 1996-703675 19960827
US 1997-897342 19970721
DT Patent
LA English
OS 2000-022266 [02]
DESC Natural ***beta*** ***amyloid*** peptide aggregation modulating compound #6.

L5 ANSWER 130 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAY49998 peptide DGENE
TI Compound comprising a peptidic structure, an amino-terminal modifying group and a carboxy-terminal modifying group, useful for treating Alzheimer's disease -
IN Wakefield J; Molineaux S; Signer E R; Kelley M; Komar-Panicucci S; Musso G; Phillips K; Hayward N J; Gefter M L; Findeis M A; Lee J; Arico-Muendel C C; Chin J
PA (PRAE-N) PRAECIS PHARM INC.
PI US 5985242 A 19991116 40p
AI US 1997-920162 19970827
PRAI US 1995-548998 19951027
US 1996-616081 19960314
US 1996-703675 19960827
US 1997-897342 19970721
DT Patent
LA English
OS 2000-022266 [02]
DESC Natural ***beta*** ***amyloid*** peptide aggregation modulating compound #5.

L5 ANSWER 131 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAY49997 peptide DGENE
TI Compound comprising a peptidic structure, an amino-terminal modifying group and a carboxy-terminal modifying group, useful for treating Alzheimer's disease -
IN Wakefield J; Molineaux S; Signer E R; Kelley M; Komar-Panicucci S; Musso G; Phillips K; Hayward N J; Gefter M L; Findeis M A; Lee J; Arico-Muendel C C; Chin J
PA (PRAE-N) PRAECIS PHARM INC.
PI US 5985242 A 19991116 40p
AI US 1997-920162 19970827
PRAI US 1995-548998 19951027
US 1996-616081 19960314
US 1996-703675 19960827
US 1997-897342 19970721
DT Patent
LA English
OS 2000-022266 [02]
DESC Natural ***beta*** ***amyloid*** peptide aggregation modulating compound #4.

L5 ANSWER 132 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAY49996 peptide DGENE
TI Compound comprising a peptidic structure, an amino-terminal modifying group and a carboxy-terminal modifying group, useful for treating Alzheimer's disease -
IN Wakefield J; Molineaux S; Signer E R; Kelley M; Komar-Panicucci S; Musso G; Phillips K; Hayward N J; Gefter M L; Findeis M A; Lee J; Arico-Muendel C C; Chin J
PA (PRAE-N) PRAECIS PHARM INC.

AI	US 1997-920162	19970827	
PRAI	US 1995-548998	19951027	
	US 1996-616081	19960314	
	US 1996-703675	19960827	
	US 1997-897342	19970721	
DT	Patent		
LA	English		
OS	2000-022266 [02]		
DESC	Natural ***beta***	***amyloid***	peptide aggregation modulating compound #3.
L5	ANSWER 133 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN		
AN	AA49995 peptide	DGENE	
TI	Compound comprising a peptidic structure, an amino-terminal modifying group and a carboxy-terminal modifying group, useful for treating Alzheimer's disease -		
IN	Wakefield J; Molineaux S; Signer E R; Kelley M; Komar-Panicucci S; Musso G; Phillips K; Hayward N J; Gefter M L; Findeis M A; Lee J; Arico-Muendel C C; Chin J		
PA	(PRAE-N)	PRAECIS PHARM INC.	
PI	US 5985242 A	19991116	40p
AI	US 1997-920162	19970827	
PRAI	US 1995-548998	19951027	
	US 1996-616081	19960314	
	US 1996-703675	19960827	
	US 1997-897342	19970721	
DT	Patent		
LA	English		
OS	2000-022266 [02]		
DESC	Natural ***beta***	***amyloid***	peptide aggregation modulating compound #2.
L5	ANSWER 134 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN		
AN	AA49994 peptide	DGENE	
TI	Compound comprising a peptidic structure, an amino-terminal modifying group and a carboxy-terminal modifying group, useful for treating Alzheimer's disease -		
IN	Wakefield J; Molineaux S; Signer E R; Kelley M; Komar-Panicucci S; Musso G; Phillips K; Hayward N J; Gefter M L; Findeis M A; Lee J; Arico-Muendel C C; Chin J		
PA	(PRAE-N)	PRAECIS PHARM INC.	
PI	US 5985242 A	19991116	40p
AI	US 1997-920162	19970827	
PRAI	US 1995-548998	19951027	
	US 1996-616081	19960314	
	US 1996-703675	19960827	
	US 1997-897342	19970721	
DT	Patent		
LA	English		
OS	2000-022266 [02]		
DESC	Natural ***beta***	***amyloid***	peptide aggregation modulating compound #1.
L5	ANSWER 135 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN		
AN	AA49993 peptide	DGENE	
TI	Compound comprising a peptidic structure, an amino-terminal modifying group and a carboxy-terminal modifying group, useful for treating Alzheimer's disease -		
IN	Wakefield J; Molineaux S; Signer E R; Kelley M; Komar-Panicucci S; Musso G; Phillips K; Hayward N J; Gefter M L; Findeis M A; Lee J; Arico-Muendel C C; Chin J		
PA	(PRAE-N)	PRAECIS PHARM INC.	
PI	US 5985242 A	19991116	40p
AI	US 1997-920162	19970827	
PRAI	US 1995-548998	19951027	
	US 1996-616081	19960314	
	US 1996-703675	19960827	
	US 1997-897342	19970721	
DT	Patent		
LA	English		
OS	2000-022266 [02]		
DESC	Natural ***beta***	***amyloid***	peptide aggregation modulating peptide #21.
L5	ANSWER 136 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN		

TI Compound comprising a peptidic structure, an amino-terminal modifying group and a carboxy-terminal modifying group, useful for treating Alzheimer's disease -
 IN Wakefield J; Molineaux S; Signer E R; Kelley M; Komar-Panicucci S; Musso G; Phillips K; Hayward N J; Gefter M L; Findeis M A; Lee J; Arico-Muendel C C; Chin J
 PA (PRAE-N) PRAECIS PHARM INC.
 PI US 5985242 A 19991116 40p
 AI US 1997-920162 19970827
 PRAI US 1995-548998 19951027
 US 1996-616081 19960314
 US 1996-703675 19960827
 US 1997-897342 19970721
 DT Patent
 LA English
 OS 2000-022266 [02]
 DESC Natural ***beta*** ***amyloid*** peptide aggregation modulating peptide #20.

L5 ANSWER 137 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAY49991 peptide DGENE
 TI Compound comprising a peptidic structure, an amino-terminal modifying group and a carboxy-terminal modifying group, useful for treating Alzheimer's disease -
 IN Wakefield J; Molineaux S; Signer E R; Kelley M; Komar-Panicucci S; Musso G; Phillips K; Hayward N J; Gefter M L; Findeis M A; Lee J; Arico-Muendel C C; Chin J
 PA (PRAE-N) PRAECIS PHARM INC.
 PI US 5985242 A 19991116 40p
 AI US 1997-920162 19970827
 PRAI US 1995-548998 19951027
 US 1996-616081 19960314
 US 1996-703675 19960827
 US 1997-897342 19970721
 DT Patent
 LA English
 OS 2000-022266 [02]
 DESC Natural ***beta*** ***amyloid*** peptide aggregation modulating peptide #19.

L5 ANSWER 138 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAY49990 peptide DGENE
 TI Compound comprising a peptidic structure, an amino-terminal modifying group and a carboxy-terminal modifying group, useful for treating Alzheimer's disease -
 IN Wakefield J; Molineaux S; Signer E R; Kelley M; Komar-Panicucci S; Musso G; Phillips K; Hayward N J; Gefter M L; Findeis M A; Lee J; Arico-Muendel C C; Chin J
 PA (PRAE-N) PRAECIS PHARM INC.
 PI US 5985242 A 19991116 40p
 AI US 1997-920162 19970827
 PRAI US 1995-548998 19951027
 US 1996-616081 19960314
 US 1996-703675 19960827
 US 1997-897342 19970721
 DT Patent
 LA English
 OS 2000-022266 [02]
 DESC Natural ***beta*** ***amyloid*** peptide aggregation modulating peptide #18.

L5 ANSWER 139 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAY49989 peptide DGENE
 TI Compound comprising a peptidic structure, an amino-terminal modifying group and a carboxy-terminal modifying group, useful for treating Alzheimer's disease -
 IN Wakefield J; Molineaux S; Signer E R; Kelley M; Komar-Panicucci S; Musso G; Phillips K; Hayward N J; Gefter M L; Findeis M A; Lee J; Arico-Muendel C C; Chin J
 PA (PRAE-N) PRAECIS PHARM INC.
 PI US 5985242 A 19991116 40p
 AI US 1997-920162 19970827
 PRAI US 1995-548998 19951027
 US 1996-616081 19960314
 US 1996-703675 19960827

DT Patent
 LA English
 OS 2000-022266 [02]
 DESC Natural ***beta*** ***amyloid*** peptide aggregation modulating peptide #17.

L5 ANSWER 140 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAY49988 peptide DGENE
 TI Compound comprising a peptidic structure, an amino-terminal modifying group and a carboxy-terminal modifying group, useful for treating Alzheimer's disease -
 IN Wakefield J; Molineaux S; Signer E R; Kelley M; Komar-Panicucci S; Musso G; Phillips K; Hayward N J; Gefter M L; Findeis M A; Lee J; Arico-Muendel C C; Chin J
 PA (PRAE-N) PRAECIS PHARM INC.
 PI US 5985242 A 19991116 40p
 AI US 1997-920162 19970827
 PRAI US 1995-548998 19951027
 US 1996-616081 19960314
 US 1996-703675 19960827
 US 1997-897342 19970721

DT Patent
 LA English
 OS 2000-022266 [02]
 DESC Natural ***beta*** ***amyloid*** peptide aggregation modulating peptide #16.

L5 ANSWER 141 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAY49987 peptide DGENE
 TI Compound comprising a peptidic structure, an amino-terminal modifying group and a carboxy-terminal modifying group, useful for treating Alzheimer's disease -
 IN Wakefield J; Molineaux S; Signer E R; Kelley M; Komar-Panicucci S; Musso G; Phillips K; Hayward N J; Gefter M L; Findeis M A; Lee J; Arico-Muendel C C; Chin J
 PA (PRAE-N) PRAECIS PHARM INC.
 PI US 5985242 A 19991116 40p
 AI US 1997-920162 19970827
 PRAI US 1995-548998 19951027
 US 1996-616081 19960314
 US 1996-703675 19960827
 US 1997-897342 19970721

DT Patent
 LA English
 OS 2000-022266 [02]
 DESC Natural ***beta*** ***amyloid*** peptide aggregation modulating peptide #15.

L5 ANSWER 142 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAY49986 peptide DGENE
 TI Compound comprising a peptidic structure, an amino-terminal modifying group and a carboxy-terminal modifying group, useful for treating Alzheimer's disease -
 IN Wakefield J; Molineaux S; Signer E R; Kelley M; Komar-Panicucci S; Musso G; Phillips K; Hayward N J; Gefter M L; Findeis M A; Lee J; Arico-Muendel C C; Chin J
 PA (PRAE-N) PRAECIS PHARM INC.
 PI US 5985242 A 19991116 40p
 AI US 1997-920162 19970827
 PRAI US 1995-548998 19951027
 US 1996-616081 19960314
 US 1996-703675 19960827
 US 1997-897342 19970721

DT Patent
 LA English
 OS 2000-022266 [02]
 DESC Natural ***beta*** ***amyloid*** peptide aggregation modulating peptide #14.

L5 ANSWER 143 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAY49985 peptide DGENE
 TI Compound comprising a peptidic structure, an amino-terminal modifying group and a carboxy-terminal modifying group, useful for treating Alzheimer's disease -
 IN Wakefield J; Molineaux S; Signer E R; Kelley M; Komar-Panicucci S; Musso

C C; Chin J
 PA (PRAE-N) PRAECIS PHARM INC.
 PI US 5985242 A 19991116 40p
 AI US 1997-920162 19970827
 PRAI US 1995-548998 19951027
 US 1996-616081 19960314
 US 1996-703675 19960827
 US 1997-897342 19970721
 DT Patent
 LA English
 OS 2000-022266 [02]
 DESC Natural ***beta*** ***amyloid*** peptide aggregation modulating peptide #13.

L5 ANSWER 144 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAY49984 peptide DGENE
 TI Compound comprising a peptidic structure, an amino-terminal modifying group and a carboxy-terminal modifying group, useful for treating Alzheimer's disease -
 IN Wakefield J; Molineaux S; Signer E R; Kelley M; Komar-Panicucci S; Musso G; Phillips K; Hayward N J; Gefter M L; Findeis M A; Lee J; Arico-Muendel C C; Chin J
 PA (PRAE-N) PRAECIS PHARM INC.
 PI US 5985242 A 19991116 40p
 AI US 1997-920162 19970827
 PRAI US 1995-548998 19951027
 US 1996-616081 19960314
 US 1996-703675 19960827
 US 1997-897342 19970721
 DT Patent
 LA English
 OS 2000-022266 [02]
 DESC Natural ***beta*** ***amyloid*** peptide aggregation modulating peptide #12.

L5 ANSWER 145 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAY49983 peptide DGENE
 TI Compound comprising a peptidic structure, an amino-terminal modifying group and a carboxy-terminal modifying group, useful for treating Alzheimer's disease -
 IN Wakefield J; Molineaux S; Signer E R; Kelley M; Komar-Panicucci S; Musso G; Phillips K; Hayward N J; Gefter M L; Findeis M A; Lee J; Arico-Muendel C C; Chin J
 PA (PRAE-N) PRAECIS PHARM INC.
 PI US 5985242 A 19991116 40p
 AI US 1997-920162 19970827
 PRAI US 1995-548998 19951027
 US 1996-616081 19960314
 US 1996-703675 19960827
 US 1997-897342 19970721
 DT Patent
 LA English
 OS 2000-022266 [02]
 DESC Natural ***beta*** ***amyloid*** peptide aggregation modulating peptide #11.

L5 ANSWER 146 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAY49982 peptide DGENE
 TI Compound comprising a peptidic structure, an amino-terminal modifying group and a carboxy-terminal modifying group, useful for treating Alzheimer's disease -
 IN Wakefield J; Molineaux S; Signer E R; Kelley M; Komar-Panicucci S; Musso G; Phillips K; Hayward N J; Gefter M L; Findeis M A; Lee J; Arico-Muendel C C; Chin J
 PA (PRAE-N) PRAECIS PHARM INC.
 PI US 5985242 A 19991116 40p
 AI US 1997-920162 19970827
 PRAI US 1995-548998 19951027
 US 1996-616081 19960314
 US 1996-703675 19960827
 US 1997-897342 19970721
 DT Patent
 LA English
 OS 2000-022266 [02]
 DESC Natural ***beta*** ***amyloid*** peptide aggregation modulating

L5 ANSWER 147 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAY49981 peptide DGENE
 TI Compound comprising a peptidic structure, an amino-terminal modifying group and a carboxy-terminal modifying group, useful for treating Alzheimer's disease -
 IN Wakefield J; Molineaux S; Signer E R; Kelley M; Komar-Panicucci S; Musso G; Phillips K; Hayward N J; Gefter M L; Findeis M A; Lee J; Arico-Muendel C C; Chin J
 PA (PRAE-N) PRAECIS PHARM INC.
 PI US 5985242 A 19991116 40p
 AI US 1997-920162 19970827
 PRAI US 1995-548998 19951027
 US 1996-616081 19960314
 US 1996-703675 19960827
 US 1997-897342 19970721
 DT Patent
 LA English
 OS 2000-022266 [02]
 DESC Natural ***beta*** ***amyloid*** peptide aggregation modulating peptide #9.

L5 ANSWER 148 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAY49980 peptide DGENE
 TI Compound comprising a peptidic structure, an amino-terminal modifying group and a carboxy-terminal modifying group, useful for treating Alzheimer's disease -
 IN Wakefield J; Molineaux S; Signer E R; Kelley M; Komar-Panicucci S; Musso G; Phillips K; Hayward N J; Gefter M L; Findeis M A; Lee J; Arico-Muendel C C; Chin J
 PA (PRAE-N) PRAECIS PHARM INC.
 PI US 5985242 A 19991116 40p
 AI US 1997-920162 19970827
 PRAI US 1995-548998 19951027
 US 1996-616081 19960314
 US 1996-703675 19960827
 US 1997-897342 19970721
 DT Patent
 LA English
 OS 2000-022266 [02]
 DESC Natural ***beta*** ***amyloid*** peptide aggregation modulating peptide #8.

L5 ANSWER 149 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAY49979 peptide DGENE
 TI Compound comprising a peptidic structure, an amino-terminal modifying group and a carboxy-terminal modifying group, useful for treating Alzheimer's disease -
 IN Wakefield J; Molineaux S; Signer E R; Kelley M; Komar-Panicucci S; Musso G; Phillips K; Hayward N J; Gefter M L; Findeis M A; Lee J; Arico-Muendel C C; Chin J
 PA (PRAE-N) PRAECIS PHARM INC.
 PI US 5985242 A 19991116 40p
 AI US 1997-920162 19970827
 PRAI US 1995-548998 19951027
 US 1996-616081 19960314
 US 1996-703675 19960827
 US 1997-897342 19970721
 DT Patent
 LA English
 OS 2000-022266 [02]
 DESC Natural ***beta*** ***amyloid*** peptide aggregation modulating peptide #7.

L5 ANSWER 150 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAY49978 peptide DGENE
 TI Compound comprising a peptidic structure, an amino-terminal modifying group and a carboxy-terminal modifying group, useful for treating Alzheimer's disease -
 IN Wakefield J; Molineaux S; Signer E R; Kelley M; Komar-Panicucci S; Musso G; Phillips K; Hayward N J; Gefter M L; Findeis M A; Lee J; Arico-Muendel C C; Chin J
 PA (PRAE-N) PRAECIS PHARM INC.
 PI US 5985242 A 19991116 40p
 AI US 1997-920162 19970827

	US 1996-616081	19960314	
	US 1996-703675	19960827	
	US 1997-897342	19970721	
DT	Patent		
LA	English		
OS	2000-022266 [02]		
DESC	Natural ***beta***	***amyloid***	peptide aggregation modulating peptide #6.
L5	ANSWER 151 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN		
AN	AA49977 peptide DGENE		
TI	Compound comprising a peptidic structure, an amino-terminal modifying group and a carboxy-terminal modifying group, useful for treating Alzheimer's disease -		
IN	Wakefield J; Molineaux S; Signer E R; Kelley M; Komar-Panicucci S; Musso G; Phillips K; Hayward N J; Gefter M L; Findeis M A; Lee J; Arico-Muendel C C; Chin J		
PA	(PRAE-N) PRAECIS PHARM INC.		
PI	US 5985242	A 19991116	40p
AI	US 1997-920162	19970827	
PRAI	US 1995-548998	19951027	
	US 1996-616081	19960314	
	US 1996-703675	19960827	
	US 1997-897342	19970721	
DT	Patent		
LA	English		
OS	2000-022266 [02]		
DESC	Natural ***beta***	***amyloid***	peptide aggregation modulating peptide #5.
L5	ANSWER 152 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN		
AN	AA49976 peptide DGENE		
TI	Compound comprising a peptidic structure, an amino-terminal modifying group and a carboxy-terminal modifying group, useful for treating Alzheimer's disease -		
IN	Wakefield J; Molineaux S; Signer E R; Kelley M; Komar-Panicucci S; Musso G; Phillips K; Hayward N J; Gefter M L; Findeis M A; Lee J; Arico-Muendel C C; Chin J		
PA	(PRAE-N) PRAECIS PHARM INC.		
PI	US 5985242	A 19991116	40p
AI	US 1997-920162	19970827	
PRAI	US 1995-548998	19951027	
	US 1996-616081	19960314	
	US 1996-703675	19960827	
	US 1997-897342	19970721	
DT	Patent		
LA	English		
OS	2000-022266 [02]		
DESC	Natural ***beta***	***amyloid***	peptide aggregation modulating peptide #4.
L5	ANSWER 153 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN		
AN	AA49975 peptide DGENE		
TI	Compound comprising a peptidic structure, an amino-terminal modifying group and a carboxy-terminal modifying group, useful for treating Alzheimer's disease -		
IN	Wakefield J; Molineaux S; Signer E R; Kelley M; Komar-Panicucci S; Musso G; Phillips K; Hayward N J; Gefter M L; Findeis M A; Lee J; Arico-Muendel C C; Chin J		
PA	(PRAE-N) PRAECIS PHARM INC.		
PI	US 5985242	A 19991116	40p
AI	US 1997-920162	19970827	
PRAI	US 1995-548998	19951027	
	US 1996-616081	19960314	
	US 1996-703675	19960827	
	US 1997-897342	19970721	
DT	Patent		
LA	English		
OS	2000-022266 [02]		
DESC	Natural ***beta***	***amyloid***	peptide aggregation modulating peptide #3.
L5	ANSWER 154 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN		
AN	AA49974 peptide DGENE		
TI	Compound comprising a peptidic structure, an amino-terminal modifying		

Alzhēimer's disease -
 IN Wakefield J; Molineaux S; Signer E R; Kelley M; Komar-Panicucci S; Musso G; Phillips K; Hayward N J; Gefter M L; Findeis M A; Lee J; Arico-Muendel C C; Chin J
 PA (PRAE-N) PRAECIS PHARM INC.
 PI US 5985242 A 19991116 40p
 AI US 1997-920162 19970827
 PRAI US 1995-548998 19951027
 US 1996-616081 19960314
 US 1996-703675 19960827
 US 1997-897342 19970721
 DT Patent
 LA English
 OS 2000-022266 [02]
 DESC Natural ***beta*** ***amyloid*** peptide aggregation modulating peptide #2.
 L5 ANSWER 155 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAY49973 peptide DGENE
 TI Compound comprising a peptidic structure, an amino-terminal modifying group and a carboxy-terminal modifying group, useful for treating Alzheimer's disease -
 IN Wakefield J; Molineaux S; Signer E R; Kelley M; Komar-Panicucci S; Musso G; Phillips K; Hayward N J; Gefter M L; Findeis M A; Lee J; Arico-Muendel C C; Chin J
 PA (PRAE-N) PRAECIS PHARM INC.
 PI US 5985242 A 19991116 40p
 AI US 1997-920162 19970827
 PRAI US 1995-548998 19951027
 US 1996-616081 19960314
 US 1996-703675 19960827
 US 1997-897342 19970721
 DT Patent
 LA English
 OS 2000-022266 [02]
 DESC Natural ***beta*** ***amyloid*** peptide aggregation modulating peptide #1.
 L5 ANSWER 156 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAB27046 Peptide DGENE
 TI Novel compounds that are useful as modulators of ***beta*** -
 amyloid peptide aggregation in treating amyloidosis, comprises
 D - ***amino*** ***acids***
 IN Findeis M A; Phillips K; Olson G L; Self C
 PA (PRAE-N) PRAECIS PHARM INC.
 PI WO 2000052048 A1 20000908 87p
 AI WO 2000-US5574 20000303
 PRAI US 1999-122736 19990304
 DT Patent
 LA English
 OS 2000-594168 [56]
 DESC ***Beta*** - ***amyloid*** peptide modulator #24.
 L5 ANSWER 157 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAB27045 Peptide DGENE
 TI Novel compounds that are useful as modulators of ***beta*** -
 amyloid peptide aggregation in treating amyloidosis, comprises
 D - ***amino*** ***acids***
 IN Findeis M A; Phillips K; Olson G L; Self C
 PA (PRAE-N) PRAECIS PHARM INC.
 PI WO 2000052048 A1 20000908 87p
 AI WO 2000-US5574 20000303
 PRAI US 1999-122736 19990304
 DT Patent
 LA English
 OS 2000-594168 [56]
 DESC ***Beta*** - ***amyloid*** peptide modulator #23.
 L5 ANSWER 158 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAB27044 Peptide DGENE
 TI Novel compounds that are useful as modulators of ***beta*** -
 amyloid peptide aggregation in treating amyloidosis, comprises
 D - ***amino*** ***acids***
 IN Findeis M A; Phillips K; Olson G L; Self C
 PA (PRAE-N) PRAECIS PHARM INC.

AI WO 2000-US5574 20000303
 PRAI US 1999-122736 19990304
 DT Patent
 LA English
 OS 2000-594168 [56]
 DESC ***Beta*** - ***amyloid*** peptide modulator #22.

L5 ANSWER 159 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAB27043 Peptide DGENE
 TI Novel compounds that are useful as modulators of ***beta*** -
 amyloid peptide aggregation in treating amyloidosis, comprises
 D - ***amino*** ***acids*** -
 IN Findeis M A; Phillips K; Olson G L; Self C
 PA (PRAE-N) PRAECIS PHARM INC.
 PI WO 2000052048 A1 20000908 87p
 AI WO 2000-US5574 20000303
 PRAI US 1999-122736 19990304
 DT Patent
 LA English
 OS 2000-594168 [56]
 DESC ***Beta*** - ***amyloid*** peptide modulator #21.

L5 ANSWER 160 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAB27042 Peptide DGENE
 TI Novel compounds that are useful as modulators of ***beta*** -
 amyloid peptide aggregation in treating amyloidosis, comprises
 D - ***amino*** ***acids*** -
 IN Findeis M A; Phillips K; Olson G L; Self C
 PA (PRAE-N) PRAECIS PHARM INC.
 PI WO 2000052048 A1 20000908 87p
 AI WO 2000-US5574 20000303
 PRAI US 1999-122736 19990304
 DT Patent
 LA English
 OS 2000-594168 [56]
 DESC ***Beta*** - ***amyloid*** peptide modulator #20.

L5 ANSWER 161 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAB27041 Peptide DGENE
 TI Novel compounds that are useful as modulators of ***beta*** -
 amyloid peptide aggregation in treating amyloidosis, comprises
 D - ***amino*** ***acids*** -
 IN Findeis M A; Phillips K; Olson G L; Self C
 PA (PRAE-N) PRAECIS PHARM INC.
 PI WO 2000052048 A1 20000908 87p
 AI WO 2000-US5574 20000303
 PRAI US 1999-122736 19990304
 DT Patent
 LA English
 OS 2000-594168 [56]
 DESC ***Beta*** - ***amyloid*** peptide modulator #19.

L5 ANSWER 162 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAB27040 Peptide DGENE
 TI Novel compounds that are useful as modulators of ***beta*** -
 amyloid peptide aggregation in treating amyloidosis, comprises
 D - ***amino*** ***acids*** -
 IN Findeis M A; Phillips K; Olson G L; Self C
 PA (PRAE-N) PRAECIS PHARM INC.
 PI WO 2000052048 A1 20000908 87p
 AI WO 2000-US5574 20000303
 PRAI US 1999-122736 19990304
 DT Patent
 LA English
 OS 2000-594168 [56]
 DESC ***Beta*** - ***amyloid*** peptide modulator #18.

L5 ANSWER 163 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAB27039 Peptide DGENE
 TI Novel compounds that are useful as modulators of ***beta*** -
 amyloid peptide aggregation in treating amyloidosis, comprises
 D - ***amino*** ***acids*** -
 IN Findeis M A; Phillips K; Olson G L; Self C
 PA (PRAE-N) PRAECIS PHARM INC.
 PI WO 2000052048 A1 20000908 87p

PRAI US 1999-122736 19990304
 DT Patent
 LA English
 OS 2000-594168 [56]
 DESC ***Beta*** - ***amyloid*** peptide modulator #17.

L5 ANSWER 164 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAB27038 Peptide DGENE
 TI Novel compounds that are useful as modulators of ***beta*** -
 amyloid peptide aggregation in treating amyloidosis, comprises
 D - ***amino*** ***acids*** -
 IN Findeis M A; Phillips K; Olson G L; Self C
 PA (PRAE-N) PRAECIS PHARM INC.
 PI WO 2000052048 A1 20000908 87p
 AI WO 2000-US5574 20000303
 PRAI US 1999-122736 19990304
 DT Patent
 LA English
 OS 2000-594168 [56]
 DESC ***Beta*** - ***amyloid*** peptide modulator #16.

L5 ANSWER 165 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAB27037 Peptide DGENE
 TI Novel compounds that are useful as modulators of ***beta*** -
 amyloid peptide aggregation in treating amyloidosis, comprises
 D - ***amino*** ***acids*** -
 IN Findeis M A; Phillips K; Olson G L; Self C
 PA (PRAE-N) PRAECIS PHARM INC.
 PI WO 2000052048 A1 20000908 87p
 AI WO 2000-US5574 20000303
 PRAI US 1999-122736 19990304
 DT Patent
 LA English
 OS 2000-594168 [56]
 DESC ***Beta*** - ***amyloid*** peptide modulator #15.

L5 ANSWER 166 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAB27036 Peptide DGENE
 TI Novel compounds that are useful as modulators of ***beta*** -
 amyloid peptide aggregation in treating amyloidosis, comprises
 D - ***amino*** ***acids*** -
 IN Findeis M A; Phillips K; Olson G L; Self C
 PA (PRAE-N) PRAECIS PHARM INC.
 PI WO 2000052048 A1 20000908 87p
 AI WO 2000-US5574 20000303
 PRAI US 1999-122736 19990304
 DT Patent
 LA English
 OS 2000-594168 [56]
 DESC ***Beta*** - ***amyloid*** peptide modulator #14.

L5 ANSWER 167 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAB27035 Peptide DGENE
 TI Novel compounds that are useful as modulators of ***beta*** -
 amyloid peptide aggregation in treating amyloidosis, comprises
 D - ***amino*** ***acids*** -
 IN Findeis M A; Phillips K; Olson G L; Self C
 PA (PRAE-N) PRAECIS PHARM INC.
 PI WO 2000052048 A1 20000908 87p
 AI WO 2000-US5574 20000303
 PRAI US 1999-122736 19990304
 DT Patent
 LA English
 OS 2000-594168 [56]
 DESC ***Beta*** - ***amyloid*** peptide modulator #13.

L5 ANSWER 168 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAB27034 Peptide DGENE
 TI Novel compounds that are useful as modulators of ***beta*** -
 amyloid peptide aggregation in treating amyloidosis, comprises
 D - ***amino*** ***acids*** -
 IN Findeis M A; Phillips K; Olson G L; Self C
 PA (PRAE-N) PRAECIS PHARM INC.
 PI WO 2000052048 A1 20000908 87p
 AI WO 2000-US5574 20000303

T Patent
A English
S 2000-594168 [56]
ESC ***Beta*** - ***amyloid*** peptide modulator #12.

5 ANSWER 169 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
N AAB27033 Peptide DGENE
I Novel compounds that are useful as modulators of ***beta*** -
amyloid peptide aggregation in treating amyloidosis, comprises
D - ***amino*** ***acids*** -
N Findeis M A; Phillips K; Olson G L; Self C
A (PRAE-N) PRAECIS PHARM INC.
I WO 2000052048 A1 20000908 87p
I WO 2000-US5574 20000303
RAI US 1999-122736 19990304
T Patent
A English
S 2000-594168 [56]
ESC ***Beta*** - ***amyloid*** peptide modulator #11.

5 ANSWER 170 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
N AAB27032 Peptide DGENE
I Novel compounds that are useful as modulators of ***beta*** -
amyloid peptide aggregation in treating amyloidosis, comprises
D - ***amino*** ***acids*** -
N Findeis M A; Phillips K; Olson G L; Self C
A (PRAE-N) PRAECIS PHARM INC.
I WO 2000052048 A1 20000908 87p
I WO 2000-US5574 20000303
RAI US 1999-122736 19990304
T Patent
A English
S 2000-594168 [56]
ESC ***Beta*** - ***amyloid*** peptide modulator #10.

5 ANSWER 171 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
N AAB27031 Peptide DGENE
I Novel compounds that are useful as modulators of ***beta*** -
amyloid peptide aggregation in treating amyloidosis, comprises
D - ***amino*** ***acids*** -
N Findeis M A; Phillips K; Olson G L; Self C
A (PRAE-N) PRAECIS PHARM INC.
I WO 2000052048 A1 20000908 87p
I WO 2000-US5574 20000303
RAI US 1999-122736 19990304
T Patent
A English
S 2000-594168 [56]
ESC ***Beta*** - ***amyloid*** peptide modulator #9.

5 ANSWER 172 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
N AAB27030 Peptide DGENE
I Novel compounds that are useful as modulators of ***beta*** -
amyloid peptide aggregation in treating amyloidosis, comprises
D - ***amino*** ***acids*** -
N Findeis M A; Phillips K; Olson G L; Self C
A (PRAE-N) PRAECIS PHARM INC.
I WO 2000052048 A1 20000908 87p
I WO 2000-US5574 20000303
RAI US 1999-122736 19990304
T Patent
A English
S 2000-594168 [56]
ESC ***Beta*** - ***amyloid*** peptide modulator #8.

5 ANSWER 173 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
N AAB27029 Peptide DGENE
I Novel compounds that are useful as modulators of ***beta*** -
amyloid peptide aggregation in treating amyloidosis, comprises
D - ***amino*** ***acids*** -
N Findeis M A; Phillips K; Olson G L; Self C
A (PRAE-N) PRAECIS PHARM INC.
I WO 2000052048 A1 20000908 87p
I WO 2000-US5574 20000303
RAI US 1999-122736 19990304

LA English
 OS 2000-594168 [56]
 DESC ***Beta*** - ***amyloid*** peptide modulator #7.

L5 ANSWER 174 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAB27028 Peptide DGENE
 TI Novel compounds that are useful as modulators of ***beta*** -
 amyloid peptide aggregation in treating amyloidosis, comprises
 D - ***amino*** ***acids*** -
 IN Findeis M A; Phillips K; Olson G L; Self C
 PA (PRAE-N) PRAECIS PHARM INC.
 PI WO 2000052048 A1 20000908 87p
 AI WO 2000-US5574 20000303
 PRAI US 1999-122736 19990304
 DT Patent
 LA English
 OS 2000-594168 [56]
 DESC ***Beta*** - ***amyloid*** peptide modulator #6.

L5 ANSWER 175 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAB27027 Peptide DGENE
 TI Novel compounds that are useful as modulators of ***beta*** -
 amyloid peptide aggregation in treating amyloidosis, comprises
 D - ***amino*** ***acids*** -
 IN Findeis M A; Phillips K; Olson G L; Self C
 PA (PRAE-N) PRAECIS PHARM INC.
 PI WO 2000052048 A1 20000908 87p
 AI WO 2000-US5574 20000303
 PRAI US 1999-122736 19990304
 DT Patent
 LA English
 OS 2000-594168 [56]
 DESC ***Beta*** - ***amyloid*** peptide modulator #5.

L5 ANSWER 176 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAB27026 Peptide DGENE
 TI Novel compounds that are useful as modulators of ***beta*** -
 amyloid peptide aggregation in treating amyloidosis, comprises
 D - ***amino*** ***acids*** -
 IN Findeis M A; Phillips K; Olson G L; Self C
 PA (PRAE-N) PRAECIS PHARM INC.
 PI WO 2000052048 A1 20000908 87p
 AI WO 2000-US5574 20000303
 PRAI US 1999-122736 19990304
 DT Patent
 LA English
 OS 2000-594168 [56]
 DESC ***Beta*** - ***amyloid*** peptide modulator #4.

L5 ANSWER 177 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAB27025 Peptide DGENE
 TI Novel compounds that are useful as modulators of ***beta*** -
 amyloid peptide aggregation in treating amyloidosis, comprises
 D - ***amino*** ***acids*** -
 IN Findeis M A; Phillips K; Olson G L; Self C
 PA (PRAE-N) PRAECIS PHARM INC.
 PI WO 2000052048 A1 20000908 87p
 AI WO 2000-US5574 20000303
 PRAI US 1999-122736 19990304
 DT Patent
 LA English
 OS 2000-594168 [56]
 DESC ***Beta*** - ***amyloid*** peptide modulator #3.

L5 ANSWER 178 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAB27024 Peptide DGENE
 TI Novel compounds that are useful as modulators of ***beta*** -
 amyloid peptide aggregation in treating amyloidosis, comprises
 D - ***amino*** ***acids*** -
 IN Findeis M A; Phillips K; Olson G L; Self C
 PA (PRAE-N) PRAECIS PHARM INC.
 PI WO 2000052048 A1 20000908 87p
 AI WO 2000-US5574 20000303
 PRAI US 1999-122736 19990304
 DT Patent

OS 2000-594168 [56]
DESC ***Beta*** - ***amyloid*** peptide modulator #2.

L5 ANSWER 179 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB27023 peptide DGENE
TI Novel compounds that are useful as modulators of ***beta*** -
amyloid peptide aggregation in treating amyloidosis, comprises
D - ***amino*** ***acids*** -
IN Findeis M A; Phillips K; Olson G L; Self C
PA (PRAE-N) PRAECIS PHARM INC.
PI WO 2000052048 A1 20000908 87p
AI WO 2000-US5574 20000303
PRAI US 1999-122736 19990304
DT Patent
LA English
OS 2000-594168 [56]
DESC ***Beta*** - ***amyloid*** peptide modulator #1.

L5 ANSWER 180 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB27022 protein DGENE
TI Novel compounds that are useful as modulators of ***beta*** -
amyloid peptide aggregation in treating amyloidosis, comprises
D - ***amino*** ***acids*** -
IN Findeis M A; Phillips K; Olson G L; Self C
PA (PRAE-N) PRAECIS PHARM INC.
PI WO 2000052048 A1 20000908 87p
AI WO 2000-US5574 20000303
PRAI US 1999-122736 19990304
DT Patent
LA English
OS 2000-594168 [56]
DESC ***Beta*** - ***amyloid*** peptide aggregation core domain #2.

L5 ANSWER 181 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB27021 protein DGENE
TI Novel compounds that are useful as modulators of ***beta*** -
amyloid peptide aggregation in treating amyloidosis, comprises
D - ***amino*** ***acids*** -
IN Findeis M A; Phillips K; Olson G L; Self C
PA (PRAE-N) PRAECIS PHARM INC.
PI WO 2000052048 A1 20000908 87p
AI WO 2000-US5574 20000303
PRAI US 1999-122736 19990304
DT Patent
LA English
OS 2000-594168 [56]
DESC ***Beta*** - ***amyloid*** peptide aggregation core domain #1.

L5 ANSWER 182 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB27020 protein DGENE
TI Novel compounds that are useful as modulators of ***beta*** -
amyloid peptide aggregation in treating amyloidosis, comprises
D - ***amino*** ***acids*** -
IN Findeis M A; Phillips K; Olson G L; Self C
PA (PRAE-N) PRAECIS PHARM INC.
PI WO 2000052048 A1 20000908 87p
AI WO 2000-US5574 20000303
PRAI US 1999-122736 19990304
DT Patent
LA English
OS 2000-594168 [56]
DESC ***Beta*** - ***amyloid*** peptide.

L5 ANSWER 183 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW51346 peptide DGENE
TI Peptide compounds which are preferably based on ***beta*** -
amyloid peptide(s) - are useful in treatment of disorders relat
to beta-amyloidosis, especially Alzheimer's disease
IN Arico-muendel C C; Chin J; Findeis M A; Gefter M L; Hayward N J; Kelley
M; Komar-panicucci S; Lee J; Molineaux S; Musso G; Phillips K; Signer E
R; Wakefield J
PA (PRAE-N) PRAECIS PHARM INC.
PI WO 9808868 A1 19980305 92p
AI WO 1997-US15166 19970827
PRAI US 1997-897342 19970721

DT Patent
LA English
OS 1998-216936 [19]
DESC Peptide #29 useful as modulator of ***beta*** - ***amyloid***
peptide aggregation.

L5 ANSWER 184 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW51345 peptide DGENE
TI Peptide compounds which are preferably based on ***beta*** -
amyloid peptide(s) - are useful in treatment of disorders relat
to beta-amyloidosis, especially Alzheimer's disease
IN Arico-muendel C C; Chin J; Findeis M A; Gefter M L; Hayward N J; Kelley
M; Komar-panicucci S; Lee J; Molineaux S; Musso G; Phillips K; Signer E
R; Wakefield J
PA (PRAE-N) PRAECIS PHARM INC.
PI WO 9808868 A1 19980305 92p
AI WO 1997-US15166 19970827
PRAI US 1997-897342 19970721
US 1996-703675 19960827

DT Patent
LA English
OS 1998-216936 [19]
DESC Peptide #28 useful as modulator of ***beta*** - ***amyloid***
peptide aggregation.

L5 ANSWER 185 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW51344 peptide DGENE
TI Peptide compounds which are preferably based on ***beta*** -
amyloid peptide(s) - are useful in treatment of disorders relat
to beta-amyloidosis, especially Alzheimer's disease
IN Arico-muendel C C; Chin J; Findeis M A; Gefter M L; Hayward N J; Kelley
M; Komar-panicucci S; Lee J; Molineaux S; Musso G; Phillips K; Signer E
R; Wakefield J
PA (PRAE-N) PRAECIS PHARM INC.
PI WO 9808868 A1 19980305 92p
AI WO 1997-US15166 19970827
PRAI US 1997-897342 19970721
US 1996-703675 19960827

DT Patent
LA English
OS 1998-216936 [19]
DESC Peptide #27 useful as modulator of ***beta*** - ***amyloid***
peptide aggregation.

L5 ANSWER 186 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW51343 peptide DGENE
TI Peptide compounds which are preferably based on ***beta*** -
amyloid peptide(s) - are useful in treatment of disorders relat
to beta-amyloidosis, especially Alzheimer's disease
IN Arico-muendel C C; Chin J; Findeis M A; Gefter M L; Hayward N J; Kelley
M; Komar-panicucci S; Lee J; Molineaux S; Musso G; Phillips K; Signer E
R; Wakefield J
PA (PRAE-N) PRAECIS PHARM INC.
PI WO 9808868 A1 19980305 92p
AI WO 1997-US15166 19970827
PRAI US 1997-897342 19970721
US 1996-703675 19960827

DT Patent
LA English
OS 1998-216936 [19]
DESC Peptide #26 useful as modulator of ***beta*** - ***amyloid***
peptide aggregation.

L5 ANSWER 187 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW51342 peptide DGENE
TI Peptide compounds which are preferably based on ***beta*** -
amyloid peptide(s) - are useful in treatment of disorders relat
to beta-amyloidosis, especially Alzheimer's disease
IN Arico-muendel C C; Chin J; Findeis M A; Gefter M L; Hayward N J; Kelley
M; Komar-panicucci S; Lee J; Molineaux S; Musso G; Phillips K; Signer E
R; Wakefield J
PA (PRAE-N) PRAECIS PHARM INC.
PI WO 9808868 A1 19980305 92p
AI WO 1997-US15166 19970827
PRAI US 1997-897342 19970721

DT Patent
 LA English
 OS 1998-216936 [19]
 DESC Peptide #25 useful as modulator of ***beta*** - ***amyloid***
 peptide aggregation.

L5 ANSWER 188 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAW51341 peptide DGENE
 TI Peptide compounds which are preferably based on ***beta*** -
 amyloid peptide(s) - are useful in treatment of disorders relat
 to beta-amyloidosis, especially Alzheimer's disease
 IN Arico-muendel C C; Chin J; Findeis M A; Gefter M L; Hayward N J; Kelley
 M; Komar-panicucci S; Lee J; Molineaux S; Musso G; Phillips K; Signer E
 R; Wakefield J
 PA (PRAE-N) PRAECIS PHARM INC.
 PI WO 9808868 A1 19980305 92p
 AI WO 1997-US15166 19970827
 PRAI US 1997-897342 19970721
 US 1996-703675 19960827

DT Patent
 LA English
 OS 1998-216936 [19]
 DESC Peptide #24 useful as modulator of ***beta*** - ***amyloid***
 peptide aggregation.

L5 ANSWER 189 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAW51339 peptide DGENE
 TI Peptide compounds which are preferably based on ***beta*** -
 amyloid peptide(s) - are useful in treatment of disorders relat
 to beta-amyloidosis, especially Alzheimer's disease
 IN Arico-muendel C C; Chin J; Findeis M A; Gefter M L; Hayward N J; Kelley
 M; Komar-panicucci S; Lee J; Molineaux S; Musso G; Phillips K; Signer E
 R; Wakefield J
 PA (PRAE-N) PRAECIS PHARM INC.
 PI WO 9808868 A1 19980305 92p
 AI WO 1997-US15166 19970827
 PRAI US 1997-897342 19970721
 US 1996-703675 19960827

DT Patent
 LA English
 OS 1998-216936 [19]
 DESC Peptide #22 useful as modulator of ***beta*** - ***amyloid***
 peptide aggregation.

L5 ANSWER 190 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAW51338 peptide DGENE
 TI Peptide compounds which are preferably based on ***beta*** -
 amyloid peptide(s) - are useful in treatment of disorders relat
 to beta-amyloidosis, especially Alzheimer's disease
 IN Arico-muendel C C; Chin J; Findeis M A; Gefter M L; Hayward N J; Kelley
 M; Komar-panicucci S; Lee J; Molineaux S; Musso G; Phillips K; Signer E
 R; Wakefield J
 PA (PRAE-N) PRAECIS PHARM INC.
 PI WO 9808868 A1 19980305 92p
 AI WO 1997-US15166 19970827
 PRAI US 1997-897342 19970721
 US 1996-703675 19960827

DT Patent
 LA English
 OS 1998-216936 [19]
 DESC Peptide #21 useful as modulator of ***beta*** - ***amyloid***
 peptide aggregation.

L5 ANSWER 191 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAW51337 peptide DGENE
 TI Peptide compounds which are preferably based on ***beta*** -
 amyloid peptide(s) - are useful in treatment of disorders relat
 to beta-amyloidosis, especially Alzheimer's disease
 IN Arico-muendel C C; Chin J; Findeis M A; Gefter M L; Hayward N J; Kelley
 M; Komar-panicucci S; Lee J; Molineaux S; Musso G; Phillips K; Signer E
 R; Wakefield J
 PA (PRAE-N) PRAECIS PHARM INC.
 PI WO 9808868 A1 19980305 92p
 AI WO 1997-US15166 19970827
 PRAI US 1997-897342 19970721

DT Patent
LA English
OS 1998-216936 [19]
DESC Peptide #20 useful as modulator of ***beta*** - ***amyloid***
peptide aggregation.

L5 ANSWER 192 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW51336 peptide DGENE
TI Peptide compounds which are preferably based on ***beta*** -
amyloid peptide(s) - are useful in treatment of disorders relate
to beta-amyloidosis, especially Alzheimer's disease
IN Arico-muendel C C; Chin J; Findeis M A; Gefter M L; Hayward N J; Kelley
M; Komar-panicucci S; Lee J; Molineaux S; Musso G; Phillips K; Signer E
R; Wakefield J
PA (PRAE-N) PRAECIS PHARM INC.
PI WO 9808868 A1 19980305 92p
AI WO 1997-US15166 19970827
PRAI US 1997-897342 19970721
US 1996-703675 19960827

DT Patent
LA English
OS 1998-216936 [19]
DESC Peptide #19 useful as modulator of ***beta*** - ***amyloid***
peptide aggregation.

L5 ANSWER 193 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW51335 peptide DGENE
TI Peptide compounds which are preferably based on ***beta*** -
amyloid peptide(s) - are useful in treatment of disorders relate
to beta-amyloidosis, especially Alzheimer's disease
IN Arico-muendel C C; Chin J; Findeis M A; Gefter M L; Hayward N J; Kelley
M; Komar-panicucci S; Lee J; Molineaux S; Musso G; Phillips K; Signer E
R; Wakefield J
PA (PRAE-N) PRAECIS PHARM INC.
PI WO 9808868 A1 19980305 92p
AI WO 1997-US15166 19970827
PRAI US 1997-897342 19970721
US 1996-703675 19960827

DT Patent
LA English
OS 1998-216936 [19]
DESC Peptide #18 useful as modulator of ***beta*** - ***amyloid***
peptide aggregation.

L5 ANSWER 194 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW51333 peptide DGENE
TI Peptide compounds which are preferably based on ***beta*** -
amyloid peptide(s) - are useful in treatment of disorders relate
to beta-amyloidosis, especially Alzheimer's disease
IN Arico-muendel C C; Chin J; Findeis M A; Gefter M L; Hayward N J; Kelley
M; Komar-panicucci S; Lee J; Molineaux S; Musso G; Phillips K; Signer E
R; Wakefield J
PA (PRAE-N) PRAECIS PHARM INC.
PI WO 9808868 A1 19980305 92p
AI WO 1997-US15166 19970827
PRAI US 1997-897342 19970721
US 1996-703675 19960827

DT Patent
LA English
OS 1998-216936 [19]
DESC Peptide #16 useful as modulator of ***beta*** - ***amyloid***
peptide aggregation.

L5 ANSWER 195 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW51332 peptide DGENE
TI Peptide compounds which are preferably based on ***beta*** -
amyloid peptide(s) - are useful in treatment of disorders relate
to beta-amyloidosis, especially Alzheimer's disease
IN Arico-muendel C C; Chin J; Findeis M A; Gefter M L; Hayward N J; Kelley
M; Komar-panicucci S; Lee J; Molineaux S; Musso G; Phillips K; Signer E
R; Wakefield J
PA (PRAE-N) PRAECIS PHARM INC.
PI WO 9808868 A1 19980305 92p
AI WO 1997-US15166 19970827
PRAI US 1997-897342 19970721

DT Patent
LA English
OS 1998-216936 [19]
DESC Peptide #15 useful as modulator of ***beta*** - ***amyloid***
peptide aggregation.

L5 ANSWER 196 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW51331 peptide DGENE
TI Peptide compounds which are preferably based on ***beta*** -
amyloid peptide(s) - are useful in treatment of disorders relat
to beta-amyloidosis, especially Alzheimer's disease
IN Arico-muendel C C; Chin J; Findeis M A; Gefter M L; Hayward N J; Kelley
M; Komar-panicucci S; Lee J; Molineaux S; Musso G; Phillips K; Signer E
R; Wakefield J
PA (PRAE-N) PRAECIS PHARM INC.
PI WO 9808868 A1 19980305 92p
AI WO 1997-US15166 19970827
PRAI US 1997-897342 19970721
US 1996-703675 19960827

DT Patent
LA English
OS 1998-216936 [19]
DESC Peptide #14 useful as modulator of ***beta*** - ***amyloid***
peptide aggregation.

L5 ANSWER 197 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW51330 peptide DGENE
TI Peptide compounds which are preferably based on ***beta*** -
amyloid peptide(s) - are useful in treatment of disorders relat
to beta-amyloidosis, especially Alzheimer's disease
IN Arico-muendel C C; Chin J; Findeis M A; Gefter M L; Hayward N J; Kelley
M; Komar-panicucci S; Lee J; Molineaux S; Musso G; Phillips K; Signer E
R; Wakefield J
PA (PRAE-N) PRAECIS PHARM INC.
PI WO 9808868 A1 19980305 92p
AI WO 1997-US15166 19970827
PRAI US 1997-897342 19970721
US 1996-703675 19960827

DT Patent
LA English
OS 1998-216936 [19]
DESC Peptide #13 useful as modulator of ***beta*** - ***amyloid***
peptide aggregation.

L5 ANSWER 198 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW51323 peptide DGENE
TI Peptide compounds which are preferably based on ***beta*** -
amyloid peptide(s) - are useful in treatment of disorders relat
to beta-amyloidosis, especially Alzheimer's disease
IN Arico-muendel C C; Chin J; Findeis M A; Gefter M L; Hayward N J; Kelley
M; Komar-panicucci S; Lee J; Molineaux S; Musso G; Phillips K; Signer E
R; Wakefield J
PA (PRAE-N) PRAECIS PHARM INC.
PI WO 9808868 A1 19980305 92p
AI WO 1997-US15166 19970827
PRAI US 1997-897342 19970721
US 1996-703675 19960827

DT Patent
LA English
OS 1998-216936 [19]
DESC Peptide #6 useful as modulator of ***beta*** - ***amyloid***
peptide aggregation.

L5 ANSWER 199 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW51334 peptide DGENE
TI Peptide compounds which are preferably based on ***beta*** -
amyloid peptide(s) - are useful in treatment of disorders relat
to beta-amyloidosis, especially Alzheimer's disease
IN Arico-muendel C C; Chin J; Findeis M A; Gefter M L; Hayward N J; Kelley
M; Komar-panicucci S; Lee J; Molineaux S; Musso G; Phillips K; Signer E
R; Wakefield J
PA (PRAE-N) PRAECIS PHARM INC.
PI WO 9808868 A1 19980305 92p
AI WO 1997-US15166 19970827
PRAI US 1997-897342 19970721

DT Patent
LA English
OS 1998-216936 [19]
DESC Peptide #17 useful as modulator of ***beta*** - ***amyloid***
peptide aggregation.

L5 ANSWER 200 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW51329 peptide DGENE
TI Peptide compounds which are preferably based on ***beta*** -
amyloid peptide(s) - are useful in treatment of disorders relate
to beta-amyloidosis, especially Alzheimer's disease
IN Arico-muendel C C; Chin J; Findeis M A; Gefter M L; Hayward N J; Kelley
M; Komar-panicucci S; Lee J; Molineaux S; Musso G; Phillips K; Signer E
R; Wakefield J
PA (PRAE-N) PRAECIS PHARM INC.
PI WO 9808868 A1 19980305 92p
AI WO 1997-US15166 19970827
PRAI US 1997-897342 19970721
US 1996-703675 19960827

DT Patent
LA English
OS 1998-216936 [19]
DESC Peptide #12 useful as modulator of ***beta*** - ***amyloid***
peptide aggregation.

L5 ANSWER 201 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW51328 peptide DGENE
TI Peptide compounds which are preferably based on ***beta*** -
amyloid peptide(s) - are useful in treatment of disorders relate
to beta-amyloidosis, especially Alzheimer's disease
IN Arico-muendel C C; Chin J; Findeis M A; Gefter M L; Hayward N J; Kelley
M; Komar-panicucci S; Lee J; Molineaux S; Musso G; Phillips K; Signer E
R; Wakefield J
PA (PRAE-N) PRAECIS PHARM INC.
PI WO 9808868 A1 19980305 92p
AI WO 1997-US15166 19970827
PRAI US 1997-897342 19970721
US 1996-703675 19960827

DT Patent
LA English
OS 1998-216936 [19]
DESC Peptide #11 useful as modulator of ***beta*** - ***amyloid***
peptide aggregation.

L5 ANSWER 202 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW51327 peptide DGENE
TI Peptide compounds which are preferably based on ***beta*** -
amyloid peptide(s) - are useful in treatment of disorders relate
to beta-amyloidosis, especially Alzheimer's disease
IN Arico-muendel C C; Chin J; Findeis M A; Gefter M L; Hayward N J; Kelley
M; Komar-panicucci S; Lee J; Molineaux S; Musso G; Phillips K; Signer E
R; Wakefield J
PA (PRAE-N) PRAECIS PHARM INC.
PI WO 9808868 A1 19980305 92p
AI WO 1997-US15166 19970827
PRAI US 1997-897342 19970721
US 1996-703675 19960827

DT Patent
LA English
OS 1998-216936 [19]
DESC Peptide #10 useful as modulator of ***beta*** - ***amyloid***
peptide aggregation.

L5 ANSWER 203 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW51326 peptide DGENE
TI Peptide compounds which are preferably based on ***beta*** -
amyloid peptide(s) - are useful in treatment of disorders relate
to beta-amyloidosis, especially Alzheimer's disease
IN Arico-muendel C C; Chin J; Findeis M A; Gefter M L; Hayward N J; Kelley
M; Komar-panicucci S; Lee J; Molineaux S; Musso G; Phillips K; Signer E
R; Wakefield J
PA (PRAE-N) PRAECIS PHARM INC.
PI WO 9808868 A1 19980305 92p
AI WO 1997-US15166 19970827
PRAI US 1997-897342 19970721

DT Patent
LA English
OS 1998-216936 [19]
DESC Peptide #9 useful as modulator of ***beta*** - ***amyloid***
peptide aggregation.

L5 ANSWER 204 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW51324 peptide DGENE
TI Peptide compounds which are preferably based on ***beta*** -
amyloid peptide(s) - are useful in treatment of disorders relat
to beta-amyloidosis, especially Alzheimer's disease
IN Arico-muendel C C; Chin J; Findeis M A; Gefter M L; Hayward N J; Kelley
M; Komar-panicucci S; Lee J; Molineaux S; Musso G; Phillips K; Signer E
R; Wakefield J
PA (PRAE-N) PRAECIS PHARM INC.
PI WO 9808868 A1 19980305 92p
AI WO 1997-US15166 19970827
PRAI US 1997-897342 19970721
US 1996-703675 19960827

DT Patent
LA English
OS 1998-216936 [19]
DESC Peptide #7 useful as modulator of ***beta*** - ***amyloid***
peptide aggregation.

L5 ANSWER 205 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW51322 peptide DGENE
TI Peptide compounds which are preferably based on ***beta*** -
amyloid peptide(s) - are useful in treatment of disorders relat
to beta-amyloidosis, especially Alzheimer's disease
IN Arico-muendel C C; Chin J; Findeis M A; Gefter M L; Hayward N J; Kelley
M; Komar-panicucci S; Lee J; Molineaux S; Musso G; Phillips K; Signer E
R; Wakefield J
PA (PRAE-N) PRAECIS PHARM INC.
PI WO 9808868 A1 19980305 92p
AI WO 1997-US15166 19970827
PRAI US 1997-897342 19970721
US 1996-703675 19960827

DT Patent
LA English
OS 1998-216936 [19]
DESC Peptide #5 useful as modulator of ***beta*** - ***amyloid***
peptide aggregation.

L5 ANSWER 206 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW51321 peptide DGENE
TI Peptide compounds which are preferably based on ***beta*** -
amyloid peptide(s) - are useful in treatment of disorders relat
to beta-amyloidosis, especially Alzheimer's disease
IN Arico-muendel C C; Chin J; Findeis M A; Gefter M L; Hayward N J; Kelley
M; Komar-panicucci S; Lee J; Molineaux S; Musso G; Phillips K; Signer E
R; Wakefield J
PA (PRAE-N) PRAECIS PHARM INC.
PI WO 9808868 A1 19980305 92p
AI WO 1997-US15166 19970827
PRAI US 1997-897342 19970721
US 1996-703675 19960827

DT Patent
LA English
OS 1998-216936 [19]
DESC Peptide #4 useful as modulator of ***beta*** - ***amyloid***
peptide aggregation.

L5 ANSWER 207 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW51320 peptide DGENE
TI Peptide compounds which are preferably based on ***beta*** -
amyloid peptide(s) - are useful in treatment of disorders relat
to beta-amyloidosis, especially Alzheimer's disease
IN Arico-muendel C C; Chin J; Findeis M A; Gefter M L; Hayward N J; Kelley
M; Komar-panicucci S; Lee J; Molineaux S; Musso G; Phillips K; Signer E
R; Wakefield J
PA (PRAE-N) PRAECIS PHARM INC.
PI WO 9808868 A1 19980305 92p
AI WO 1997-US15166 19970827
PRAI US 1997-897342 19970721

DT Patent
LA English
OS 1998-216936 [19]
DESC Peptide #3 useful as modulator of ***beta*** - ***amyloid*** peptide aggregation.

L5 ANSWER 208 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW51319 peptide DGENE
TI Peptide compounds which are preferably based on ***beta*** - ***amyloid*** peptide(s) - are useful in treatment of disorders related to beta-amyloidosis, especially Alzheimer's disease
IN Arico-muendel C C; Chin J; Findeis M A; Gefter M L; Hayward N J; Kelley M; Komar-panicucci S; Lee J; Molineaux S; Musso G; Phillips K; Signer E R; Wakefield J
PA (PRAE-N) PRAECIS PHARM INC.
PI WO 9808868 A1 19980305 92p
AI WO 1997-US15166 19970827
PRAI US 1997-897342 19970721
US 1996-703675 19960827

DT Patent
LA English
OS 1998-216936 [19]
DESC Peptide #2 useful as modulator of ***beta*** - ***amyloid*** peptide aggregation.

L5 ANSWER 209 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW51318 peptide DGENE
TI Peptide compounds which are preferably based on ***beta*** - ***amyloid*** peptide(s) - are useful in treatment of disorders related to beta-amyloidosis, especially Alzheimer's disease
IN Arico-muendel C C; Chin J; Findeis M A; Gefter M L; Hayward N J; Kelley M; Komar-panicucci S; Lee J; Molineaux S; Musso G; Phillips K; Signer E R; Wakefield J
PA (PRAE-N) PRAECIS PHARM INC.
PI WO 9808868 A1 19980305 92p
AI WO 1997-US15166 19970827
PRAI US 1997-897342 19970721
US 1996-703675 19960827

DT Patent
LA English
OS 1998-216936 [19]
DESC Peptide #1 useful as modulator of ***beta*** - ***amyloid*** peptide aggregation.

L5 ANSWER 210 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW51317 peptide DGENE
TI Peptide compounds which are preferably based on ***beta*** - ***amyloid*** peptide(s) - are useful in treatment of disorders related to beta-amyloidosis, especially Alzheimer's disease
IN Arico-muendel C C; Chin J; Findeis M A; Gefter M L; Hayward N J; Kelley M; Komar-panicucci S; Lee J; Molineaux S; Musso G; Phillips K; Signer E R; Wakefield J
PA (PRAE-N) PRAECIS PHARM INC.
PI WO 9808868 A1 19980305 92p
AI WO 1997-US15166 19970827
PRAI US 1997-897342 19970721
US 1996-703675 19960827

DT Patent
LA English
OS 1998-216936 [19]
DESC Natural ***beta*** - ***amyloid*** peptide-770, from position 672 to C-terminus.

L5 ANSWER 211 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW51316 peptide DGENE
TI Peptide compounds which are preferably based on ***beta*** - ***amyloid*** peptide(s) - are useful in treatment of disorders related to beta-amyloidosis, especially Alzheimer's disease
IN Arico-muendel C C; Chin J; Findeis M A; Gefter M L; Hayward N J; Kelley M; Komar-panicucci S; Lee J; Molineaux S; Musso G; Phillips K; Signer E R; Wakefield J
PA (PRAE-N) PRAECIS PHARM INC.
PI WO 9808868 A1 19980305 92p
AI WO 1997-US15166 19970827
PRAI US 1997-897342 19970721

DT Patent
 LA English
 OS 1998-216936 [19]
 DESC Natural ***beta*** - ***amyloid*** peptide fragment.

L5 ANSWER 212 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAW51340 peptide DGENE
 TI Peptide compounds which are preferably based on ***beta*** -
 amyloid peptide(s) - are useful in treatment of disorders relate
 to beta-amyloidosis, especially Alzheimer's disease
 IN Arico-muendel C C; Chin J; Findeis M A; Gefter M L; Hayward N J; Kelley
 M; Komar-panicucci S; Lee J; Molineaux S; Musso G; Phillips K; Signer E
 R; Wakefield J
 PA (PRAE-N) PRAECIS PHARM INC.
 PI WO 9808868 A1 19980305 92p
 AI WO 1997-US15166 19970827
 PRAI US 1997-897342 19970721
 US 1996-703675 19960827

DT Patent
 LA English
 OS 1998-216936 [19]
 DESC Peptide #23 useful as modulator of ***beta*** - ***amyloid***
 peptide aggregation.

L5 ANSWER 213 OF 367 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAW51325 peptide DGENE
 TI Peptide compounds which are preferably based on ***beta*** -
 amyloid peptide(s) - are useful in treatment of disorders relate
 to beta-amyloidosis, especially Alzheimer's disease
 IN Arico-muendel C C; Chin J; Findeis M A; Gefter M L; Hayward N J; Kelley
 M; Komar-panicucci S; Lee J; Molineaux S; Musso G; Phillips K; Signer E
 R; Wakefield J
 PA (PRAE-N) PRAECIS PHARM INC.
 PI WO 9808868 A1 19980305 92p
 AI WO 1997-US15166 19970827
 PRAI US 1997-897342 19970721
 US 1996-703675 19960827

DT Patent
 LA English
 OS 1998-216936 [19]
 DESC Peptide #7 useful as modulator of ***beta*** - ***amyloid***
 peptide aggregation.

L5 ANSWER 214 OF 367 FEDRIP COPYRIGHT 2004 NTIS on STN
 AN 2004:141711 FEDRIP
 NR CRISP 5R44AG17787-03
 TI Inhibitors of Alzheimer's Disease Amyloidosis
 SF Principal Investigator: CASTILLO, GERARDO M; CASTILLO@PROTEOTECH.COM,
 PROTEOTECH, INC, 12026 115TH AVE NE
 CSP PROTEOTECH, INC., KIRKLAND, WASHINGTON
 CSS Supported By: NATIONAL INSTITUTE ON AGING
 DB 2004 (/01/00)
 FYR 2003
 DE 2005 (/31/05)
 FU Noncompeting Continuation (Type 5)
 FS National Institutes of Health

L5 ANSWER 215 OF 367 FEDRIP COPYRIGHT 2004 NTIS on STN
 AN 2004:140378 FEDRIP
 NR CRISP 1Z01AG00408-04
 TI TOXICITY OF ***BETA*** - ***AMYLOID*** IN ALZHEIMER'S DISEASE AND
 DOWN SYNDROME
 SF Principal Investigator: GALDZICKI, Z
 CSS Supported By: NATIONAL INSTITUTE ON AGING
 FYR 1997
 FU Not Applicable
 FS National Institutes of Health

L5 ANSWER 216 OF 367 IFIPAT COPYRIGHT 2004 IFI on STN
 AN 10491766 IFIPAT;IFIUDB;IFICDB
 TI MODULATORS OF ***BETA*** - ***AMYLOID*** PEPTIDE AGGREGATION
 IN Findeis Mark A; Olson Gary L; Phillips Kathryn; Self Christopher
 PA Praecis Pharmaceuticals Inc (46269)
 PI US 2003236197 A1 20031225
 AI US 2003-395290 20030324

PRAI US 1999-122736P 19990304 (Provisional)
FI US 2003236197 20031225
US 6610658
DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION
CLMN 14
GI 2 Figure(s).

FIG. 1 is a table depicting the results from a brain uptake assay.
FIG. 2 is a graph depicting the results from the fibril binding assay described in Example 2.

L5 ANSWER 217 OF 367 IFIPAT COPYRIGHT 2004 IFI on STN
AN 10442451 IFIPAT;IFIUDB;IFICDB
TI HELICAL PEPTIDOMIMETICS
IN Wolfe Michael S
PA Brigham and Women's Hospital (8822)
PI US 2003186877 A1 20031002
AI US 2003-367599 20030214
PRAI US 2002-357023P 20020214 (Provisional)
FI US 2003186877 20031002
DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION

CLMN 46
GI 1 Figure(s).

FIG. 1 is a schematic diagram showing various cleavage sites and fragments of APP. Among the fragments are A beta (including A beta 40 and A beta 42).

L5 ANSWER 218 OF 367 IFIPAT COPYRIGHT 2004 IFI on STN
AN 10408140 IFIPAT;IFIUDB;IFICDB
TI VITRO MICRO-ORGANS, AND USES RELATED THERETO
IN Mitrani Eduardo N (IL)
PI US 2003152562 A1 20030814
AI US 2003-376506 20030303
RLI WO 2001-IL976 20011023 CONTINUATION
FI US 2003152562 20030814
DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION

CLMN 73
GI 18 Figure(s).

FIG. 1 is a diagrammatic representation of a micro-organ depicting the dimensions that determine Aleph where x =thickness and a =width of tissue.

FIG. 2 is a histogram showing cell proliferation in a guinea pig micro-organ culture as determined by BrdU labeling after incubation for different time periods.

FIG. 3 is a histogram showing cell proliferation in a human back skin micro-organ culture as determined by BrdU labeling after incubation of cultures for 1-8 days.

FIGS. 4A-4D are micrographs showing immunofluorescence corresponding to replicating cells of mouse skin (mag. 50 x) (FIG. 4A), guinea pig skin (mag. 75 x) (FIG. 4B) human foreskin (mag. 50 x) (FIG. 4C) and human foreskin (mag. 75 x) (FIG. 4D).

FIGS. 5A-5C are transverse sections of human epidermal microorgan explants. (mag x 75) showing tissue architecture at zero (FIG. 5A), three (FIG. 5B) and six (FIG. 6D) days in culture.

FIG. 6 is a histogram demonstrating the effect on epidermal proliferation of varying thickness (x) of guinea pig skin microorgan cultures using BrdU incorporation where (a) has been kept constant at 4 mm.

FIGS. 7A-7B are micrographs showing immunofluorescence corresponding to proliferating cells in pancreas-derived microorgan cultures (mag 75 x).

FIG. 8 is a histogram showing amounts of insulin released by adult pig pancreas micro-organ cultures.

FIG. 9 is a histogram showing 3H-Thymidine incorporation in proliferating cells in micro-organ cultures of the colon, liver, kidney, duodenum and esophagus, at three days, four days and six days of culture.

FIGS. 10A-10C are micrographs showing active proliferation of hair follicles in micro-organ cultures as determined by immunofluorescence. Magnification 40 x (FIG. 10A), 40 x (FIG. 10B), and 75 x (FIG. 10C).

FIG. 11 is a histogram showing the size distribution of hair shafts at the beginning and end of the microculture.

FIG. 12 is a histogram showing the inhibition of mitogenesis in micro-organ cultures in the presence of 2.5 ng/ml TGF-beta in guinea-pig

FIG. 13 is a diagrammatic representation of a micro-organ explant for treatment of chronic skin ulcers showing incomplete sectioning of tissue slices so as to maintain a structure that can be readily manipulated in vivo.

FIG. 14 is a photograph of the surface of a mouse after replacement of a piece of normal skin with a micro-organ culture; healing, generation of new hair shafts in the implant, and incorporation of the implant into the normal mouse skin can be observed (mag 10 x).

FIG. 15 is a graphic representation of the expression of a luciferase reporter gene in a guinea pig skin micro-organ culture after transfection (of the culture with a plasmid encoding the luciferase reporter gene).

FIG. 16 is a graphic representation of the expression of a luciferase gene in rat lung and thymus micro-organ cultures after cationic lipid mediated transfection of the culture with plasmid encoding the luciferase reporter gene.

FIG. 17 is a graphic representation of the activation of telogen follicles upon treatment with FGF in micro-organ cultures of the present invention.

FIG. 18 is a graphic representation of the expression of a transgenic luciferase gene in micro-organ explants of the present invention.

L5 ANSWER 219 OF 367 IFIPAT COPYRIGHT 2004 IFI on STN
AN 10342993 IFIPAT;IFIUDB;IFICDB
TI PEPTIDES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR TREATMENT OF
DISORDERS OR DISEASES ASSOCIATED WITH ABNORMAL PROTEIN FOLDING INTO
AMYLOID OR AMYLOID-LIKE DEPOSITS; INHIBITORY PEPTIDE FOR USE IN THE
TREATMENT, PREVENTION AND DIAGNOSIS ALZHEIMER'S AND BRAIN DISORDERS
IN Baumann Marc H (FI); Frangione Blas; Soto-Jara Claudio
PA New York University (59449)
PI US 2003087407 A1 20030508
AI US 2002-235483 20020906
RLI US 1996-766596 19961212 CONTINUATION 6462171
US 1995-478326 19950607 CONTINUATION-IN-PART ABANDONED
US 1996-630645 19960410 CONTINUATION-IN-PART 5948763
FI US 2003087407 20030508
US 6462171
US 5948763
DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION

CLMN 8
GI

27 Figure(s).

FIGS. 1A-B provide a consensus sequence for amyloidogenesis in terms of hydrophobicity and secondary structure properties. FIG. 1A is the primary structure of the amyloidogenic sequence of peptides involved in the formation of several amyloid deposits. The sequences correspond to:
amyloid ***beta*** -peptide (SEQ ID NO: 1) found in Alzheimer's disease, its Dutch variant and Downs Syndrome; amyloid A (SEQ ID NO: 2) found in secondary amyloidosis and familial Mediterranean fever; gelsolin amyloid (SEQ ID NO: 3) related to familial amyloidosis of Finnish type; amyloid L (SEQ ID NO: 4) found in immunoglobulin-related primary amyloidosis; beta 2-microglobulin amyloid (SEQ ID NO: 5) found in patients with chronic hemodialysis-related amyloidosis; and apolipoprotein A1 amyloid (SEQ ID NO: 6) related to familial amyloidotic polyneuropathy. Amino acids written in bold correspond to hydrophobic residues and those underlined represent positions with mutation related to the hereditary form of the disease. FIG. 1B provides the betasheet prediction for the 15 amino acid fragments containing the sequences shown in FIG. 1A. The solid bar represents regions with a high probability of adopting a beta-sheet structure.

FIGS. 2A-B provide the amino acid sequence for several anti-amyloid peptides. FIG. 2A shows the amino acid sequences four anti-amyloid peptides labeled as anti-amyloid 1 (SEQ ID NO: 7), anti-amyloid 2 (SEQ ID NO: 8), anti-amyloid 3 (SEQ ID NO: 9) and anti-amyloid 4 (SEQ ID NO: 10). Hydro-phobic amino acids are highlighted in bold. FIG. 2B shows the circular dichroism spectrum of the anti-amyloid peptide 1 (SEQ ID NO: 7) recorded as described in Example 1.

FIG. 3 is a schematic representation of the beta-cross conformation for amyloid fibrils showing the crucial importance of the interactions by hydrogen bonding between the monomeric beta-strand to form the intermolecular beta-cross structure.

FIGS. 4A-B show the effect of anti-amyloid peptide 2 having the sequence of SEQ ID NO: 8 on the amyloid formation by A beta in vitro. Amyloid formation was quantitated by the fluorometric assay described in Example 1. FIG. 4A shows the dose-dependent inhibition of amyloidogenesis, using anti-amyloid peptide 2 (shown as filled squares) and a 12 amino acid-non

time was 24 hours at room temperature and the A beta concentration was 1 mg/ml in 0.1 M Tris, pH 7.4. FIG. 4B shows the effect of anti-amyloid peptide 2 (SEQ ID NO: 8) on the amyloid formation after various incubation times.

The inhibitory effect of the peptide remained unaltered over several days of incubation. Incubations containing A beta, alone, are depicted by unfilled squares; incubations of A beta, and a control peptide are depicted by unfilled circles; and incubations of A beta and anti-amyloid peptide 2 are depicted by filled squares. The A beta concentration used was 1 mg/ml incubated in a molar ratio of anti-amyloid peptide 2 or control peptide of 1:20. Neither the anti-amyloid peptide 2 nor the control peptide gave fluorescence values over the background level of 1-2 fluorescence units.

FIGS. 5A-C show electron micrographs of negative-stained preparations of A beta (FIG. 5A), A beta incubated with anti-amyloid peptide 1 (SEQ ID NO: 7: FIG. 5B) and anti-amyloid peptide 1 alone (FIG. 5C). Aliquots of A beta were incubated at 1 mg/ml with or without the anti-amyloid peptide 1 in a molar ratio 1:50 (A beta :anti-amyloid) for 6 days at room temperature.

FIGS. 6A-B show the effects of anti-amyloid peptide 1 on the redissolution of preformed fibrils. Amyloid fibrils were formed by incubating A beta (1 mg/ml) for 3 days at room temperature. Anti-amyloid peptide 1 was then added in a molar ratio 1:50 (A beta :anti-amyloid peptide 1). The incubation was continued for 15 minutes, 6 hours or 24 hours and the amyloid formation was quantitated by the fluorometric assay (FIG. 6A). Fluorescence values represent the amount of amyloid formed. FIG. 6B provides electron micrographs of the nonincubated (left side picture) and incubated fibrils for 24 hours with anti-amyloid peptide 1 (right side picture). Magnification is 50,000 x.

FIGS. 7A-C show the physio-chemical characterization of the amphotericin (HMG-1) derived amyloid fragment, ATNp. FIG. 7A provides the amino acid sequence of the fragment ATNp (SEQ ID NO: 11). Hydrophobic amino acid residues are highlighted in bold. FIG. 7B shows the Chou-Fasman prediction for beta-sheet structure of ATNp. The sequence with the highest beta-sheet structure probability is indicated with a bar. FIG. 7C is an electron micrograph of negative-stained preparations of ATNp with formed amyloid-like fibrils.

FIG. 8 is a bar graph showing the effect of anti-amyloid peptide 1 on the amyloid formation by A beta and of peptides derived from the amyloidogenic sequence of gelsolin amyloid and amyloid A. Either A beta or the fifteen amino acid peptides containing the amyloidogenic sequence of gelsolin amyloid (SEQ ID NO: 12) and amyloid A (SEQ ID NO: 13) were incubated in a concentration of 1 mg/ml for 24 hours without and with anti-amyloid peptide 1 in a molar ratio of 1:5 or 1:20.

FIG. 9 shows the structural characteristics of anti-amyloid peptide 2 (iA beta). The amino acid sequence and beta-sheet probability for iA beta (SEQ ID NO: 8) and for the region of A beta (SEQ ID NO: 14) used as a template for iA beta is shown underneath the beta-sheet probability profile where the solid bar represents the region of A beta having a high probability of beta-sheet structure.

FIG. 10 shows the circular dichroism spectra of iA beta at different peptide concentration.

FIG. 11 shows the A beta-iA beta interaction as quantitated by the quenching of the intrinsic fluorescence of A beta (tyrosine 10) induced by the binding of iA beta. The inset shows the fluorescence spectra of A beta incubated alone or in the presence of 4 μ M iA beta.

FIG. 12 shows the dose-dependent inhibition of A beta 1-40 and A beta 1-42 fibrillogenesis by iA beta. ***beta***. ***Amyloid*** formation was quantitated by the fluorometric assay, as described in Example 1. The A beta concentration was 1 mg/ml in 0.1M Tris, pH 7.6 and an incubation time of 24 h.

FIG. 13 shows the effect of iA beta on amyloid formation by A beta 1-40, after different incubation periods. The molar ratio A beta :iA beta (or control) was 1:20; A beta concentration 1 mg/ml. Amyloid formation was quantitated as in FIG. 12. iA beta or the control peptide alone did not give fluorescence values above the background level.

FIGS. 14A and 14B shows the dissolution of preformed A beta fibrils by iA beta in vitro. Amyloid fibrils were first preformed by incubating A beta 1-40 or A beta 1-42 at a concentration of 1 mg/ml for 6 days at room temperature. Fluorometric quantitation of amyloid as described in Example 1. FIG. 14A shows the effect of different molar ratios of iA beta or control peptide on fibril disassembly after 24 h of incubation. FIG. 14B fibril dissolution induced by a 40-fold molar excess of iA beta or control peptide after different incubation periods at room temperature.

FIGS. 15a-f shows the electron microscopy analysis of the effect of iA

mg/ml) were incubated at 37 degrees C. with or without iA beta or control peptide at a molar ratio 1:40 (A beta :iA beta), centrifuged and the pellet loaded on electron microscopy grids, stained and visualized as described in the Materials and Methods. FIG. 15a shows A beta incubated for 6 days; FIG. 15b shows A beta incubated with iA beta for 6 days; FIG. 15c shows A beta incubated alone for 5 days and then for 1 day with iA beta; FIG. 15d shows iA beta incubated for 6 days at the same concentration as in FIGS. 15b and c; FIG. 15e shows A beta incubated with the control peptide for 6 days; and FIG. 15f shows control peptide incubated alone for 6 days at the same concentration used in FIG. 15e. FIG. 16 shows the inhibition of amyloid formation after long period of incubation (days) in the presence of low concentrations of iA beta. 30 mu g of A beta 1-42 was incubated in 30 mu l of 0.1M tris, pH 7.4 with a molar ratio 1:5 (A beta :iA beta) of the inhibitor for different times at room temperature. Amyloid was quantitated by the thioflavine T fluorometric assay and expressed as a percentage of the amount of amyloid incubated for the same time in the absence of the inhibitor. FIG. 17 shows the inhibition of A beta fibrillogenesis by iA beta containing all ***D*** - ***amino*** ***acids***. FIG. 18 shows the effect of iA beta on the promotion of A beta fibrillogenesis induced by apolipoprotein E. 30 mu g of A beta 1-40 were incubated with or without 2.4 mu g of human plasma apolipoprotein E (apoE). Samples of A beta alone or A beta / apoE were incubated also with 1:10 (A beta :iA beta) of the inhibitor. All the incubations were performed for 24 h at room temperature. Amyloid formation was evaluated by the thioflavine T fluorometric assay. The average of two different experiments is shown. FIG. 19 shows Alzheimer's amyloid plaque dissolution by iA beta. FIG. 20 shows the effect of iA beta on the A beta-induced cell toxicity. FIG. 21 shows the change in the conformation of the PrP 109-141 fragment as evaluated by circular dichroism at time points of 0, 1, 3, 5, 7 and 10 days. FIG. 22 shows samples of the PrP 109-141 fragment in a random coil or beta-sheet conformation being treated with proteinase K and electrophoresed on SDS polyacrylamide gel. Arrows on the left indicate the position of molecular weight standards. FIGS. 23A and 23B show the effect of the presence (FIG. 23B) or absence (FIG. 23A) of peptide iPrP-12aa on PrP109-141 fibrillogenesis as evaluated by electron microscopy. FIG. 24 shows the dose-dependent inhibition of PrP106-126 peptide fibrillogenesis by iPrP-12aa. The control peptide is CP1 (SEQ ID NO: 49). FIG. 25 shows the influence of iPrP-12aa on proteinase K degradation of PrP109-141 as determined by SDS-PAGE. Aliquots of PrP109-141 were converted from random coil to beta-sheet by incubation for 7 days under the conditions described in Example 2 for the circular dichroism study in the absence (lane 3) or in the presence of 10-fold molar excess of an unrelated control peptide (CP1) (lane 4) or iPrP-12aa (lane 5). The sample was then lyophilized and resuspended in PBS. A similar aliquot of the fragment that was not pre-incubated (adopting a random coil conformation) was also lyophilized and resuspended in PBS (lane 2). The samples were treated with proteinase K (1:400 w/w) for 60 min. The reactions were then stopped and the samples analyzed by electrophoresis as described above for the results shown in FIG. 22. Lane 1 corresponds to molecular weight standards. FIG. 26 shows the inhibition of PrP109-141 conformational transition with inhibitor peptide iPrP-12aa as evaluated by circular dichroism at t=0 and t=7 days. !

L5 ANSWER 220 OF 367 IFIPAT COPYRIGHT 2004 IFI on STN
AN 10269246 IFIPAT;IFIUDB;IFICDB
TI PEPTIDES FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER ***BETA***
- ***AMYLOID*** PROTEIN FIBRILLOGENESIS DISORDERS; ADMINISTERING
LAMININ
IN Castillo Gerardo; Snow Alan D
PA Unassigned Or Assigned To Individual (68000)
PI US 2003013648 A1 20030116
AI US 2001-962955 20010924
RLI US 1997-947057 19971008 CONTINUATION ABANDONED
US 2001-938275 20010822 CONTINUATION-IN-PART PENDING
PRAI US 1996-27981P 19961008 (Provisional)
FI US 2003013648 20030116
DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION
OS CA 138:66664

GI

11 Figure(s).

FIG. 1 is a graph demonstrating an inhibitory effect of A ***beta***
amyloid deposition into rodent hippocampus by laminin.
FIG. 2 is a copy of a black and white photograph of a Coomassie blue
stained gel demonstrating purification and isolation of fragments of
laminin which strongly interact with A beta .
FIG. 3 is a graph demonstrating the strong binding interaction of
Alzheimer's A beta to the 55 kilodalton laminin fragment. A single
dissociation constant with a $K_d = 2.0 \times 10^{-9}$ was determined.
FIG. 4 is a graph demonstrating the inhibition of Alzheimer's A beta
fibril formation by selected fragments disclosed herein.
FIG. 5 is a schematic representation of the sequence of human alpha-3
chain globular domain peptides disclosed herein.
FIG. 6 is a schematic representation of the sequence of murine alpha-4
chain globular domain peptides disclosed herein.
FIG. 7 is a schematic representation of the sequence of murine alpha-5
chain globular domain peptides disclosed herein.
FIG. 8 is a table which includes laminin globular domain-derived peptides
which can disrupt/disassemble pre-formed Alzheimer's A beta 1-40 fibrils.
FIG. 9 is a graph demonstrating further testing of selected laminin
globular-domain derived peptides against pre-formed Alzheimer's A beta
1-42 fibrils.
FIG. 10 is a graph demonstrating dose-dependent disruption/ disassembly of
pre-formed A beta 1-42 fibrils by laminin globular domain-derived
peptides.
FIG. 11 is a composite color photograph demonstrating amyloid enhancing
effects of laminin-derived peptides.

L5

ANSWER 221 OF 367 IFIPAT COPYRIGHT 2004 IFI on STN

AN

10189297 IFIPAT;IFIUDB;IFICDB

TI

THERAPEUTIC AGENTS AND METHODS OF USE THEREOF FOR TREATING AN
AMYLOIDGENIC DISEASE; COMPOUND FOR USE IN THE TREATMENT OF ALZHEIMER'S
AND CREUZSFELDT-JACOB DISEASES

IN

Gefer Malcolm L; Gosselin Michael; Israel David I; Joyal John L

PA

Praecis Pharmaceuticals Inc (46269)

PI

US 2002133001 A1 20020919

AI

US 2001-996357 20011127

PRAI

US 2000-250198P 20001129 (Provisional)

US 2000-253302P 20001127 (Provisional)

US 2000-257186P 20001220 (Provisional)

FI

US 2002133001 20020919

DT

Utility; Patent Application - First Publication

FS

CHEMICAL
APPLICATION

CLMN

78

GI

13 Figure(s).

FIG. 1 depicts a Western blot analysis of COS cell lysates and medium
harvested from COS cells expressing the Fc region of mouse IgG1 fused to
amino acid residues 1-40, 1-42, 10-25, 1630, 17-21, or 17-21 (A21L) of
P-amyloid with or without an Nterminal triple glycine cap.
FIG. 2 depicts an immunohistochemistry analysis of coronal brain sections
from 20-22 week mice transgenic for both the Swedish mutation of
amyloid ***precursor*** ***protein*** and presenilin of
mouse IgG1 fused to various segments of P-amyloid, medium from
nontransfected COS cells, or anti- ***beta*** - ***amyloid***
polyclonal antibody.
FIG. 3 depicts the synthetic oligonucleotides that were used to assemble
the synthetic APP/IgG gene. These oligonucleotides contain unique
restriction endonuclease sites needed for the assembly.
FIG. 4 is a schematic representation of the pTIg expression vector.
FIG. 5 is a schematic representation of the assembly of synthetic A beta
1-40 and A beta 1-42, with and without a triple Gly linker group between
the tPA propeptide and the ***beta*** - ***amyloid*** peptide.
FIG. 6 depicts the DNA sequence, amino acid composition, and restriction
endonuclease recognition sites of the synthetic ***beta*** -
amyloid gene.
FIG. 7A depicts the sequence of the oligonucleotides used to assemble
subfragments of the synthetic ***beta*** - ***amyloid*** gene and a
compilation of the chimeric ***beta*** - ***amyloid*** /IgG1
constructs that were made.
FIG. 7B depicts the sequence of the oligonucleotides used to assemble
subfragments of the synthetic ***beta*** - ***amyloid*** gene and a
compilation of the chimeric ***beta*** - ***amyloid*** /IgG1
constructs that were made.
FIG. 8 is a graph demonstrating that Fc receptor-mediated fibril uptake by

protein or the alpha- ***beta*** - ***amyloid*** antibody.
 FIG. 9 is a graph demonstrating that the A beta (16-30)-Fc fusion protein interferes with the binding of soluble betaamyloid peptide to amyloid fibrils.
 FIG. 10 is brain section stained with Thioflavin S, demonstrating that treatment of an Alzheimer's disease model transgenic mouse with the A beta (16-30)-Fc fusion protein results in a decrease in plaque at the site of administration.
 FIG. 11 depicts the coding region of the tPA Delta pro/16-30/Fc cDNA synthetic gene (SEQ ID NO:11).
 FIG. 12 depicts the amino acid sequence of the tPA Delta pro/1630/Fc fusion protein (SEQ ID NO:12). Annotated functional elements are also shown. The A beta (16-30)-Fc protein is set forth herein as SEQ ID NO: 13

L5 ANSWER 222 OF 367 IFIPAT COPYRIGHT 2004 IFI on STN
 AN 10159492 IFIPAT;IFIUDB;IFICDB
 TI MODULATORS OF ***BETA*** - ***AMYLOID*** PEPTIDE AGGREGATION
 COMPRISING ***D*** - ***AMINO*** ***ACIDS*** ; AMINO-TERMINAL
 MODIFYING GROUPS INCLUDE CYCLIC, HETEROCYCLIC, POLYCYCLIC AND BRANCHED
 ALKYL, AND CARBOXY-TERMINAL MODIFYING GROUPS INCLUDE AN AMIDE, AN ALKYL
 AMIDE, AN ARYL AMIDE OR A HYDROXY; TREATING ALZHEIMER'S DISEASE
 IN Arico-Muendel Christopher C; Chin Joseph; Findeis Mark A; Gefter Malcolm
 L; Hayward Neil J; Kelley Michael; Komar-Panicucci Sonja; Lee Jung-Ja;
 Molineaux Susan; Musso Gary; Phillips Kathryn; Signer Ethan R; Wakefield
 James
 PA Praecis Pharmaceuticals Inc (46269)
 PI US 2002103134 A1 20020801
 AI US 2001-895443 20010629
 RLI US 1997-920162 19970827 CONTINUATION GRANTED
 US 1999-356931 19990719 CONTINUATION GRANTED
 US 1995-548998 19951027 CONTINUATION-IN-PART ABANDONED
 US 1996-616081 19960314 CONTINUATION-IN-PART ABANDONED
 US 1996-703675 19960827 CONTINUATION-IN-PART GRANTED
 US 1997-897342 19970721 CONTINUATION-IN-PART ABANDONED
 FI US 2002103134 20020801
 US 6689752 20040210
 DT Utility; Patent Application - First Publication
 FS CHEMICAL
 APPLICATION
 CLMN 16
 GI 4 Figure(s).
 FIG. 1 is a bar graph depicting the stability of an L-amino acidbased
 modulator compound (PPI-368) and two ***D*** - ***amino***
 acid -based modulator compounds (PPI-433 and PPI-457) in
 cerebrospinal fluid.
 FIG. 2 is a graph depicting the levels of PPI-558 in the plasma at 2, 8
 and 24 hours following a single subcutaneous injection of PPI-558 (4.6
 mg/kg) to male Sprague-Dawley rats. Each point is the mean +-standard
 error for four rats.
 FIG. 3 is a graph depicting the levels of PPI-558 in the brain parenchyma
 (void of blood and brain capillaries) at 2, 8 and 24 hours following a
 single subcutaneous injection of PPI-558 (4.6 mg/kg) to male
 Sprague-Dawley rats. Each point is the mean +-standard error for four
 rats.
 FIG. 4 is a graph depicting the ratio of brain parenchyma versus plasma
 levels of PPI-558 at 2, 8 and 24 hours following a single subcutaneous
 injection of PPI-558 (4.6 mg/kg) to male Sprague-Dawley rats. Each point
 is the mean +-standard error for four rats.

L5 ANSWER 223 OF 367 IFIPAT COPYRIGHT 2004 IFI on STN
 AN 03607375 IFIPAT;IFIUDB;IFICDB
 TI MODULATORS OF AMYLOID AGGREGATION; AMYLOIDOGENIC PROTEIN, OR FRAGMENT
 THEREOF, MODIFIED WITH CIS-DECALIN GROUP, CHOLANOYL STRUCTURE, CHOLYL
 GROUP, DIETHYLENETRIAMINEPENTAACETYL GROUP, MENTHOXYACETYL GROUP,
 IN FLUORESCIEIN-CONTAINING GROUP, OR N-ACETYLNEURAMINYL GROUP
 Benjamin Howard; Findeis Mark A; Garnick Marc B; Gefter Malcolm L; Hundal
 Arvind; Kasman Laura; Musso Gary; Reed Michael J; Signer Ethan R;
 Wakefield James
 PA Praecis Pharmaceuticals Inc (46269)
 PI US 6319498 B1 20011120
 AI US 1996-617267 19960314
 RLI US 1995-404831 19950314 CONTINUATION-IN-PART 5817626
 US 1995-475579 19950607 CONTINUATION-IN-PART 5854215
 US 1995-548998 19951027 CONTINUATION-IN-PART ABANDONED
 FI US 6319498 20011120

US 5854215
 DT Utility; CERTIFICATE OF CORRECTION
 CDAT 15 Apr 2003
 FS CHEMICAL
 GRANTED
 OS CA 135:376521
 MRN 007985 MFN: 0785
 007988 0534
 008259 0771
 008729 0818
 CLMN 52
 GI 4 Drawing Sheet(s), 9 Figure(s).

L5 ANSWER 224 OF 367 IFIPAT COPYRIGHT 2004 IFI on STN
 AN 03444263 IFIPAT;IFIUDB;IFICDB
 TI TREATMENTS FOR NEUROTOXICITY IN ALZHEIMER'S DISEASE CAUSED BY
 BETA ***AMYLOID*** PEPTIDES; GENETIC ENGINEERED POLYPEPTIDE
 IN Blanchard Barbara J; Ingram Vernon M
 PA Massachusetts Institute of Technology (52912)
 PI US 6172043 B1 20010109
 AI US 1998-5215 19980109
 RLI US 1997-960188 19971029 CONTINUATION-IN-PART ABANDONED
 PRAI US 1997-35847P 19970110 (Provisional)
 FI US 6172043 20010109
 DT Utility; CERTIFICATE OF CORRECTION
 CDAT 26 Feb 2002
 FS CHEMICAL
 GRANTED
 OS CA 134:87979
 MRN 009363 MFN: 0622
 CLMN 18
 GI 12 Drawing Sheet(s), 10 Figure(s).

L5 ANSWER 225 OF 367 JICST-Eplus COPYRIGHT 2004 JST on STN
 AN 980168420 JICST-Eplus
 TI Molecular biology of "Alzheimer disease". Racemization of . ***BETA***
 . ***amyloid*** protein. Roles of ***D*** - ***amino***
 acid contained . ***BETA*** . ***amyloid*** protein in
 emergence of Alzheimer disease.
 AU KANEKO ISAO
 CS Sankyo Co., Ltd.
 SO Brain Med, (1997) vol. 9, no. 4, pp. 375-381. Journal Code: L1063A (Fig.
 5, Tbl. 1, Ref. 25)
 ISSN: 0915-5759
 CY Japan
 DT Journal; General Review
 LA Japanese
 STA New

L5 ANSWER 226 OF 367 JICST-Eplus COPYRIGHT 2004 JST on STN
 AN 960869136 JICST-Eplus
 TI Roles of ***D*** - ***amino*** ***acid*** containing .
 BETA . ***amyloid*** protein in Alzheimer disease crisis.
 AU KANEKO ISAO; YAMADA NORIKO; KUBO TAKEKAZU; ODA TOMIICHIRO
 CS Sankyo Co., Ltd.
 SO Shinkei Kagaku (Bulletin of the Japanese Society for Neurochemistry),
 (1996) vol. 35, no. 3, pp. 340-341. Journal Code: Y0225A (Fig. 2, Ref. 1)
 ISSN: 0037-3796
 CY Japan
 DT Conference; Short Communication
 LA Japanese
 STA New

L5 ANSWER 227 OF 367 PROUSDDR COPYRIGHT 2004 PROUS SCIENCE on STN
 AN 1998:5227 PROUSDDR
 DN 264073
 CN (3alpha,5beta,7alpha,12alpha)-Trihydroxycholesterol-24-oxy-L-leucyl-L-valyl-L-
 phenylalanyl-L-phenylalanyl-L-alanine
 CN DRUG NAME: PPI-368
 RN 183746-33-0
 MF C56 H83 N5 O10
 HDP BIOLOGICAL TESTING
 CO ORIGINATOR: Praecis
 CC Cognition Disorders, Treatment of
 OS SYNTHLINE 2000002537

STRUCTURE:

/ BINARY DATA / D-Amyloid I 8.30.04001.TIF

RTX RefID: 470169

ACTION - Low-molecular-weight peptido-organic compound that acts as a potent and selective inhibitor of ***amyloid*** -peptide (Abeta) polymerization and blocks the formation of all neurotoxic species of Abeta oligomers and fibril growth. Potentially useful as a lead for the development of therapeutic agents for the treatment of Alzheimer's disease.

PATENT REFERENCES:

TI Modulators of ***beta*** - ***amyloid*** peptide aggregation
IN comprising ***D*** - ***amino*** ***acids***
Geffer, M.L.; Findeis, M.A.; Kelley, M.; Signer, E.R.; Musso, G.;
Wakefield, J.; Molineaux, S.; Chin, J.; Lee, J.-J.; Komer-Panicucci, S.;
Arico-Muendel, C.C.; Phillips, K.; Hayward, N.J.
PA Praecis
PI JP 2001500852 20010123
WO 9808868 19980305
PRAI US 1996-703675 19960827
US 1997-897342 19970721

START LOCAL KERMIT RECEIVE PROCESS

BINARY DATA HAVE BEEN DOWNLOADED TO MULTIPLES FILES 'IMAGEennn.TIF'

L5 ANSWER 228 OF 367 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation,
on STN
AN 97:229257 SCISEARCH
GA The Genuine Article (R) Number: WN147
TI All-D-enantiomers of ***beta*** - ***amyloid*** exhibit similar
biological properties to all-L- ***beta*** - ***amyloids***
AU Cribbs D H (Reprint); Pike C J; Weinstein S L; Velazquez P; Cotman C W
CS UNIV CALIF IRVINE, INST BRAIN AGING & DEMENTIA, DEPT PSYCHOBIOLOG, IRVINE,
CA 92717 (Reprint); UNIV CALIF IRVINE, INST BRAIN AGING & DEMENTIA, DEPT
NEUROL, IRVINE, CA 92717
CYA USA
SO JOURNAL OF BIOLOGICAL CHEMISTRY, (14 MAR 1997) Vol. 272, No. 11, pp.
7431-7436.
Publisher: AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC, 9650 ROCKVILLE
PIKE, BETHESDA, MD 20814.
ISSN: 0021-9258.
DT Article; Journal
FS LIFE
LA English
REC Reference Count: 61
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L5 ANSWER 229 OF 367 TOXCENTER COPYRIGHT 2004 ACS on STN
AN 2003:153109 TOXCENTER
DN CRISP-2002-AG17787-02
TI Inhibitors of Alzheimer's Disease Amyloidosis
AU CASTILLO G M
CS CASTILLO@PROTEOTECH.COM, PROTEOTECH, INC, 12026 115TH AVE NE, KIRKLAND, WA
98034 WASHINGTON
CSS U.S. DEPT. OF HEALTH AND HUMAN SERVICES; PUBLIC HEALTH SERVICE; NATIONAL
INSTITUTES OF HEALTH, NATIONAL INSTITUTE ON AGING
SO Crisp Data Base National Institutes of Health.
DT (Research)
FS CRISP
LA English
ED Entered STN: 20030708
Last Updated on STN: 20030708

L5 ANSWER 230 OF 367 TOXCENTER COPYRIGHT 2004 ACS on STN
AN 2003:153013 TOXCENTER
DN CRISP-1997-AG00408-04
TI TOXICITY OF ***BETA*** - ***AMYLOID*** IN ALZHEIMER'S DISEASE AND
DOWN SYNDROME

CSS U.S. DEPT. OF HEALTH AND HUMAN SERVICES; PUBLIC HEALTH SERVICE; NATIONAL
INSTITUTES OF HEALTH, NATIONAL INSTITUTE ON AGING
SO Crisp Data Base National Institutes of Health.
DT (Research)
FS CRISP
LA English
ED Entered STN: 20030708
Last Updated on STN: 20030708

L5 ANSWER 231 OF 367 TOXCENTER COPYRIGHT 2004 ACS on STN
AN 2002:546351 TOXCENTER
DN CRISP-98-G00408-04
TI TOXICITY OF ***BETA*** - ***AMYLOID*** IN ALZHEIMER'S DISEASE AND
DOWN SYNDROME
AU GALDZICKI Z
CS NIA, NIH
CSS U.S. DEPT. OF HEALTH AND HUMAN SERVICES; PUBLIC HEALTH SERVICE; NATIONAL
INST. OF HEALTH, NATIONAL INSTITUTE ON AGING
SO Crisp Data Base National Institutes Of Health.
DT (Research)
FS CRISP
LA English
ED Entered STN: 20021200
Last Updated on STN: 20021200

L5 ANSWER 232 OF 367 TOXCENTER COPYRIGHT 2004 ACS on STN
AN 2002:69105 TOXCENTER
CP Copyright 2004 ACS
TI Designed helical peptides as gamma-secreatase inhibitors
AU Das, Chittaranjan; Wolfe, Michael S.; Tsai, Jui-Yi; Diehl, Thekla S.
CS Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard
Medical school, Boston, MA, 02115, USA.
SO Abstracts of Papers, 223rd ACS National Meeting, Orlando, FL, United
States, April 7-11, 2002, (2002) pp. MEDI-011.
CODEN: 69CKQP.
CY UNITED STATES
DT Conference
FS CAPLUS
OS CAPLUS 2002:190130
LA English
ED Entered STN: 20020319
Last Updated on STN: 20020319

L5 ANSWER 233 OF 367 USPATFULL on STN
AN 2004:211476 USPATFULL
TI Polynucleotide encoding neuromedin U receptor
IN Harland, Lee, Kent, UNITED KINGDOM
PA Pfizer Inc., New York, NY, United States (U.S. corporation)
PI US 6780611 B1 20040824
AI US 2000-684725 20001006 (9)
PRAI GB 1999-23888 19991008
DT Utility
FS GRANTED
LN.CNT 3220
INCL INCLM: 435/069.100
INCLS: 435/320.100; 435/325.000; 435/252.300; 435/254.110; 536/023.500
NCL NCLM: 435/069.100
NCLS: 435/320.100; 435/325.000; 435/252.300; 435/254.110; 536/023.500
IC [7]
ICM: C12N015-00
ICS: C12N015-63; C12N015-85; C12N001-21; C07H021-04
EXF 536/23.5; 536/23.1; 536/24.3; 435/320.1; 435/325; 435/252.3; 435/254.11;
435/254.2; 435/69.1; 435/254.1; 435/455

L5 ANSWER 234 OF 367 USPATFULL on STN
AN 2004:203889 USPATFULL
TI Peptide binding the KLVFF-sequence of ***amyloid*** - ***beta***
IN Nordstedt, Christer, Mulhouse, FRANCE
Naslund, Jan, Stockholm, SWEDEN
Thyberg, Johan, Stockholm, SWEDEN
Tjernberg, Lars O., Spanga, SWEDEN
Terenius, Lars, Uppsala, SWEDEN
PA Karolinska Innovations AB, Stockholm, SWEDEN (non-U.S. corporation)
PI US 2004157781 A1 20040812
AI US 2003-721774 A1 20031126 (10)

Division of Ser. No. US 1998-95106, filed on 10 Jun 1998, GRANTED, Pat.
No. US 6331440 Continuation of Ser. No. WO 1996-SE1621, filed on 9 Dec
1996, UNKNOWN

PRAI SE 1995-4467 19951212
US 1995-9386P 19951229 (60)
DT Utility
FS APPLICATION
LN.CNT 724
INCL INCLM: 514/016.000
INCLS: 530/329.000
NCL NCLM: 514/016.000
NCLS: 530/329.000
IC [7]
ICM: A61K038-08
ICS: C07K007-06

L5 ANSWER 235 OF 367 USPATFULL on STN

AN 2004:202975 USPATFULL

TI Immunogenic HBC chimera particles having enhanced stability

IN Birkett, Ashley J., Escondido, CA, UNITED STATES

PI US 2004156864 A1 20040812

AI US 2004-805913 A1 20040322 (10)

RLI Continuation-in-part of Ser. No. US 2001-930915, filed on 15 Aug 2001,
PENDING

PRAI WO 2001-US41759 20010816
US 2000-226867P 20000822 (60)
US 2000-225843P 20000816 (60)

DT Utility
FS APPLICATION

LN.CNT 7005

INCL INCLM: 424/189.100
INCLS: 530/350.000

NCL NCLM: 424/189.100
NCLS: 530/350.000

IC [7]
ICM: A61K039-29
ICS: C12P021-04; C07K014-02

L5 ANSWER 236 OF 367 USPATFULL on STN

AN 2004:202974 USPATFULL

TI Stabilized HBC chimera particles as therapeutic vaccine for chronic
hepatitis

IN Page, Mark, Allestree, UNITED KINGDOM

Friede, Martin, Cergue, SWITZERLAND

Schmidt, Annette Elisabeth, Planegg, GERMANY, FEDERAL REPUBLIC OF

Stober, Detlef, Muenchen, GERMANY, FEDERAL REPUBLIC OF

PI US 2004156863 A1 20040812

AI US 2003-677074 A1 20031001 (10)

RLI Continuation-in-part of Ser. No. US 2003-372076, filed on 21 Feb 2003,
PENDING Continuation-in-part of Ser. No. US 2002-82014, filed on 21 Feb
2002, ABANDONED Continuation-in-part of Ser. No. US 2002-80299, filed on
21 Feb 2002, PENDING

DT Utility
FS APPLICATION

LN.CNT 5846

INCL INCLM: 424/189.100

NCL NCLM: 424/189.100

IC [7]
ICM: A61K039-29

L5 ANSWER 237 OF 367 USPATFULL on STN

AN 2004:197569 USPATFULL

TI Immunogenic HBC chimera particles having enhanced stability

IN Birkett, Ashley J., Escondido, CA, UNITED STATES

PI US 2004152876 A1 20040805

AI US 2004-806006 A1 20040322 (10)

RLI Division of Ser. No. US 2001-930915, filed on 15 Aug 2001, PENDING

PRAI WO 2001-US41759 20010816
US 2000-226867P 20000822 (60)
US 2000-225843P 20000816 (60)

DT Utility
FS APPLICATION

LN.CNT 7068

INCL INCLM: 530/350.000

NCL NCLM: 530/350.000

ICM: C07K014-005

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 238 OF 367 USPATFULL on STN
AN 2004:189756 USPATFULL
TI Stabilized immunogenic HBC chimer particles
IN Lyons, Katelonne, Carlsbad, CA, UNITED STATES
Birkett, Ashley J., Escondido, CA, UNITED STATES
Haron, Jay A., Jamul, CA, UNITED STATES
PI US 2004146524 A1 20040729
AI US 2003-732862 A1 20031210 (10)
RLI Continuation-in-part of Ser. No. US 2002-274616, filed on 21 Oct 2002,
PENDING Continuation-in-part of Ser. No. US 2002-80299, filed on 21 Feb
2002, PENDING Continuation-in-part of Ser. No. US 2002-82014, filed on
21 Feb 2002, PENDING
PRAI US 2002-432123P 20021210 (60)
DT Utility
FS APPLICATION
LN.CNT 8390
INCL INCLM: 424/189.100
INCLS: 530/350.000
NCL NCLM: 424/189.100
NCLS: 530/350.000
IC [7]
ICM: A61K039-29
ICS: C07K014-02

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 239 OF 367 USPATFULL on STN
AN 2004:178983 USPATFULL
TI Treatment of neurodegenerative diseases using proteasome modulators
IN Ramesh, Tennore, Dublin, OH, UNITED STATES
Scott, Sean, San Francisco, CA, UNITED STATES
PA ALS Therapy Development Foundation (U.S. corporation)
PI US 2004138153 A1 20040715
AI US 2003-453912 A1 20030603 (10)
PRAI US 2002-385489P 20020603 (60)
US 2002-385625P 20020603 (60)
DT Utility
FS APPLICATION
LN.CNT 2167
INCL INCLM: 514/043.000
INCLS: 514/220.000
NCL NCLM: 514/043.000
NCLS: 514/220.000
IC [7]
ICM: A61K031-7056
ICS: A61K031-551

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 240 OF 367 USPATFULL on STN
AN 2004:174261 USPATFULL
TI Passive immunization treatment of Alzheimer's disease
IN Schenk, Dale B., Burlingame, CA, United States
PA Neuralab Limited, BERMUDA (non-U.S. corporation)
PI US 6761888 B1 20040713
AI US 2000-580018 20000526 (9)
DT Utility
FS GRANTED
LN.CNT 5303
INCL INCLM: 424/130.100
INCLS: 530/300.000; 530/350.000; 530/387.100
NCL NCLM: 424/130.100
NCLS: 530/300.000; 530/350.000; 530/387.100
IC [7]
ICM: C07K016-00
ICS: C07K016-18; A61K039-00
EXF 530/300; 530/350; 530/387.1; 424/130.1; 424/131.1; 424/141.1; 424/141.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 241 OF 367 USPATFULL on STN
AN 2004:160529 USPATFULL
TI Methods of treating neurodegenerative diseases
IN Lu, Kun Ping, Newton, MA, UNITED STATES
Hunter, Tony R., Del Mar, CA, UNITED STATES

PA BETH ISRAEL DEACONESS MEDICAL CENTER, Boston, MA (U.S. corporation)
The Salk Institute for Biological Studies, La Jolla, CA (U.S.
corporation)
PI US 2004123334 A1 20040624
AI US 2004-641815 A1 20040112 (10)
PRAI US 2002-404030P 20020815 (60)
US 2003-469546P 20030508 (60)
DT Utility
FS APPLICATION
LN.CNT 1932
INCL INCLM: 800/003.000
INCLS: 424/009.200; 800/012.000
NCL NCLM: 800/003.000
NCLS: 424/009.200; 800/012.000
IC [7]
ICM: A01K067-00
ICS: A61K049-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 242 OF 367 USPATFULL on STN
AN 2004:146997 USPATFULL
TI Humanized and chimeric N-terminal ***amyloid*** ***beta***
-antibodies
IN Schenk, Dale B., Burlingame, CA, United States
Bard, Frederique, Pacifica, CA, United States
Yednock, Theodore, Forest Knolls, CA, United States
PA Neuralab Limited, BERMUDA (non-U.S. corporation)
PI US 6750324 B1 20040615
AI US 2000-724552 20001128 (9)
RLI Continuation of Ser. No. US 2000-580018, filed on 26 May 2000
Continuation-in-part of Ser. No. US 1999-322289, filed on 28 May 1999
Continuation-in-part of Ser. No. US 1998-201430, filed on 30 Nov 1998
PRAI US 1998-80970P 19980407 (60)
US 1997-67740P 19971202 (60)
DT Utility
FS GRANTED
LN.CNT 5272
INCL INCLM: 530/387.100
INCLS: 530/300.000; 530/350.000; 424/130.100
NCL NCLM: 530/387.100
NCLS: 424/130.100; 530/300.000; 530/350.000
IC [7]
ICM: C07K016-00
ICS: C07K016-18; A61K039-00
EXF 530/300; 530/350; 530/387.1; 424/130.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 243 OF 367 USPATFULL on STN
AN 2004:135611 USPATFULL
TI Prevention and treatment of amyloidogenic disease
IN Schenk, Dale B., Burlingame, CA, United States
PA Neuralab Limited, BERMUDA (non-U.S. corporation)
PI US 6743427 B1 20040601
AI US 2000-724961 20001128 (9)
RLI Continuation of Ser. No. US 2000-580015, filed on 26 May 2000
Continuation-in-part of Ser. No. US 1999-322289, filed on 28 May 1999
Continuation-in-part of Ser. No. US 1998-201430, filed on 30 Nov 1998
PRAI US 1998-80970P 19980407 (60)
US 1997-67740P 19971202 (60)
DT Utility
FS GRANTED
LN.CNT 5449
INCL INCLM: 424/130.100
INCLS: 530/300.000; 530/350.000; 530/387.100
NCL NCLM: 424/130.100
NCLS: 530/300.000; 530/350.000; 530/387.100
IC [7]
ICM: C07K016-00
ICS: C07K016-18; A61K039-00
EXF 530/300; 530/350; 530/387.1; 724/130.1; 724/133.1; 724/139.1; 724/141;
724/142.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 244 OF 367 USPATFULL on STN
AN 2004:114174 USPATFULL

peptides and uses therefor
IN Holmes, Todd, Belmont, MA, UNITED STATES
Zhang, Shuguang, Lexington, MA, UNITED STATES
Rich, Alexander, Cambridge, MA, UNITED STATES
DiPersio, C. Michael, Norton, MA, UNITED STATES
Lockshin, Curtis, Lexington, MA, UNITED STATES
PI US 2004087013 A1 20040506
AI US 2003-390472 A1 20030317 (10)
RLI Continuation of Ser. No. US 1997-824515, filed on 26 Mar 1997, GRANTED,
Pat. No. US 5987623 Continuation of Ser. No. US 1994-293284, filed on 22
Aug 1994, GRANTED, Pat. No. US 5955343 Continuation-in-part of Ser. No.
US 1992-973326, filed on 28 Dec 1992, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 2512
INCL INCLM: 435/325.000
INCLS: 530/329.000
NCL NCLM: 435/325.000
NCLS: 530/329.000
IC [7]
ICM: C12N005-02
ICS: C07K007-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 245 OF 367 USPATFULL on STN
AN 2004:114052 USPATFULL
TI Dehydrogenase oligomeric modulators
IN Tatton, William G., Yorktown Heights, NY, UNITED STATES
Borden, Katherine, New Rochelle, NY, UNITED STATES
PI US 2004086891 A1 20040506
AI US 2003-414809 A1 20030416 (10)
RLI Continuation of Ser. No. US 1999-327200, filed on 7 Jun 1999, ABANDONED
PRAI US 1998-88771P 19980610 (60)
US 1998-92054P 19980708 (60)
DT Utility
FS APPLICATION
LN.CNT 1546
INCL INCLM: 435/006.000
NCL NCLM: 435/006.000
IC [7]
ICM: C12Q001-68
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 246 OF 367 USPATFULL on STN
AN 2004:113677 USPATFULL
TI Methods
IN Foxwell, Brian Maurice John, London, UNITED KINGDOM
Feldmann, Marc, London, UNITED KINGDOM
PI US 2004086516 A1 20040506
AI US 2003-450786 A1 20031010 (10)
WO 2001-GB5724 20011221
PRAI GB 2000-31454 20001222
GB 2001-27625 20011117
DT Utility
FS APPLICATION
LN.CNT 2822
INCL INCLM: 424/184.100
NCL NCLM: 424/184.100
IC [7]
ICM: A61K039-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 247 OF 367 USPATFULL on STN
AN 2004:107249 USPATFULL
TI Adzymes and uses thereof
IN Afeyan, Noubar B., Lexington, MA, UNITED STATES
Lee, Frank D., Chestnut Hill, MA, UNITED STATES
Wong, Gordon G., Brookline, MA, UNITED STATES
Das Gupta, Ruchira, Auburndale, MA, UNITED STATES
Baynes, Brian, Somerville, MA, UNITED STATES
PI US 2004081648 A1 20040429
AI US 2003-650592 A1 20030827 (10)
PRAI US 2002-406517P 20020827 (60)
US 2002-423754P 20021105 (60)
US 2002-430001P 20021127 (60)

FS APPLICATION
LN.CNT 8325
INCL INCLM: 424/094.630
INCLS: 435/226.000
NCL NCLM: 424/094.630
NCLS: 435/226.000
IC [7]
ICM: A61K038-48
ICS: C12N009-64
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 248 OF 367 USPATFULL on STN
AN 2004:107248 USPATFULL
TI Adzymes and uses thereof
IN Afeyan, Noubar B., Lexington, MA, UNITED STATES
Lee, Frank D., Chestnut Hill, MA, UNITED STATES
Wong, Gordon G., Brookline, MA, UNITED STATES
DasGupta, Ruchira, Auburndale, MA, UNITED STATES
Baynes, Brian, Somerville, MA, UNITED STATES
PI US 2004081647 A1 20040429
AI US 2003-650591 A1 20030827 (10)
PRAI US 2002-406517P 20020827 (60)
US 2002-423754P 20021105 (60)
US 2002-430001P 20021127 (60)
DT Utility

FS APPLICATION
LN.CNT 7919
INCL INCLM: 424/094.630
INCLS: 435/069.700; 435/226.000
NCL NCLM: 424/094.630
NCLS: 435/069.700; 435/226.000
IC [7]
ICM: A61K038-48
ICS: C12N009-64; C12P021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 249 OF 367 USPATFULL on STN
AN 2004:88231 USPATFULL
TI Macrocyclic chelants for metallopharmaceuticals
IN Liu, Shuang, Chelmsford, MA, UNITED STATES
PI US 2004067200 A1 20040408
AI US 2003-663090 A1 20030915 (10)
RLI Division of Ser. No. US 2000-660377, filed on 12 Sep 2000, GRANTED, Pat.
No. US 6685914
PRAI US 1999-153512P 19990913 (60)
DT Utility
FS APPLICATION
LN.CNT 2942
INCL INCLM: 424/009.363
INCLS: 540/465.000; 540/474.000
NCL NCLM: 424/009.363
NCLS: 540/465.000; 540/474.000
IC [7]
ICM: A61K049-00
ICS: C07F005-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 250 OF 367 USPATFULL on STN
AN 2004:77121 USPATFULL
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical
compositions comprising same, and methods for inhibiting beta-amyloid
peptide release and/or its synthesis by use of such compounds
IN Wu, Jing, San Mateo, CA, UNITED STATES
Tung, Jay S., Belmont, CA, UNITED STATES
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
Pleiss, Michael A., Sunnyvale, CA, UNITED STATES
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES
Neitz, R. Jeffrey, San Francisco, CA, UNITED STATES
Latimer, Lee H., Oakland, CA, UNITED STATES
John, Varghese, San Francisco, CA, UNITED STATES
Freedman, Stephen, Walnut Creek, CA, UNITED STATES
Britton, Thomas C., Carmel, IN, UNITED STATES
Audia, James A., Indianapolis, IN, UNITED STATES
Reel, Jon K., Carmel, IN, UNITED STATES
Mabry, Thomas E., Indianapolis, IN, UNITED STATES

Cwi, Cynthia L., Indianapolis, IN, UNITED STATES
Droste, James J., Indianapolis, IN, UNITED STATES
Henry, Steven S., New Palestine, IN, UNITED STATES
Mcdaniel, Stacey L., Indianapolis, IN, UNITED STATES
Scott, William Leonard, Indianapolis, IN, UNITED STATES
Stucky, Russell D., Indianapolis, IN, UNITED STATES
Porter, Warren J., Indianapolis, IN, UNITED STATES

PI US 2004058900 A1 20040325
AI US 2003-336767 A1 20030106 (10)
RLI Division of Ser. No. US 2001-915342, filed on 27 Jul 2001, PENDING
Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING
PRAI US 1996-64851P 19961223 (60)
DT Utility
FS APPLICATION
LN.CNT 25655
INCL INCLM: 514/183.000
INCLS: 514/212.020; 514/317.000; 514/284.000; 514/212.070; 514/221.000;
514/220.000; 514/211.050; 514/457.000; 514/471.000; 514/732.000
NCL NCLM: 514/183.000
NCLS: 514/212.020; 514/317.000; 514/284.000; 514/212.070; 514/221.000;
514/220.000; 514/211.050; 514/457.000; 514/471.000; 514/732.000
IC [7]
ICM: A61K031-553
ICS: A61K031-55; A61K031-554; A61K031-551; A61K031-5513; A61K031-473
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 251 OF 367 USPATFULL on STN
AN 2004:77072 USPATFULL
TI Specific autoimmune reactions against isomerised/optically inverted
epitopes: application for diagnosis of autoimmune diseases
IN Cloos, Paul, Kobenhavn, DENMARK
Christgau, Stephan, Gentofte, DENMARK
PI US 2004058851 A1 20040325
AI US 2002-75372 A1 20020215 (10)
RLI Continuation of Ser. No. WO 2000-EP7973, filed on 16 Aug 2000, UNKNOWN
PRAI GB 1999-19452 19990817
DT Utility
FS APPLICATION
LN.CNT 1711
INCL INCLM: 514/002.000
INCLS: 435/007.210
NCL NCLM: 514/002.000
NCLS: 435/007.210
IC [7]
ICM: G01N033-567
ICS: A61K038-17
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 252 OF 367 USPATFULL on STN
AN 2004:70761 USPATFULL
TI Dithiolthione compounds for the treatment of neurological disorders and
for memory enhancement
IN Prendergast, Patrick T., Straffan, IRELAND
Armstrong, Paul, Belfast, UNITED KINGDOM
PA Patrick Prendergast, Straffan, IRELAND (non-U.S. corporation)
PI US 2004053989 A1 20040318
AI US 2003-612476 A1 20030702 (10)
RLI Continuation of Ser. No. US 2000-627641, filed on 28 Jul 2000, ABANDONED
PRAI IE 2000-20000302 20000413
IE 2000-20000304 20000413
US 1999-145964P 19990729 (60)
US 2000-198338P 20000418 (60)
DT Utility
FS APPLICATION
LN.CNT 4051
INCL INCLM: 514/440.000
INCLS: 514/210.190; 514/217.030; 514/326.000; 514/422.000
NCL NCLM: 514/440.000
NCLS: 514/210.190; 514/217.030; 514/326.000; 514/422.000
IC [7]
ICM: A61K031-385
ICS: A61K031-55; A61K031-453; A61K031-4025
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 253 OF 367 USPATFULL on STN

TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
 IN Wu, Jing, San Mateo, CA, UNITED STATES
 Tung, Jay S., Belmont, CA, UNITED STATES
 Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
 Pleiss, Michael A., Sunnyvale, CA, UNITED STATES
 Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES
 Neitz, Jeffrey, San Francisco, CA, UNITED STATES
 Latimer, Lee H., Oakland, CA, UNITED STATES
 John, Varghese, San Francisco, CA, UNITED STATES
 Freedman, Stephen, Walnut Creek, CA, UNITED STATES
 Britton, Thomas C., Carmel, IN, UNITED STATES
 Audia, James E., Indianapolis, IN, UNITED STATES
 Reel, Jon K., Carmel, IN, UNITED STATES
 Mabry, Thomas E., Indianapolis, IN, UNITED STATES
 Dressman, Bruce A., Indianapolis, IN, UNITED STATES
 Cwi, Cynthia L., Indianapolis, IN, UNITED STATES
 Droste, James J., Indianapolis, IN, UNITED STATES
 Henry, Steven S., New Palestine, IN, UNITED STATES
 McDaniel, Stacey L., Bloomington, IN, UNITED STATES
 Scott, William Leonard, Indianapolis, IN, UNITED STATES
 Stucky, Russell D., Indianapolis, IN, UNITED STATES
 Porter, Warren J., Indianapolis, IN, UNITED STATES
 PI US 2004043977 A1 20040304
 AI US 2003-336687 A1 20030106 (10)
 RLI Division of Ser. No. US 2001-915362, filed on 27 Jul 2001, GRANTED, Pat. No. US 6541466 Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING
 PRAI US 1996-64851P 19961223 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 25738
 INCL INCLM: 514/183.000
 INCLS: 514/212.030; 514/212.070; 514/312.000; 514/220.000; 514/221.000; 514/288.000; 514/327.000; 514/460.000; 540/451.000; 540/496.000; 540/504.000; 540/523.000; 540/484.000; 546/153.000; 546/158.000; 546/076.000; 546/216.000; 549/273.000; 549/283.000; 514/659.000; 514/662.000; 564/454.000
 NCL NCLM: 514/183.000
 NCLS: 514/212.030; 514/212.070; 514/312.000; 514/220.000; 514/221.000; 514/288.000; 514/327.000; 514/460.000; 540/451.000; 540/496.000; 540/504.000; 540/523.000; 540/484.000; 546/153.000; 546/158.000; 546/076.000; 546/216.000; 549/273.000; 549/283.000; 514/659.000; 514/662.000; 564/454.000
 IC [7]
 ICM: A61K031-5513
 ICS: A61K031-551; A61K031-55; A61K031-4706; A61K031-473; A61K031-445; A61K031-366; A61K031-137
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L5 ANSWER 254 OF 367 USPATFULL on STN
 AN 2004:51633 USPATFULL
 TI Amine 1,2- and 1,3-diol compounds
 IN Romero, Arthur G., Kalamazoo, MI, UNITED STATES
 Schostarez, Heinrich J., Portage, MI, UNITED STATES
 Roels, Christina M., Battle Creek, MI, UNITED STATES
 PI US 2004039064 A1 20040226
 AI US 2002-299739 A1 20021119 (10)
 PRAI US 2001-333081P 20011119 (60)
 US 2001-334000P 20011128 (60)
 US 2002-362752P 20020308 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 10130
 INCL INCLM: 514/651.000
 INCLS: 564/355.000
 NCL NCLM: 514/651.000
 NCLS: 564/355.000
 IC [7]
 ICM: A61K031-137
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L5 ANSWER 255 OF 367 USPATFULL on STN
 AN 2004:51445 USPATFULL

IN Pepinsky, R. Blake, Arlington, MA, UNITED STATES
Taylor, Frederick R., Milton, MA, UNITED STATES
Garber, Ellen A., Cambridge, MA, UNITED STATES
PI US 2004038876 A1 20040226
AI US 2002-244095 A1 20020912 (10)
RLI Continuation of Ser. No. US 979752, ABANDONED A 371 of International
Ser. No. WO 2000-US14741, filed on 26 May 2000, PENDING
PRAI US 1999-137011P 19990601 (60)
US 1999-149016P 19990813 (60)
DT Utility
FS APPLICATION
LN.CNT 4595
INCL INCLM: 514/012.000
INCLS: 530/350.000
NCL NCLM: 514/012.000
NCLS: 530/350.000
IC [7]
ICM: A61K038-17
ICS: C07K014-47

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 256 OF 367 USPATFULL on STN
AN 2004:38077 USPATFULL
TI Dopamine agonist formulations for enhanced central nervous system
delivery
IN Quay, Steven C., Edmonds, WA, UNITED STATES
PA Natestch Pharmaceutical Company Inc, Hauppauge, NY (U.S. corporation)
PI US 2004028613 A1 20040212
AI US 2001-891630 A1 20010625 (9)
DT Utility
FS APPLICATION
LN.CNT 8045
INCL INCLM: 424/045.000
INCLS: 514/295.000
NCL NCLM: 424/045.000
NCLS: 514/295.000
IC [7]
ICM: A61K031-473
ICS: A61L009-04

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 257 OF 367 USPATFULL on STN
AN 2004:31067 USPATFULL
TI Method of recovering a nucleic acid encoding a proteinaceous binding
domain which binds a target material
IN Ladner, Robert Charles, Ijamsville, MD, UNITED STATES
Guterman, Sonia Kosow, Belmont, MA, UNITED STATES
Roberts, Bruce Lindsay, Milford, MA, UNITED STATES
Markland, William, Milford, MA, UNITED STATES
Ley, Arthur Charles, Newton, MA, UNITED STATES
Kent, Rachel Baribault, Boxborough, MA, UNITED STATES
PI US 2004023205 A1 20040205
AI US 2002-126544 A1 20020422 (10)
RLI Continuation of Ser. No. US 1997-993776, filed on 18 Dec 1997, ABANDONED
Continuation of Ser. No. US 1995-415922, filed on 3 Apr 1995, GRANTED,
Pat. No. US 5837500 Continuation of Ser. No. US 1993-9319, filed on 26
Jan 1993, GRANTED, Pat. No. US 5403484 Division of Ser. No. US
1991-664989, filed on 1 Mar 1991, GRANTED, Pat. No. US 5223409
Continuation-in-part of Ser. No. US 1990-487063, filed on 2 Mar 1990,
ABANDONED Continuation-in-part of Ser. No. US 1988-240160, filed on 2
Sep 1988, ABANDONED
PRAI WO 1989-US3731 19890901
DT Utility
FS APPLICATION
LN.CNT 15868
INCL INCLM: 435/005.000
INCLS: 435/006.000; 536/023.100; 536/023.720
NCL NCLM: 435/005.000
NCLS: 435/006.000; 536/023.100; 536/023.720
IC [7]
ICM: C12Q001-70
ICS: C12Q001-68; C07H021-04

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 258 OF 367 USPATFULL on STN

TI Macrocyclic chelants for metallopharmaceuticals
IN Liu, Shuang, Chelmsford, MA, United States
PA Bristol-Myers Squibb Pharma Company, Princeton, NJ, United States (U.S.
 corporation)
PI US 6685914 B1 20040203
AI US 2000-660377 20000912 (9)
PRAI US 1999-153512P 19990913 (60)
DT Utility
FS GRANTED
LN.CNT 2889
INCL INCLM: 424/009.300
 INCLS: 424/001.110; 424/009.100; 424/001.650; 540/465.000; 534/010.000;
 534/014.000
NCL NCLM: 424/009.300
 NCLS: 424/001.110; 424/001.650; 424/009.100; 534/010.000; 534/014.000;
 540/465.000
IC [7]
 ICM: A61B049-00
EXF 424/1.11; 424/1.65; 424/9.1; 424/9.3; 424/9.4; 424/9.5; 424/9.6;
 424/9.7; 424/9.8; 534/7; 534/10-16; 540/450; 540/465
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 259 OF 367 USPATFULL on STN
AN 2004:24723 USPATFULL
TI Receptor detection
IN Rouhani, Riaz, Concord, CA, UNITED STATES
 Naqvi, Tabassum, Fremont, CA, UNITED STATES
 Singh, Rajendra, San Jose, CA, UNITED STATES
PI US 2004018562 A1 20040129
AI US 2003-448609 A1 20030529 (10)
PRAI US 2002-384060P 20020529 (60)
DT Utility
FS APPLICATION
LN.CNT 918
INCL INCLM: 435/007.100
 INCLS: 435/007.200
NCL NCLM: 435/007.100
 NCLS: 435/007.200
IC [7]
 ICM: G01N033-53
 ICS: G01N033-567
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 260 OF 367 USPATFULL on STN
AN 2004:7420 USPATFULL
TI Method of producing polyvalent antigens
IN Chou, Szu-Yi, Sunnyvale, CA, UNITED STATES
PI US 2004005654 A1 20040108
AI US 2002-231114 A1 20020828 (10)
PRAI US 2002-361166P 20020301 (60)
 US 2002-363445P 20020308 (60)
DT Utility
FS APPLICATION
LN.CNT 3452
INCL INCLM: 435/068.100
 INCLS: 435/252.300; 435/235.100; 530/350.000; 530/351.000; 530/395.000;
 424/085.100; 424/185.100; 424/234.100; 424/204.100
NCL NCLM: 435/068.100
 NCLS: 435/252.300; 435/235.100; 530/350.000; 530/351.000; 530/395.000;
 424/085.100; 424/185.100; 424/234.100; 424/204.100
IC [7]
 ICM: C12P021-06
 ICS: A61K039-00; A61K039-12; A61K039-02; C12N007-00; C12N001-20;
 C07K014-52; C07K014-715; C07K014-02; C07K014-195
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 261 OF 367 USPATFULL on STN
AN 2004:7306 USPATFULL
TI Nucleic acids, genetic constructs, and library of nucleic acids encoding
 fusion proteins
IN Ladner, Robert Charles, Ijamsville, MD, UNITED STATES
 Guterman, Sonia Kosow, Belmont, MA, UNITED STATES
 Roberts, Bruce Lindsay, Milford, MA, UNITED STATES
 Markland, William, Milford, MA, UNITED STATES
 Ley, Arthur Charles, Newton, MA, UNITED STATES

PI US 2004005539 A1 20040108
AI US 2002-127028 A1 20020422 (10)
RLI Continuation of Ser. No. US 1997-993776, filed on 18 Dec 1997, ABANDONED
Continuation of Ser. No. US 1995-415922, filed on 3 Apr 1995, GRANTED,
Pat. No. US 5837500 Continuation of Ser. No. US 1993-9319, filed on 26
Jan 1993, GRANTED, Pat. No. US 5403484 Division of Ser. No. US
1991-664989, filed on 1 Mar 1991, GRANTED, Pat. No. US 5223409
Continuation-in-part of Ser. No. US 1990-487063, filed on 2 Mar 1990,
ABANDONED Continuation-in-part of Ser. No. US 1988-240160, filed on 2
Sep 1988, ABANDONED
PRAI WO 1989-US3731 19890901
DT Utility
FS APPLICATION
LN.CNT 16057
INCL INCLM: 435/005.000
INCLS: 435/006.000; 435/007.100; 435/069.700; 435/456.000; 435/252.300;
435/320.100; 536/023.720
NCL NCLM: 435/005.000
NCLS: 435/006.000; 435/007.100; 435/069.700; 435/456.000; 435/252.300;
435/320.100; 536/023.720
IC [7]
ICM: C12Q001-70
ICS: C12Q001-68; G01N033-53; C07H021-04; C12P021-02; C12N001-21;
C12N015-86
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 262 OF 367 USPATFULL on STN
AN 2004:7074 USPATFULL
TI Modulators of amyloid aggregation
IN Findeis, Mark A., Cambridge, MA, UNITED STATES
Benjamin, Howard, Lexington, MA, UNITED STATES
Garnick, Marc B., Brookline, MA, UNITED STATES
Gefter, Malcolm L., Lincoln, MA, UNITED STATES
Hundal, Arvind, Brighton, MA, UNITED STATES
Kasman, Laura, Athens, GA, UNITED STATES
Musso, Gary, Hopkinton, MA, UNITED STATES
Signer, Ethan R., Cambridge, MA, UNITED STATES
Wakefield, James, Brookline, MA, UNITED STATES
Reed, Michael J., Marietta, GA, UNITED STATES
PA Praecis Pharmaceuticals, Inc., Waltham, MA (U.S. corporation)
PI US 2004005307 A1 20040108
AI US 2003-463729 A1 20030617 (10)
RLI Continuation of Ser. No. US 2001-972475, filed on 4 Oct 2001, PENDING
Continuation of Ser. No. US 1996-617267, filed on 14 Mar 1996, GRANTED,
Pat. No. US 6319498 Continuation-in-part of Ser. No. US 1995-404831,
filed on 14 Mar 1995, GRANTED, Pat. No. US 5817626 Continuation-in-part
of Ser. No. US 1995-475579, filed on 7 Jun 1995, GRANTED, Pat. No. US
5854215 Continuation-in-part of Ser. No. US 1995-548998, filed on 27 Oct
1995, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 4197
INCL INCLM: 424/094.300
INCLS: 514/012.000
NCL NCLM: 424/094.300
NCLS: 514/012.000
IC [7]
ICM: A61K038-54
ICS: A61K038-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 263 OF 367 USPATFULL on STN
AN 2004:1829 USPATFULL
TI Method of producing disease-specific antigens
IN Chou, Szu-Yi, Sunnyvale, CA, UNITED STATES
PI US 2004001848 A1 20040101
AI US 2002-231213 A1 20020828 (10)
PRAI US 2002-361166P 20020301 (60)
US 2002-363445P 20020308 (60)
DT Utility
FS APPLICATION
LN.CNT 3423
INCL INCLM: 424/186.100
INCLS: 424/185.100; 424/191.100; 424/190.100; 435/069.300
NCL NCLM: 424/186.100

IC [7]
ICM: A61K039-00
ICS: A61K039-12; A61K039-02; A61K039-002; C12P021-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 264 OF 367 USPATFULL on STN
AN 2003:329844 USPATFULL
TI Innate immune system-directed vaccines
IN Medzhitov, Ruslan, New Haven, CT, UNITED STATES
PI US 2003232055 A1 20031218
AI US 2003-353316 A1 20030129 (10)
RLI Continuation of Ser. No. WO 2001-US24228, filed on 31 Jul 2001, PENDING
PRAI US 2000-258329P 20001228 (60)
US 2001-282604P 20010409 (60)
US 2000-222042P 20000731 (60)
DT Utility
FS APPLICATION
LN.CNT 3106
INCL INCLM: 424/185.100
INCLS: 424/186.100; 424/190.100; 424/191.100; 530/350.000; 530/359.000;
530/395.000
NCL NCLM: 424/185.100
NCLS: 424/186.100; 424/190.100; 424/191.100; 530/350.000; 530/359.000;
530/395.000

IC [7]
ICM: A61K039-00
ICS: A61K039-12; A61K039-02; A61K039-002; C07K014-02; C07K014-195;
C07K014-435; C07K014-775
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 265 OF 367 USPATFULL on STN
AN 2003:318732 USPATFULL
TI Method of producing transglutaminase reactive compound
IN Chou, Szu-Yi, Sunnyvale, CA, UNITED STATES
PI US 2003224476 A1 20031204
AI US 2002-231063 A1 20020828 (10)
PRAI US 2002-361166P 20020301 (60)
US 2002-363445P 20020308 (60)
DT Utility
FS APPLICATION
LN.CNT 3307
INCL INCLM: 435/068.100
INCLS: 530/350.000; 530/351.000; 530/395.000; 435/235.100
NCL NCLM: 435/068.100
NCLS: 530/350.000; 530/351.000; 530/395.000; 435/235.100

IC [7]
ICM: C12P021-06
ICS: C12N007-00; C07K014-52; C07K014-435; C07K014-02; C07K014-195
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 266 OF 367 USPATFULL on STN
AN 2003:312289 USPATFULL
TI Directed evolution of novel binding proteins
IN Ladner, Robert Charles, Ijamsville, MD, UNITED STATES
Guterman, Sonia Kosow, Belmont, MA, UNITED STATES
Roberts, Bruce Lindsay, Milford, MA, UNITED STATES
Markland, William, Milford, MA, UNITED STATES
Ley, Arthur Charles, Newton, MA, UNITED STATES
Kent, Rachel Baribault, Boxborough, MA, UNITED STATES
PI US 2003219886 A1 20031127
AI US 2001-896095 A1 20010629 (9)
RLI Continuation of Ser. No. US 1997-993776, filed on 18 Dec 1997, PENDING
Continuation of Ser. No. US 1995-415922, filed on 3 Apr 1995, GRANTED,
Pat. No. US 5837500 Continuation of Ser. No. US 1993-9319, filed on 26
Jan 1993, GRANTED, Pat. No. US 5403484 Division of Ser. No. US
1991-664989, filed on 1 Mar 1991, GRANTED, Pat. No. US 5223409
Continuation-in-part of Ser. No. US 1990-487063, filed on 2 Mar 1990,
ABANDONED Continuation-in-part of Ser. No. US 1988-240160, filed on 2
Sep 1988, ABANDONED
PRAI WO 1989-US3731 19890901
DT Utility
FS APPLICATION
LN.CNT 15529
INCL INCLM: 435/184.000
INCLS: 435/007.100

IC NCLS: 435/007.100
[7]
ICM: C12N009-99
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 267 OF 367 USPATFULL on STN
AN 2003:312260 USPATFULL
TI Method of producing transglutaminase having broad substrate activity
IN Chou, Szu-Yi, Sunnyvale, CA, UNITED STATES
PI US 2003219857 A1 20031127
AI US 2002-231470 A1 20020828 (10)
PRAI US 2002-361166P 20020301 (60)
US 2002-363445P 20020308 (60)
DT Utility
FS APPLICATION
LN.CNT 3442
INCL INCLM: 435/069.100
INCLS: 435/193.000; 435/320.100; 435/325.000; 435/252.300; 536/023.200
NCL NCLM: 435/069.100
NCLS: 435/193.000; 435/320.100; 435/325.000; 435/252.300; 536/023.200
IC [7]
ICM: C12P021-02
ICS: C07H021-04; C12N009-10; C12N001-21
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 268 OF 367 USPATFULL on STN
AN 2003:312256 USPATFULL
TI Method of cross-linking a compound
IN Chou, Szu-Yi, Sunnyvale, CA, UNITED STATES
PI US 2003219853 A1 20031127
AI US 2002-231298 A1 20020828 (10)
PRAI US 2002-361166P 20020301 (60)
US 2002-363445P 20020308 (60)
DT Utility
FS APPLICATION
LN.CNT 3367
INCL INCLM: 435/068.100
INCLS: 435/252.300; 435/235.100; 530/350.000; 530/351.000; 530/395.000
NCL NCLM: 435/068.100
NCLS: 435/252.300; 435/235.100; 530/350.000; 530/351.000; 530/395.000
IC [7]
ICM: C12P021-06
ICS: C12N007-00; C12N001-20; C07K014-52; C07K014-715; C07K014-195;
C07K014-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 269 OF 367 USPATFULL on STN
AN 2003:312125 USPATFULL
TI Fusion proteins, modified filamentous bacteriophage, and populations or
libraries of same
IN Ladner, Robert Charles, Ijamsville, MD, UNITED STATES
Guterman, Sonia Kosow, Belmont, MA, UNITED STATES
Roberts, Bruce Lindsay, Milford, MA, UNITED STATES
Markland, William, Milford, MA, UNITED STATES
Ley, Arthur Charles, Newton, MA, UNITED STATES
Kent, Rachel Baribault, Boxborough, MA, UNITED STATES
PI US 2003219722 A1 20031127
AI US 2002-126685 A1 20020422 (10)
RLI Continuation of Ser. No. US 1997-993776, filed on 18 Dec 1997, PENDING
Continuation of Ser. No. US 1995-415922, filed on 3 Apr 1995, GRANTED,
Pat. No. US 5837500 Continuation of Ser. No. US 1993-9319, filed on 26
Jan 1993, GRANTED, Pat. No. US 5403484 Division of Ser. No. US
1991-664989, filed on 1 Mar 1991, GRANTED, Pat. No. US 5223409
Continuation-in-part of Ser. No. US 1990-487063, filed on 2 Mar 1990,
ABANDONED Continuation-in-part of Ser. No. US 1988-240160, filed on 2
Sep 1988, ABANDONED
PRAI WO 1989-US3731 19890901
DT Utility
FS APPLICATION
LN.CNT 16459
INCL INCLM: 435/005.000
INCLS: 435/069.700; 435/320.100; 435/252.300; 530/350.000; 536/023.720
NCL NCLM: 435/005.000
NCLS: 435/069.700; 435/320.100; 435/252.300; 530/350.000; 536/023.720
IC [7]

ICS: C12Q001-70; C07H021-04; C12P021-04; C12N001-21; C12N015-74
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 270 OF 367 USPATFULL on STN
AN 2003:306883 USPATFULL
TI Specific autoimmune reactions against isomerised/optically inverted
epitopes: application for treatment of autoimmune diseases
IN Cloos, Paul A.C., Kobenhavn, DENMARK
Christgau, Stephan, Gentofte, DENMARK
PI US 2003216319 A1 20031120
AI US 2003-367571 A1 20030214 (10)
RLI Continuation of Ser. No. WO 2001-EP9205, filed on 9 Aug 2001, UNKNOWN
PRAI GB 2000-20238 20000816
DT Utility
FS APPLICATION
LN.CNT 2516
INCL INCLM: 514/013.000
INCLS: 514/014.000; 514/015.000; 514/016.000
NCL NCLM: 514/013.000
NCLS: 514/014.000; 514/015.000; 514/016.000
IC [7]
ICM: A61K038-10
ICS: A61K038-08

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 271 OF 367 USPATFULL on STN
AN 2003:282304 USPATFULL
TI Stabilized Hbc chimera particles as therapeutic vaccine for chronic
hepatitis
IN Page, Mark, Allestree, UNITED KINGDOM
Friede, Martin, Cardiff, CA, UNITED STATES
PI US 2003198645 A1 20031023
AI US 2003-372076 A1 20030221 (10)
RLI Continuation-in-part of Ser. No. US 2002-82014, filed on 21 Feb 2002,
PENDING Continuation-in-part of Ser. No. US 2002-80299, filed on 21 Feb
2002, PENDING
DT Utility
FS APPLICATION
LN.CNT 5638
INCL INCLM: 424/192.100
INCLS: 424/191.100; 530/826.000; 424/189.100; 536/023.720; 536/023.700
NCL NCLM: 424/192.100
NCLS: 424/191.100; 530/826.000; 424/189.100; 536/023.720; 536/023.700
IC [7]
ICM: C07H021-04
ICS: A61K039-29; A61K039-00; A61K039-002; C07K001-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 272 OF 367 USPATFULL on STN
AN 2003:279186 USPATFULL
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical
compositions comprising same, and methods for inhibiting .beta.-amyloid
peptide release and/or its synthesis by use of such compounds
IN Wu, Jing, San Mateo, CA, United States
Tung, Jay S., Belmont, CA, United States
Thorsett, Eugene D., Moss Beach, CA, United States
Pleiss, Michael A., Sunnyvale, CA, United States
Nissen, Jeffrey S., Indianapolis, IN, United States
Neitz, R. Jeffrey, San Francisco, CA, United States
Latimer, Lee H., Oakland, CA, United States
John, Varghese, San Francisco, CA, United States
Freedman, Stephen, Walnut Creek, CA, United States
Britton, Thomas C., Carmel, IN, United States
Audia, James A., Indianapolis, IN, United States
Reel, Jon K., Carmel, IN, United States
Mabry, Thomas E., Indianapolis, IN, United States
Dressman, Bruce A., Indianapolis, IN, United States
Cwi, Cynthia L., Indianapolis, IN, United States
Droste, James J., Indianapolis, IN, United States
Henry, Steven S., New Palestine, IN, United States
McDaniel, Stacey L., Indianapolis, IN, United States
Scott, William Leonard, Indianapolis, IN, United States
Stucky, Russell D., Indianapolis, IN, United States
Porter, Warren J., Indianapolis, IN, United States
PA Athena Neurosciences, Inc., South San Francisco, CA, United States (U.S.)

Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)
PI US 6635632 B1 20031021
AI US 1997-996422 19971222 (8)
PRAI US 1996-64851P 19961223 (60)
DT Utility
FS GRANTED
LN.CNT 22179
INCL INCLM: 514/212.030
INCLS: 514/212.040; 514/212.070; 514/212.080
NCL NCLM: 514/212.030
NCLS: 514/212.040; 514/212.070; 514/212.080
IC [7]
ICM: A61K031-55
ICS: A61P025-28
EXF 514/212.03; 514/212.04; 514/212.07; 514/212.08
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 273 OF 367 USPATFULL on STN
AN 2003:265929 USPATFULL
TI Suppression of cytotoxic protein conformers
IN Cooper, Garth James Smith, Auckland, NEW ZEALAND
Loomes, Kerry Martin, Auckland, NEW ZEALAND
Aitken, Jacqueline Fiona, Auckland, NEW ZEALAND
PI US 2003186946 A1 20031002
AI US 2003-354893 A1 20030129 (10)
PRAI NZ 2002-516920 20020129
DT Utility
FS APPLICATION
LN.CNT 2367
INCL INCLM: 514/150.000
INCLS: 514/228.200; 514/297.000; 514/280.000; 514/152.000; 514/765.000
NCL NCLM: 514/150.000
NCLS: 514/228.200; 514/297.000; 514/280.000; 514/152.000; 514/765.000
IC [7]
ICM: A61K031-655
ICS: A61K031-65; A61K031-542; A61K031-4745; A61K031-473; A61K031-015
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 274 OF 367 USPATFULL on STN
AN 2003:264844 USPATFULL
TI Immunogenic HBc chimera particles stabilized with an N-terminal cysteine
IN Birkett, Ashley J., Escondido, CA, UNITED STATES
PI US 2003185858 A1 20031002
AI US 2002-82014 A1 20020221 (10)
RLI Continuation-in-part of Ser. No. US 2001-930915, filed on 15 Aug 2001,
PENDING
DT Utility
FS APPLICATION
LN.CNT 5511
INCL INCLM: 424/227.100
INCLS: 424/191.100; 530/350.000; 424/278.100; 435/320.100; 536/023.720
NCL NCLM: 424/227.100
NCLS: 424/191.100; 530/350.000; 424/278.100; 435/320.100; 536/023.720
IC [7]
ICM: C07H021-04
ICS: A61K039-002; A61K045-00; C12N015-00; C12N015-63; C12N015-74;
C07K014-00; A61K039-00; A61K047-00; C12N015-70; C07K017-00; A61K039-29;
C12N015-09; C07K001-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 275 OF 367 USPATFULL on STN
AN 2003:251033 USPATFULL
TI Methods for identifying modulators of apoptosis
IN Reed, John C., Rancho Santa Fe, CA, UNITED STATES
Guo, Bin, San Diego, CA, UNITED STATES
PI US 2003175819 A1 20030918
AI US 2002-306878 A1 20021127 (10)
PRAI US 2001-334149P 20011128 (60)
DT Utility
FS APPLICATION
LN.CNT 3438
INCL INCLM: 435/007.200
INCLS: 424/009.200
NCL NCLM: 435/007.200
NCLS: 424/009.200

ICM: G01N033-53

ICS: G01N033-567; G01N033-574; A61K049-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 276 OF 367 USPATFULL on STN
AN 2003:250501 USPATFULL
TI Innate immune system-directed vaccines
IN Medzhitov, Ruslan M., Branford, CT, UNITED STATES
Kopp, Elizabeth, Fairfield, CT, UNITED STATES
PA Yale University, New Haven, CT (U.S. corporation)
PI US 2003175287 A1 20030918
AI US 2002-319854 A1 20021213 (10)
RLI Continuation-in-part of Ser. No. US 2001-752832, filed on 3 Jan 2001,
ABANDONED
PRAI US 2001-340174P 20011214 (60)
DT Utility
FS APPLICATION
LN.CNT 2991
INCL INCLM: 424/185.100
INCLS: 435/069.700; 435/320.100; 435/325.000; 530/350.000; 536/023.500
NCL NCLM: 424/185.100
NCLS: 435/069.700; 435/320.100; 435/325.000; 530/350.000; 536/023.500
IC [7]
ICM: A61K039-00
ICS: C07H021-04; C12P021-04; C12N005-06; C07K014-47
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 277 OF 367 USPATFULL on STN
AN 2003:244343 USPATFULL
TI Alpha-fetoprotein peptides and uses thereof
IN Andersen, Thomas T., Albany, NY, UNITED STATES
Bennett, James A., Delmar, NY, UNITED STATES
Jacobson, Herbert I., Albany, NY, UNITED STATES
Mesfin, Fassil B., Albany, NY, UNITED STATES
PI US 2003170752 A1 20030911
AI US 2001-872623 A1 20010602 (9)
PRAI US 2000-208614P 20000601 (60)
DT Utility
FS APPLICATION
LN.CNT 1173
INCL INCLM: 435/007.230
INCLS: 530/326.000; 530/327.000; 530/328.000; 530/317.000
NCL NCLM: 435/007.230
NCLS: 530/326.000; 530/327.000; 530/328.000; 530/317.000
IC [7]
ICM: G01N033-574
ICS: C07K007-08; C07K007-64
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 278 OF 367 USPATFULL on STN
AN 2003:238482 USPATFULL
TI Reverse-turn mimetics and methods relating thereto
IN Urban, Jan, Kirkland, WA, UNITED STATES
Nakanishi, Hiroshi, Newcastle, WA, UNITED STATES
Lee, Min S., Sammamish, WA, UNITED STATES
PA Molecumetics, Ltd., Bellevue, WA (U.S. corporation)
PI US 2003166640 A1 20030904
AI US 2002-150481 A1 20020516 (10)
PRAI US 2001-291663P 20010516 (60)
DT Utility
FS APPLICATION
LN.CNT 1913
INCL INCLM: 514/224.200
INCLS: 514/249.000; 514/250.000; 514/230.500; 435/007.100; 436/518.000;
544/095.000; 544/014.000; 544/350.000; 544/345.000
NCL NCLM: 514/224.200
NCLS: 514/249.000; 514/250.000; 514/230.500; 435/007.100; 436/518.000;
544/095.000; 544/014.000; 544/350.000; 544/345.000
IC [7]
ICM: G01N033-53
ICS: C07D498-04; C07D487-04; A61K031-542; A61K031-5383; A61K031-498
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 279 OF 367 USPATFULL on STN
AN 2003:237328 USPATFULL

Protein S in relation to adult neural stem or progenitor cells

IN Bertilsson, Goran, Vasterhaninge, SWEDEN
 Falk, Anna, Solna, SWEDEN
 Frisen, Jonas, Stockholm, SWEDEN
 Heidrich, Jessica, Arsta, SWEDEN
 Hellstrom, Kristina, Sodertalje, SWEDEN
 Kortesmaa, Jarkko, Stockholm, SWEDEN
 Lindquist, Per, Bromma, SWEDEN
 Lundh, Hanna, Solna, SWEDEN
 McGuire, Jacqueline, Huddinge, SWEDEN
 Mercer, Alex, Bromma, SWEDEN
 Patrone, Cesare, Hagersten, SWEDEN
 Ronnholm, Harriet, Trangsund, SWEDEN
 Wikstrom, Lillian, Spanga, SWEDEN
 Zachrisson, Olof, Spanga, SWEDEN

PI US 2003165485 A1 20030904
 AI US 2002-291171 A1 20021108 (10)
 PRAI US 2001-344725P 20011109 (60)
 US 2002-393263P 20020702 (60)
 US 2001-345064P 20011109 (60)
 US 2002-394397P 20020708 (60)

DT Utility
 FS APPLICATION
 LN.CNT 3554
 INCL INCLM: 424/094.600
 INCLS: 424/146.100
 NCL NCLM: 424/094.600
 NCLS: 424/146.100
 IC [7]
 ICM: A61K038-46
 ICS: A61K039-395

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 280 OF 367 USPATFULL on STN
 AN 2003:225306 USPATFULL
 TI Novel method for down-regulation of amyloid
 IN Rasmussen, Peter Birk, Horsholm, DENMARK
 Jensen, Martin Roland, Horsholm, DENMARK
 Nielsen, Klaus Gregorius, Horsholm, DENMARK
 Koefoed, Peter, Horsholm, DENMARK
 Degan, Florence Dal, Horsholm, DENMARK

PI US 2003157117 A1 20030821
 AI US 2002-223809 A1 20020820 (10)
 PRAI DK 2001-1231 20010820
 DK 2002-58 20020416
 US 2001-337543P 20011022 (60)
 US 2002-373027P 20020416 (60)

DT Utility
 FS APPLICATION
 LN.CNT 3681
 INCL INCLM: 424/185.100
 INCLS: 435/226.000
 NCL NCLM: 424/185.100
 NCLS: 435/226.000
 IC [7]
 ICM: A61K039-00
 ICS: C12N009-64

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 281 OF 367 USPATFULL on STN
 AN 2003:220227 USPATFULL
 TI Activation and inhibition of the immune system
 IN Foxwell, Brian, London, UNITED KINGDOM
 Feldmann, Marc, London, UNITED KINGDOM

PI US 2003153518 A1 20030814
 AI US 2003-168805 A1 20030131 (10)
 WO 2000-GB4925 20001222
 PRAI GB 1999-30616 19991224

DT Utility
 FS APPLICATION
 LN.CNT 2235
 INCL INCLM: 514/044.000
 INCLS: 424/185.100
 NCL NCLM: 514/044.000
 NCLS: 424/185.100

ICM: A61K048-00

ICS: A61K039-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 282 OF 367 USPATFULL on STN
AN 2003:200784 USPATFULL
TI Immunogenic HBC chimera particles having enhanced stability
IN Birkett, Ashley J., Escondido, CA, UNITED STATES
PI US 2003138769 A1 20030724
AI US 2001-930915 A1 20010815 (9)
RLI Continuation-in-part of Ser. No. US 2000-226867, filed on 22 Aug 2000,
PENDING Continuation-in-part of Ser. No. US 2000-225843, filed on 16 Aug
2000, PENDING
DT Utility
FS APPLICATION
LN.CNT 6993
INCL INCLM: 435/005.000
INCLS: 530/350.000; 435/069.300; 435/325.000; 435/320.100
NCL NCLM: 435/005.000
NCLS: 530/350.000; 435/069.300; 435/325.000; 435/320.100
IC [7]
ICM: C12Q001-70
ICS: C12P021-02; C12N005-06; C07K014-02

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 283 OF 367 USPATFULL on STN
AN 2003:166652 USPATFULL
TI Treatments for neurotoxicity in alzheimer's disease
IN Ingram, Vernon M., Cambridge, MA, UNITED STATES
Blanchard, Barbara J., Cambridge, MA, UNITED STATES
Stockwell, Brent R., Boston, MA, UNITED STATES
PI US 2003114510 A1 20030619
AI US 2002-51663 A1 20020118 (10)
RLI Continuation-in-part of Ser. No. US 2000-706574, filed on 3 Nov 2000,
PENDING
DT Utility
FS APPLICATION
LN.CNT 2115
INCL INCLM: 514/417.000
NCL NCLM: 514/417.000
IC [7]
ICM: A61K031-4035

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 284 OF 367 USPATFULL on STN
AN 2003:165862 USPATFULL
TI Directed evolution of novel binding proteins
IN Ladner, Robert Charles, Ijamsville, MD, UNITED STATES
Guterman, Sonia Kosow, Belmont, MA, UNITED STATES
Roberts, Bruce Lindsay, Milford, MA, UNITED STATES
Markland, William, Milford, MA, UNITED STATES
Ley, Arthur Charles, Newton, MA, UNITED STATES
Kent, Rachel Baribault, Boxborough, MA, UNITED STATES
PI US 2003113717 A1 20030619
AI US 2001-893878 A1 20010629 (9)
RLI Continuation of Ser. No. US 1997-993776, filed on 18 Dec 1997, PENDING
Continuation of Ser. No. US 1995-415922, filed on 3 Apr 1995, PATENTED
Continuation of Ser. No. US 1993-9319, filed on 26 Jan 1993, PATENTED
Division of Ser. No. US 1991-664989, filed on 1 Mar 1991, PATENTED
Continuation-in-part of Ser. No. US 1990-487063, filed on 2 Mar 1990,
ABANDONED Continuation-in-part of Ser. No. US 1988-240160, filed on 2
Sep 1988, ABANDONED
PRAI WO 1989-US3731 19890901
DT Utility
FS APPLICATION
LN.CNT 15933
INCL INCLM: 435/006.000
INCLS: 435/007.200; 435/455.000; 435/091.200
NCL NCLM: 435/006.000
NCLS: 435/007.200; 435/455.000; 435/091.200
IC [7]
ICM: C12Q001-68
ICS: G01N033-53; G01N033-567; C12P019-34; C12N015-87

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2003:153484 USPATFULL
TI Treatments for neurotoxicity in Alzheimer's disease
IN Ingram, Vernon M., Cambridge, MA, UNITED STATES
Blanchard, Barbara J., Cambridge, MA, UNITED STATES
Stockwell, Brent R., Boston, MA, UNITED STATES
PI US 2003105152 A1 20030605
AI US 2002-143534 A1 20020510 (10)
RLI Continuation-in-part of Ser. No. US 2002-51663, filed on 18 Jan 2002,
PENDING Continuation-in-part of Ser. No. US 2000-706574, filed on 3 Nov
2000, PENDING
DT Utility
FS APPLICATION
LN.CNT 2249
INCL INCLM: 514/417.000
INCLS: 435/004.000
NCL NCLM: 514/417.000
NCLS: 435/004.000
IC [7]
ICM: A61K031-4035
ICS: C12Q001-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 286 OF 367 USPATFULL on STN
AN 2003:146345 USPATFULL
TI Metalloprotease-disintegrin ADAM23 (SVPH3-17)
IN Cerretti, Douglas P., Seattle, WA, UNITED STATES
PA Immunex Corporation (U.S. corporation)
PI US 2003100091 A1 20030529
AI US 2002-202675 A1 20020723 (10)
RLI Division of Ser. No. US 634252, PENDING Continuation of Ser. No. WO
1999-US3016, filed on 11 Feb 1999, PENDING
PRAI US 1998-74310P 19980211 (60)
DT Utility
FS APPLICATION
LN.CNT 3070
INCL INCLM: 435/196.000
INCLS: 435/069.100; 435/320.100; 435/325.000; 536/023.200
NCL NCLM: 435/196.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 536/023.200
IC [7]
ICM: C12N009-16
ICS: C07H021-04; C12P021-02; C12N005-06

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 287 OF 367 USPATFULL on STN
AN 2003:146281 USPATFULL
TI Methods and compositions using coiled binding partners
IN Colyer, John, West Yorkshire, UNITED KINGDOM
Lightowler, Joanne, York, UNITED KINGDOM
PI US 2003100027 A1 20030529
AI US 2000-491614 A1 20000126 (9)
RLI Continuation-in-part of Ser. No. US 1999-259474, filed on 26 Feb 1999,
ABANDONED
DT Utility
FS APPLICATION
LN.CNT 2588
INCL INCLM: 435/007.400
NCL NCLM: 435/007.400
IC [7]
ICM: G01N033-53

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 288 OF 367 USPATFULL on STN
AN 2003:140906 USPATFULL
TI Methods and compositions for the treatment of diseases associated with
signal transduction aberrations
IN Holoshitz, Joseph, Ann Arbor, MI, UNITED STATES
Ling, Song, Ann Arbor, MI, UNITED STATES
PA The Regents Of The University Of Michigan (U.S. corporation)
PI US 2003096748 A1 20030522
AI US 2002-161959 A1 20020603 (10)
PRAI US 2001-295691P 20010604 (60)
DT Utility
FS APPLICATION
LN.CNT 2986

INCLS: 530/359.000
NCL NCLM: 514/012.000
NCLS: 530/359.000
IC [7]
ICM: A61K038-17
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 289 OF 367 USPATFULL on STN
AN 2003:126727 USPATFULL
TI Novel methods for down-regulation of amyloid
IN Jensen, Martin Roland, Horsholm, DENMARK
Birk, Peter, Horsholm, DENMARK
Nielsen, Klaus Gregorius, Horsholm, DENMARK
PI US 2003086938 A1 20030508
AI US 2002-204362 A1 20020816 (10)
WO 2001-DK113 20010219
PRAI DK 2000-265 20000221
DT Utility
FS APPLICATION
LN.CNT 3114
INCL INCLM: 424/185.100
NCL NCLM: 424/185.100
IC [7]
ICM: A61K039-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 290 OF 367 USPATFULL on STN
AN 2003:120290 USPATFULL
TI Nucleic acids encoding human adamalysin SVPH1-8
IN Cerretti, Douglas P., Seattle, WA, UNITED STATES
PA Immunex Corporation (U.S. corporation)
PI US 2003082771 A1 20030501
AI US 2002-265125 A1 20021003 (10)
RLI Division of Ser. No. US 2000-617145, filed on 14 Jul 2000, GRANTED, Pat.
No. US 6485956 Continuation of Ser. No. WO 1999-US603, filed on 12 Jan
1999, PENDING
PRAI US 1998-71505P 19980114 (60)
DT Utility
FS APPLICATION
LN.CNT 2031
INCL INCLM: 435/189.000
INCLS: 435/006.000; 435/069.100; 435/320.100; 435/325.000; 536/023.200
NCL NCLM: 435/189.000
NCLS: 435/006.000; 435/069.100; 435/320.100; 435/325.000; 536/023.200
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12N009-02; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 291 OF 367 USPATFULL on STN
AN 2003:120026 USPATFULL
TI Identification of modulatory molecules using inducible promoters
IN Brown, Steven J., San Diego, CA, UNITED STATES
Dunnington, Damien J., San Diego, CA, UNITED STATES
Clark, Imran, San Diego, CA, UNITED STATES
PI US 2003082511 A1 20030501
AI US 2001-965201 A1 20010925 (9)
DT Utility
FS APPLICATION
LN.CNT 5526
INCL INCLM: 435/004.000
INCLS: 435/006.000
NCL NCLM: 435/004.000
NCLS: 435/006.000
IC [7]
ICM: C12Q001-00
ICS: C12Q001-68
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 292 OF 367 USPATFULL on STN
AN 2003:113007 USPATFULL
TI Presenilin/Crk binding polypeptides (PCBP) and methods of use thereof
IN Schubert, David R., La Jolla, CA, UNITED STATES
Kashiwa, Atsushi, Yokohama, JAPAN
Kimura, Hideo, Tokyo, JAPAN

AI US 2002-234961 A1 20020903 (10)
 RLI Continuation of Ser. No. WO 2001-US7024, filed on 5 Mar 2001, PENDING
 DT Utility
 FS APPLICATION
 LN.CNT 4003
 INCL INCLM: 435/069.100
 INCLS: 435/320.100; 435/226.000; 435/325.000; 536/023.200
 NCL NCLM: 435/069.100
 NCLS: 435/320.100; 435/226.000; 435/325.000; 536/023.200
 IC [7]
 ICM: C12P021-02
 ICS: C12N005-06; C07H021-04; C12N009-64
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 293 OF 367 USPATFULL on STN
 AN 2003:112909 USPATFULL
 TI Methods of suppressing microglial activation and systemic inflammatory responses
 IN Laskowitz, Daniel T., Chapel Hill, NC, UNITED STATES
 Matthew, William D., Durham, NC, UNITED STATES
 McMillian, Michael, Rareton, NJ, UNITED STATES
 PI US 2003077641 A1 20030424
 AI US 2002-252120 A1 20020923 (10)
 RLI Continuation-in-part of Ser. No. US 2001-957909, filed on 21 Sep 2001, PENDING Continuation-in-part of Ser. No. US 1999-260430, filed on 1 Mar 1999, ABANDONED
 PRAI US 1998-77551P 19980311 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 3107
 INCL INCLM: 435/006.000
 INCLS: 514/013.000; 435/235.100; 435/325.000; 424/186.100
 NCL NCLM: 435/006.000
 NCLS: 514/013.000; 435/235.100; 435/325.000; 424/186.100
 IC [7]
 ICM: A61K038-17
 ICS: A61K038-10; C12Q001-68; A61K038-00; C12N007-00; C12N007-01; C12N005-00; C12N005-02; A61K039-12
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 294 OF 367 USPATFULL on STN
 AN 2003:106698 USPATFULL
 TI Yeast screens for treatment of human disease
 IN Lindquist, Susan, Chestnut Hill, MA, UNITED STATES
 Krobtsch, Sylvia, Berlin, GERMANY, FEDERAL REPUBLIC OF
 Outeiro, Tiago Fleming, Cambridge, MA, UNITED STATES
 PA The University of Chicago (U.S. corporation)
 PI US 2003073610 A1 20030417
 AI US 2002-77584 A1 20020215 (10)
 PRAI US 2001-269157P 20010215 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 3198
 INCL INCLM: 514/001.000
 INCLS: 435/007.310; 435/254.200; 435/483.000
 NCL NCLM: 514/001.000
 NCLS: 435/007.310; 435/254.200; 435/483.000
 IC [7]
 ICM: A61K031-00
 ICS: G01N033-53; G01N033-569; C12N001-18; C12N015-74
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 295 OF 367 USPATFULL on STN
 AN 2003:102440 USPATFULL
 TI Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor
 IN Zhang, Shuguang, Cambridge, MA, United States
 Lockshin, Curtis, Lexington, MA, United States
 Rich, Alexander, Cambridge, MA, United States
 Holmes, Todd, Cambridge, MA, United States
 PA Massachusetts Institute of Technology, Cambridge, MA, United States (U.S. corporation)
 PI US 6548630 B1 20030415
 AI US 1997-898300 19970722 (8)
 RLI Continuation of Ser. No. US 1994-346849, filed on 30 Nov 1994, now

filed on 28 Dec 1992, now abandoned

DT Utility
FS GRANTED
LN.CNT 2187
INCL INCLM: 530/300.000
INCLS: 530/324.000; 530/325.000; 530/326.000; 530/327.000; 530/350.000;
514/012.000; 514/013.000; 514/014.000
NCL NCLM: 530/300.000
NCLS: 530/324.000; 530/325.000; 530/326.000; 530/327.000; 530/350.000
IC [7]
ICM: C07K007-00
ICS: C07K016-00; A61K038-00
EXF 514/12; 514/13; 514/14; 530/300; 530/324; 530/325; 530/326; 530/327;
530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 296 OF 367 USPATFULL on STN
AN 2003:99212 USPATFULL
TI Anti-ADDL antibodies and uses thereof
IN Klein, William L., Winnetka, IL, UNITED STATES
Krafft, Grant A., Glenview, IL, UNITED STATES
Lambert, Mary P., Glenview, IL, UNITED STATES
Viola, Kirsten L., Chicago, IL, UNITED STATES
Chromy, Brett A., Pleasanton, CA, UNITED STATES
Gong, Yue Song, Evanston, IL, UNITED STATES
Chang, Lei, Evanston, IL, UNITED STATES
Morgan, Todd E., Los Angeles, CA, UNITED STATES
Rozofsky, Irina, Pasadena, CA, UNITED STATES
Finch, Caleb E., Altadena, CA, UNITED STATES
PI US 2003068316 A1 20030410
AI US 2002-166856 A1 20020611 (10)
RLI Continuation-in-part of Ser. No. US 1999-369236, filed on 4 Aug 1999,
PENDING Continuation-in-part of Ser. No. US 1997-796089, filed on 5 Feb
1997, GRANTED, Pat. No. US 6218506
PRAI US 1998-95264P 19980804 (60)
DT Utility
FS APPLICATION
LN.CNT 2982
INCL INCLM: 424/130.100
NCL NCLM: 424/130.100
IC [7]
ICM: A61K039-395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 297 OF 367 USPATFULL on STN
AN 2003:37643 USPATFULL
TI Methods of screening for agents that inhibit aggregation of polypeptides
IN Housman, David E., Newton, MA, UNITED STATES
Preisinger, Elizabeth A., Roslindale, MA, UNITED STATES
Kazantsev, Aleksey G., Boston, MA, UNITED STATES
PA Massachusetts Institute of Technology, a Massachusetts corporation (U.S.
corporation)
PI US 2003027288 A1 20030206
AI US 2002-194584 A1 20020712 (10)
RLI Division of Ser. No. US 1999-405048, filed on 27 Sep 1999, GRANTED, Pat.
No. US 6420122
DT Utility
FS APPLICATION
LN.CNT 1058
INCL INCLM: 435/091.100
INCLS: 435/091.330; 424/186.100; 424/208.100
NCL NCLM: 435/091.100
NCLS: 435/091.330; 424/186.100; 424/208.100
IC [7]
ICM: C12P019-34
ICS: A61K039-12; A61K039-21
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 298 OF 367 USPATFULL on STN
AN 2003:30296 USPATFULL
TI Protein aggregation assays and uses thereof
IN Kondejewski, Les, St. Lazare, CANADA
Chakrabartty, Avijit, Vaughan, CANADA
Qi, Xiao-Fei, Toronto, CANADA
Cashman, Neil, Toronto, CANADA

AI US 2002-176809 A1 20020620 (10)
PRAI US 2001-299849P 20010620 (60)
DT Utility
FS APPLICATION
LN.CNT 2602
INCL INCLM: 435/007.100
INCLS: 435/007.210
NCL NCLM: 435/007.100
NCLS: 435/007.210
IC [7]
ICM: G01N033-53
ICS: G01N033-567
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 299 OF 367 USPATFULL on STN
AN 2003:4068 USPATFULL
TI Method of preventing cell death using segments of neural thread proteins
IN Averbach, Paul A., Beaconsfield, CANADA
PI US 2003004107 A1 20030102
AI US 2002-146130 A1 20020516 (10)
PRAI US 2001-290971P 20010516 (60)
DT Utility
FS APPLICATION
LN.CNT 1698
INCL INCLM: 514/012.000
INCLS: 514/013.000; 514/014.000; 514/015.000; 514/016.000
NCL NCLM: 514/012.000
NCLS: 514/013.000; 514/014.000; 514/015.000; 514/016.000
IC [7]
ICM: A61K038-17
ICS: A61K038-10; A61K038-08
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 300 OF 367 USPATFULL on STN
AN 2003:4060 USPATFULL
TI The use of copolymer 1 and related peptides and polypeptides and T cells
treated therewith for neuroprotective therapy
IN Eisenbach-schwartz, Michael, Rehovot, ISRAEL
Cohen, Irun R., Rehovot, ISRAEL
Sela, Michael, Rehovot, ISRAEL
Yoles, Eti, Nahal Sorek, ISRAEL
Kipnis, Jonathan, Modiin, ISRAEL
PI US 2003004099 A1 20030102
AI US 2001-765644 A1 20010122 (9)
RLI Continuation-in-part of Ser. No. US 2000-620216, filed on 20 Jul 2000,
ABANDONED Continuation-in-part of Ser. No. US 2000-487793, filed on 20
Jan 2000, ABANDONED
PRAI US 2000-209799P 20000607 (60)
DT Utility
FS APPLICATION
LN.CNT 2844
INCL INCLM: 514/012.000
INCLS: 424/093.700
NCL NCLM: 514/012.000
NCLS: 424/093.700
IC [7]
ICM: A61K045-00
ICS: A61K038-17
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 301 OF 367 USPATFULL on STN
AN 2003:3410 USPATFULL
TI Method of preventing cell death using antibodies to neural thread
proteins
IN Averbach, Paul A., Quebec, CANADA
PI US 2003003445 A1 20030102
AI US 2002-138516 A1 20020506 (10)
PRAI US 2001-288463P 20010504 (60)
DT Utility
FS APPLICATION
LN.CNT 1705
INCL INCLM: 435/005.000
INCLS: 435/069.100; 435/345.000; 435/007.100
NCL NCLM: 435/005.000
NCLS: 435/069.100; 435/345.000; 435/007.100

ICM: C12Q001-70
ICS: G01N033-53; C12P021-06; C12N005-06; C12N005-16
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 302 OF 367 USPATFULL on STN
AN 2002:343880 USPATFULL
TI Compositions and methods for monitoring the modification of modification
dependent binding partner polypeptides
IN Craig, Roger, Smallwood, UNITED KINGDOM
PI US 2002197606 A1 20021226
AI US 2001-770102 A1 20010125 (9)
PRAI US 2000-179283P 20000131 (60)
DT Utility
FS APPLICATION
LN.CNT 3550
INCL INCLM: 435/006.000
NCL NCLM: 435/006.000
IC [7]
ICM: C12Q001-68
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 303 OF 367 USPATFULL on STN
AN 2002:329478 USPATFULL
TI Novel method for down-regulation of amyloid
IN Jensen, Martin Roland, Holte, DENMARK
Rasmussen, Peter Birk, Frederiksberg, DENMARK
Nielsen, Klaus Gregorius, Soborg, DENMARK
PI US 2002187157 A1 20021212
AI US 2001-785215 A1 20010220 (9)
PRAI PA 2000-200000265 20000221
US 2000-186295P 20000301 (60)
DT Utility
FS APPLICATION
LN.CNT 3272
INCL INCLM: 424/185.100
INCLS: 424/085.100; 424/085.200
NCL NCLM: 424/185.100
NCLS: 424/085.100; 424/085.200
IC [7]
ICM: A61K039-00
ICS: A61K038-19; A61K038-20
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 304 OF 367 USPATFULL on STN
AN 2002:310800 USPATFULL
TI Testis-specific human SVPH1-8 proteinase
IN Cerretti, Douglas P., Seattle, WA, United States
PA Immunex Corporation, Seattle, WA, United States (U.S. corporation)
PI US 6485956 B1 20021126
AI US 2000-617145 20000714 (9)
DT Utility
FS GRANTED
LN.CNT 2072
INCL INCLM: 435/219.000
INCLS: 435/069.100; 435/183.000; 435/218.000
NCL NCLM: 435/219.000
NCLS: 435/069.100; 435/183.000; 435/218.000
IC [7]
ICM: C12P021-06
ICS: C12N009-00; C12N009-66; C12N009-50
EXF 435/69.1; 435/183; 435/212; 435/219
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 305 OF 367 USPATFULL on STN
AN 2002:308378 USPATFULL
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical
compositions comprising same, and methods for inhibiting B-amyloid
peptide release and/or its synthesis by use of such compounds
IN Wu, Jing, San Mateo, CA, UNITED STATES
Tung, Jay S., Belmont, CA, UNITED STATES
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
Pleiss, Michael A., Sunnyvale, CA, UNITED STATES
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES
Neitz, Jeffrey, San Francisco, CA, UNITED STATES
Latimer, Lee H., Oakland, CA, UNITED STATES

Freedman, Stephen, Walnut Creek, CA, UNITED STATES
Britton, Thomas C., Carmel, IN, UNITED STATES
Audia, James E., Indianapolis, IN, UNITED STATES
Reel, Jon K., Carmel, IN, UNITED STATES
Mabry, Thomas E., Indianapolis, IN, UNITED STATES
Dressman, Bruce A., Indianapolis, IN, UNITED STATES
Cwi, Cynthia L., Indianapolis, IN, UNITED STATES
Droste, James J., Indianapolis, IN, UNITED STATES
Henry, Steven S., New Palestine, IN, UNITED STATES
McDaniel, Stacey L., Bloomington, IN, UNITED STATES
Scott, William Leonard, Indianapolis, IN, UNITED STATES
Stucky, Russell D., Indianapolis, IN, UNITED STATES
Porter, Warren J., Indianapolis, IN, UNITED STATES

PI US 2002173504 A1 20021121
AI US 2001-915519 A1 20010727 (9)
RLI Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING
PRAI US 1996-64851P 19961223 (60)
DT Utility
FS APPLICATION
LN.CNT 25650
INCL INCLM: 514/212.040
INCLS: 514/327.000; 514/424.000; 514/659.000
NCL NCLM: 514/212.040
NCLS: 514/327.000; 514/424.000; 514/659.000
IC [7]
ICM: A61K031-55
ICS: A61K031-445; A61K031-4015; A61K031-13
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 306 OF 367 USPATFULL on STN
AN 2002:301123 USPATFULL
TI Hybridization probe and target nucleic acid detecting kit, target
nucleic acid detecting apparatus and target nucleic acid detecting
method using the same
IN Kinoshita, Takatoshi, Aichi, JAPAN
Washizu, Shintaro, Shizuoka, JAPAN
PA FUJI PHOTO FILM CO., LTD. (3)
PI US 2002168666 A1 20021114
AI US 2002-103830 A1 20020325 (10)
PRAI JP 2001-86306 20010323
DT Utility
FS APPLICATION
LN.CNT 1137
INCL INCLM: 435/006.000
INCLS: 536/024.300; 435/287.200
NCL NCLM: 435/006.000
NCLS: 536/024.300; 435/287.200
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12M001-34
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 307 OF 367 USPATFULL on STN
AN 2002:295299 USPATFULL
TI Iron regulating protein -2 (IRP-2) as a diagnostic for neurodegenerative
disease
IN Kirsch, Wolff M., Redlands, CA, UNITED STATES
Lennart, Anto, Loma Linda, CA, UNITED STATES
Kelln, Wayne J., Loma Linda, CA, UNITED STATES
Kang, Dae-Kyung, Rockville, MD, UNITED STATES
Levine, Rodney L., Rockville, MD, UNITED STATES
Rouault, Tracey A., North Bethesda, MD, UNITED STATES
PI US 2002165349 A1 20021107
AI US 2001-924396 A1 20010806 (9)
PRAI US 2000-222863P 20000804 (60)
DT Utility
FS APPLICATION
LN.CNT 3514
INCL INCLM: 530/350.000
INCLS: 536/023.500; 435/006.000; 435/007.100
NCL NCLM: 530/350.000
NCLS: 536/023.500; 435/006.000; 435/007.100
IC [7]
ICM: C12Q001-68
ICS: G01N033-53; C07H021-04; C07K014-705

L5 ANSWER 308 OF 367 USPATFULL on STN
 AN 2002:294746 USPATFULL
 TI Methods of suppressing microglial activation
 IN Laskowitz, Daniel T., Chapel Hill, NC, UNITED STATES
 Matthew, William D., Durham, NC, UNITED STATES
 McMillian, Michael, Rareton, NJ, UNITED STATES
 PI US 2002164789 A1 20021107
 AI US 2001-957909 A1 20010921 (9)
 RLI Continuation-in-part of Ser. No. US 1999-260430, filed on 1 Mar 1999,
 PENDING
 PRAI US 1998-77551P 19980311 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1534
 INCL INCLM: 435/343.000
 INCLS: 514/012.000; 514/044.000; 435/005.000
 NCL NCLM: 435/343.000
 NCLS: 514/012.000; 514/044.000; 435/005.000
 IC [7]
 ICM: A61K038-17
 ICS: C12Q001-70; A61K038-00; A61K031-70; A01N043-04; C12N005-06;
 C12N005-16
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 309 OF 367 USPATFULL on STN
 AN 2002:290938 USPATFULL
 TI N-hydroxy 4-sulfonyl butanamide compounds
 IN Villamil, Clara I., Glenview, IL, United States
 Freskos, John N., Clayton, MO, United States
 Mischke, Brent V., Defiance, MO, United States
 Mullins, Patrick B., St. Louis, MO, United States
 Heintz, Robert M., Ballwin, MO, United States
 Getman, Daniel P., Chesterfield, MO, United States
 McDonald, Joseph J., Ballwin, MO, United States
 DeCrescenzo, Gary A., St. Charles, MO, United States
 Barta, Thomas E., Evanston, IL, United States
 Becker, Daniel P., Glenview, IL, United States
 PA Monsanto Company, St. Louis, MO, United States (U.S. corporation)
 PI US 6476027 B1 20021105
 WO 9839316 19980911
 AI US 1999-254531 19991206 (9)
 WO 1998-US4297 19980304
 19991206 PCT 371 date
 PRAI US 1997-35182P 19970304 (60)
 DT Utility
 FS GRANTED
 LN.CNT 3634
 INCL INCLM: 514/237.800
 INCLS: 514/330.000; 514/331.000; 514/357.000; 514/428.000; 514/486.000;
 514/575.000; 544/159.000; 546/225.000; 546/226.000; 546/233.000;
 546/340.000; 548/568.000; 560/013.000; 562/621.000; 562/623.000
 NCL NCLM: 514/237.800
 NCLS: 514/330.000; 514/331.000; 514/357.000; 514/428.000; 514/486.000;
 514/575.000; 544/159.000; 546/225.000; 546/226.000; 546/233.000;
 546/340.000; 548/568.000; 560/013.000; 562/621.000; 562/623.000
 IC [7]
 ICM: A61K031-16
 ICS: A61K031-4406; C07C323-32; C07D211-90
 EXF 562/621; 562/623; 546/225; 546/226; 546/233; 546/340; 544/159; 548/568;
 560/13; 514/237.8; 514/330; 514/331; 514/357; 514/428; 514/456; 514/575
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 310 OF 367 USPATFULL on STN
 AN 2002:273410 USPATFULL
 TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical
 compositions comprising same, and methods for inhibiting beta-amyloid
 peptide release and/or its synthesis by use of such compounds
 IN Wu, Jing, San Mateo, CA, UNITED STATES
 Tung, Jay S., Belmont, CA, UNITED STATES
 Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
 Pleiss, Michael A., Sunnyvale, CA, UNITED STATES
 Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES
 Neitz, Jeffrey, San Francisco, CA, UNITED STATES
 Latimer, Lee H., Oakland, CA, UNITED STATES

Freedman, Stephen, Walnut Creek, CA, UNITED STATES
Britton, Thomas C., Carmel, IN, UNITED STATES
Audia, James A., Indianapolis, IN, UNITED STATES
Reel, Jon K., Carmel, IN, UNITED STATES
Mabry, Thomas E., Indianapolis, IN, UNITED STATES
Dressman, Bruce A., Indianapolis, IN, UNITED STATES
Droste, James J., Indianapolis, IN, UNITED STATES
Henry, Steven S., New Palestine, IN, UNITED STATES
McDaniel, Stacey L., Bloomington, IN, UNITED STATES
Stucky, Russell D., Indianapolis, IN, UNITED STATES
Porter, Warren J., Indianapolis, IN, UNITED STATES

PI US 2002151538 A1 20021017
US 6579867 B2 20030617
AI US 2001-915379 A1 20010727 (9)
RLI Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING
PRAI US 1996-64851P 19961223 (60)
DT Utility
FS APPLICATION
LN.CNT 26543
INCL INCLM: 514/212.040
INCLS: 514/327.000; 514/424.000; 514/659.000
NCL NCLM: 514/211.060
NCLS: 514/211.070; 514/212.040; 514/212.060; 514/212.070; 514/212.080
IC [7]
ICM: A61K031-55
ICS: A61K031-445; A61K031-4015; A61K031-13
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 311 OF 367 USPATFULL on STN
AN 2002:273336 USPATFULL
TI Methods for preventing neural tissue damage and for the treatment of
alpha-synuclein diseases
IN Wolozin, Benjamin, Hinsdale, IL, UNITED STATES
Ostretova-Golts, Natalie, Forrest Park, IL, UNITED STATES
Lebowitz, Michael S., Baltimore, MD, UNITED STATES
PI US 2002151464 A1 20021017
US 6780971 B2 20040824
AI US 2001-901187 A1 20010709 (9)
PRAI US 2000-217319P 20000707 (60)
US 2001-279199P 20010328 (60)
DT Utility
FS APPLICATION
LN.CNT 1374
INCL INCLM: 514/002.000
INCLS: 435/007.200; 435/025.000
NCL NCLM: 530/329.000
NCLS: 514/002.000; 514/016.000
IC [7]
ICM: A61K038-16
ICS: G01N033-53; G01N033-567; C12Q001-26
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 312 OF 367 USPATFULL on STN
AN 2002:272761 USPATFULL
TI Directed evolution of novel binding proteins
IN Ladner, Robert Charles, Ijamsville, MD, UNITED STATES
Guterman, Sonia Kosow, Belmont, MA, UNITED STATES
Roberts, Bruce Lindsay, Milford, MA, UNITED STATES
Markland, William, Milford, MA, UNITED STATES
Ley, Arthur Charles, Newton, MA, UNITED STATES
Kent, Rachel Baribault, Boxborough, MA, UNITED STATES
PI US 2002150881 A1 20021017
AI US 2001-781988 A1 20010214 (9)
RLI Continuation of Ser. No. US 1998-192067, filed on 16 Nov 1998, ABANDONED
Continuation of Ser. No. US 1995-415922, filed on 3 Apr 1995, PATENTED
Continuation of Ser. No. US 1993-9319, filed on 26 Jan 1993, PATENTED
Division of Ser. No. US 1991-664989, filed on 1 Mar 1991, PATENTED
Continuation-in-part of Ser. No. US 1990-487063, filed on 2 Mar 1990,
ABANDONED Continuation-in-part of Ser. No. US 1988-240160, filed on 2
Sep 1988, ABANDONED
PRAI WO 1989-US3731 19890901
DT Utility
FS APPLICATION
LN.CNT 15696
INCL INCLM: 435/005.000

NCL NCLM: 435/005.000
NCLS: 435/006.000; 435/007.100; 435/235.100

IC [7]
ICM: C12Q001-70
ICS: C12Q001-68; G01N033-53; C12N007-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 313 OF 367 USPATFULL on STN
AN 2002:259378 USPATFULL
TI Methods for enhancing the bioavailability of a drug
IN Hayward, Neil J., North Grafton, MA, UNITED STATES
Gefter, Malcolm L., Lincoln, MA, UNITED STATES

PI US 2002142950 A1 20021003
AI US 2001-781133 A1 20010209 (9)
PRAI US 2000-181833P 20000211 (60)
US 2000-181943P 20000211 (60)

DT Utility
FS APPLICATION

LN.CNT 2566

INCL INCLM: 514/012.000
INCLS: 514/224.800

NCL NCLM: 514/012.000
NCLS: 514/224.800

IC [7]
ICM: A61K038-17
ICS: A61K031-5415

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 314 OF 367 USPATFULL on STN
AN 2002:251785 USPATFULL
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical
compositions comprising same, and methods for inhibiting beta-amyloid
peptide release and/or its synthesis by use of such compounds

IN Wu, Jing, San Mateo, CA, UNITED STATES
Tung, Jay S., Belmont, CA, UNITED STATES
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
Pleiss, Michael A., Sunnyvale, CA, UNITED STATES
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES
Neitz, Jeffrey, San Francisco, CA, UNITED STATES
Latimer, Lee H., Oakland, CA, UNITED STATES
John, Varghese, San Francisco, CA, UNITED STATES
Freedman, Stephen, Walnut Creek, CA, UNITED STATES
Britton, Thomas C., Carmel, IN, UNITED STATES
Audia, James E., Indianapolis, IN, UNITED STATES
Reel, Jon K., Carmel, IN, UNITED STATES
Mabry, Thomas E., Indianapolis, IN, UNITED STATES
Dressman, Bruce A., Indianapolis, IN, UNITED STATES
Cwi, Cynthia L., Indianapolis, IN, UNITED STATES
Droste, James J., Indianapolis, IN, UNITED STATES
Henry, Steven S., New Palestine, IN, UNITED STATES
McDaniel, Stacey L., Bloomington, IN, UNITED STATES
Scott, William Leonard, Indianapolis, IN, UNITED STATES
Stucky, Russell D., Indianapolis, IN, UNITED STATES
Porter, Warren J., Indianapolis, IN, UNITED STATES

PI US 2002137738 A1 20020926
US 6559141 B2 20030506
AI US 2001-915564 A1 20010727 (9)

RLI Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING

PRAI US 1996-64851P 19961223 (60)

DT Utility
FS APPLICATION

LN.CNT 26049

INCL INCLM: 514/212.030
INCLS: 514/327.000; 514/424.000; 514/659.000

NCL NCLM: 514/211.060
NCLS: 514/211.070; 514/212.040; 514/212.060; 514/212.070; 514/212.080;
540/488.000; 540/521.000; 540/522.000; 540/523.000; 540/524.000;
540/527.000

IC [7]
ICM: A61K031-55
ICS: A61K031-445; A61K031-4015; A61K031-13

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 315 OF 367 USPATFULL on STN
AN 2002:243567 USPATFULL

with molecular crystallization
IN Shell, John W., Hillsborough, CA, UNITED STATES
PI US 2002132758 A1 20020919
AI US 2002-52712 A1 20020117 (10)
PRAI US 2001-262987P 20010118 (60)
DT Utility
FS APPLICATION
LN.CNT 1620
INCL INCLM: 514/002.000
INCLS: 435/007.100
NCL NCLM: 514/002.000
NCLS: 435/007.100
IC [7]
ICM: G01N033-53
ICS: A61K038-17
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 316 OF 367 USPATFULL on STN
AN 2002:228326 USPATFULL
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
IN Wu, Jing, San Mateo, CA, UNITED STATES
Tung, Jay S., Belmont, CA, UNITED STATES
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
Pleiss, Michael A., Sunnyvale, CA, UNITED STATES
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES
Neitz, Jeffrey, San Francisco, CA, UNITED STATES
Latimer, Lee H., Oakland, CA, UNITED STATES
John, Varghese, San Francisco, CA, UNITED STATES
Freedman, Stephen, Walnut Creek, CA, UNITED STATES
Britton, Thomas C., Carmel, IN, UNITED STATES
Audia, James E., Indianapolis, IN, UNITED STATES
Reel, Jon K., Carmel, IN, UNITED STATES
Mabry, Thomas E., Indianapolis, IN, UNITED STATES
Dressman, Bruce A., Indianapolis, IN, UNITED STATES
Cwi, Cynthia L., Indianapolis, IN, UNITED STATES
Droste, James J., Indianapolis, IN, UNITED STATES
Henry, Steven S., New Palestine, IN, UNITED STATES
McDaniel, Stacey L., Bloomington, IN, UNITED STATES
Scott, William Leonard, Indianapolis, IN, UNITED STATES
Stucky, Russell D., Indianapolis, IN, UNITED STATES
Porter, Warren J., Indianapolis, IN, UNITED STATES
PI US 2002123486 A1 20020905
US 6632811 B2 20031014
AI US 2001-915342 A1 20010727 (9)
RLI Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING
PRAI US 1996-64851P 19961223 (60)
DT Utility
FS APPLICATION
LN.CNT 26177
INCL INCLM: 514/212.020
INCLS: 514/659.000
NCL NCLM: 514/220.000
NCLS: 514/221.000
IC [7]
ICM: A61K031-55
ICS: A61K031-13
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 317 OF 367 USPATFULL on STN
AN 2002:227618 USPATFULL
TI Ascorbic acid analogs for metalloradiopharmaceuticals
IN Liu, Shuang, Chelmsford, MA, UNITED STATES
PI US 2002122769 A1 20020905
US 6713042 B2 20040330
AI US 2002-81258 A1 20020222 (10)
PRAI US 2001-271389P 20010226 (60)
DT Utility
FS APPLICATION
LN.CNT 1882
INCL INCLM: 424/001.110
INCLS: 514/424.000; 514/474.000; 514/690.000
NCL NCLM: 424/001.650
NCLS: 424/001.110; 424/009.100; 548/400.000; 548/401.000; 549/200.000;

IC [7]
ICM: A61K051-00
ICS: A61K031-4015; A61K031-375
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 318 OF 367 USPATFULL on STN
AN 2002:227617 USPATFULL
TI Stable radiopharmaceutical compositions and methods for preparation thereof
IN Liu, Shuang, Chelmsford, MA, UNITED STATES
Barrett, John A., Groton, MA, UNITED STATES
Carpenter, Alan P., JR., Carlisle, MA, UNITED STATES
PI US 2002122768 A1 20020905
AI US 2001-899629 A1 20010705 (9)
PRAI US 2000-216396P 20000706 (60)
DT Utility
FS APPLICATION
LN.CNT 4115
INCL INCLM: 424/001.110
NCL NCLM: 424/001.110
IC [7]

ICM: A61K051-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 319 OF 367 USPATFULL on STN
AN 2002:224705 USPATFULL
TI Hydrophobically-modified hedgehog protein compositions and methods
IN Pepinsky, R. Blake, Arlington, MA, United States
Baker, Darren P., Hingham, MA, United States
Wen, Dingyi, Waltham, MA, United States
Williams, Kevin P., Natick, MA, United States
Garber, Ellen A., Cambridge, MA, United States
Taylor, Frederick R., Milton, MA, United States
Galdes, Alphonse, Lexington, MA, United States
Porter, Jeffrey, Cambridge, MA, United States
PA Curis, Inc., Cambridge, MA, United States (U.S. corporation)
Biogen, Inc., Cambridge, MA, United States (U.S. corporation)
PI US 6444793 B1 20020903
AI US 1999-325256 19990603 (9)
RLI Continuation of Ser. No. WO 1998-US25676, filed on 3 Dec 1998
PRAI US 1998-99800P 19980910 (60)
US 1998-89685P 19980617 (60)
US 1998-78935P 19980320 (60)
US 1997-67423P 19971203 (60)
DT Utility
FS GRANTED
LN.CNT 5426
INCL INCLM: 530/402.000
INCLS: 530/350.000; 530/399.000; 530/359.000; 436/071.000; 514/012.000;
514/506.000; 514/762.000
NCL NCLM: 530/402.000
NCLS: 436/071.000; 530/350.000; 530/359.000; 530/399.000
IC [7]
ICM: C07K014-435
ICS: C07K001-107
EXF 436/71; 530/350; 530/399; 530/402; 530/359; 514/12; 514/506; 514/762
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 320 OF 367 USPATFULL on STN
AN 2002:221784 USPATFULL
TI Inhibitors of IAPP fibril formation and uses thereof
IN Fraser, Paul, Toronto, CANADA
PI US 2002119926 A1 20020829
AI US 2001-956625 A1 20010919 (9)
PRAI US 2000-233482P 20000919 (60)
DT Utility
FS APPLICATION
LN.CNT 1753
INCL INCLM: 514/012.000
INCLS: 435/184.000; 514/014.000; 514/015.000; 514/016.000; 514/017.000
NCL NCLM: 514/012.000
NCLS: 435/184.000; 514/014.000; 514/015.000; 514/016.000; 514/017.000
IC [7]
ICM: A61K038-17
ICS: A61K038-10; A61K038-08; C12N009-99

L5 ANSWER 321 OF 367 USPATFULL on STN
 AN 2002:216831 USPATFULL
 TI Epithelial cell targeting agent
 IN Hein, Mich B., Fallbrook, CA, United States
 Hiatt, Andrew C., San Diego, CA, United States
 Fitchen, John H., La Jolla, CA, United States
 PA Epicyte Pharmaceutical, Inc., San Diego, CA, United States (U.S.
 corporation)
 PI US 6440419 B1 20020827
 AI US 1998-176741 19981020 (9)
 RLI Continuation-in-part of Ser. No. US 1997-954211, filed on 20 Oct 1997,
 now patented, Pat. No. US 6251392
 DT Utility
 FS GRANTED
 LN.CNT 3177
 INCL INCLM: 424/178.100
 INCLS: 424/134.100; 424/143.100; 424/172.100; 514/002.000
 NCL NCLM: 424/178.100
 NCLS: 424/134.100; 424/143.100; 424/172.100; 514/002.000
 IC [7]
 ICM: A61K039-395
 EXF 435/320.1; 435/455; 536/23.1; 536/24.5; 514/44; 514/2; 512/2; 424/134.1;
 424/143.1; 424/172.1; 424/178.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 322 OF 367 USPATFULL on STN
 AN 2002:214328 USPATFULL
 TI Amyloid targeting imaging agents and uses thereof
 IN Gervais, Francine, Ile Bizard, CANADA
 Kong, Xianqi, Dollard-des-Ormeaux, CANADA
 Chalifour, Robert, Ile Bizard, CANADA
 Migneault, David, Laval, CANADA
 PI US 2002115717 A1 20020822
 AI US 2001-915092 A1 20010724 (9)
 PRAI US 2000-220808P 20000725 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 2210
 INCL INCLM: 514/553.000
 INCLS: 424/001.110
 NCL NCLM: 514/553.000
 NCLS: 424/001.110
 IC [7]
 ICM: A61K031-185
 ICS: A61K051-00
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 323 OF 367 USPATFULL on STN
 AN 2002:214264 USPATFULL
 TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical
 compositions comprising same, and methods for inhibiting beta-amyloid
 peptide release and/or its synthesis by use of such compounds
 IN Wu, Jing, San Mateo, CA, UNITED STATES
 Tung, Jay S., Belmont, CA, UNITED STATES
 Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
 Pleiss, Michael A., Sunnyvale, CA, UNITED STATES
 Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES
 Neitz, Jeffrey, San Francisco, CA, UNITED STATES
 Latimer, Lee H., Oakland, CA, UNITED STATES
 John, Varghese, San Francisco, CA, UNITED STATES
 Freedman, Stephen, Walnut Creek, CA, UNITED STATES
 Britton, Thomas C., Carmel, IN, UNITED STATES
 Audia, James E., Indianapolis, IN, UNITED STATES
 Reel, Jon K., Carmel, IN, UNITED STATES
 Mabry, Thomas E., Indianapolis, IN, UNITED STATES
 Dressman, Bruce A., Indianapolis, IN, UNITED STATES
 Cwi, Cynthia L., Indianapolis, IN, UNITED STATES
 Droste, James J., Indianapolis, IN, UNITED STATES
 Henry, Steven S., New Palestine, IN, UNITED STATES
 McDaniel, Stacey L., Bloomington, IN, UNITED STATES
 Scott, William Leonard, Indianapolis, IN, UNITED STATES
 Stucky, Russell D., Indianapolis, IN, UNITED STATES
 Porter, Warren J., Indianapolis, IN, UNITED STATES
 PI US 2002115652 A1 20020822

AI US 2001-915362 A1 20010727 (9)
RLI Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING
PRAI US 1996-64851P 19961223 (60)
DT Utility
FS APPLICATION
LN.CNT 25618
INCL INCLM: 514/212.010
INCLS: 514/248.000; 514/258.000; 514/279.000; 514/410.000; 514/659.000
NCL NCLM: 514/211.060
NCLS: 514/211.070; 514/212.040; 514/212.060; 514/212.070; 514/212.080;
540/488.000; 540/521.000; 540/522.000; 540/523.000; 540/524.000;
540/527.000
IC [7]
ICM: A61K031-55
ICS: A61K031-519; A61K031-5025; A61K031-4745; A61K031-407; A61K031-13
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 324 OF 367 USPATFULL on STN
AN 2002:206646 USPATFULL
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical
compositions comprising same, and methods for inhibiting beta-Amyloid
peptide release and/or its synthesis by use of such compounds
IN Wu, Jing, San Mateo, CA, UNITED STATES
Tung, Jay S., Belmont, CA, UNITED STATES
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
Pleiss, Michael A., Sunnyvale, CA, UNITED STATES
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES
Neitz, Jeffrey, San Francisco, CA, UNITED STATES
Latimer, Lee H., Oakland, CA, UNITED STATES
Varghese, John, San Francisco, CA, UNITED STATES
Freedman, Stephen, Walnut Creek, CA, UNITED STATES
Britton, Thomas C., Carmel, IN, UNITED STATES
Audia, James E., Indianapolis, IN, UNITED STATES
Reel, Jon K., Carmel, IN, UNITED STATES
Mabry, Thomas E., Indianapolis, IN, UNITED STATES
Dressman, Bruce A., Indianapolis, IN, UNITED STATES
Cwi, Cynthia L., Indianapolis, IN, UNITED STATES
Droste, James J., Indianapolis, IN, UNITED STATES
Henry, Steven S., New Palestine, IN, UNITED STATES
McDaniel, Stacey L., Bloomington, IN, UNITED STATES
Scott, William Leonard, Indianapolis, IN, UNITED STATES
Stucky, Russell D., Indianapolis, IN, UNITED STATES
Porter, Warren J., Indianapolis, IN, UNITED STATES

PI US 2002111343 A1 20020815
AI US 2001-915547 A1 20010727 (9)
RLI Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING
PRAI US 1996-64851P 19961223 (60)
DT Utility
FS APPLICATION
LN.CNT 25803
INCL INCLM: 514/212.030
INCLS: 514/327.000; 514/424.000; 514/659.000
NCL NCLM: 514/212.030
NCLS: 514/327.000; 514/424.000; 514/659.000
IC [7]
ICM: A61K031-55
ICS: A61K031-445; A61K031-4015; A61K031-13
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 325 OF 367 USPATFULL on STN
AN 2002:192279 USPATFULL
TI Sequences characteristic of hypoxia-regulated gene transcription
IN Einat, Paz, Nes-Ziona, ISRAEL
Skaliter, Rami, Nes-Zional, ISRAEL
Feinstein, Elena, Rehovot, ISRAEL
PI US 2002103353 A1 20020801
AI US 2001-802472 A1 20010309 (9)
RLI Continuation-in-part of Ser. No. US 1999-384096, filed on 27 Aug 1999,
ABANDONED Continuation-in-part of Ser. No. US 1998-138109, filed on 21
Aug 1998, ABANDONED
PRAI US 1998-98158P 19980827 (60)
US 2001-132684P 20010905 (60)
US 1997-56453P 19970821 (60)
DT Utility
FS APPLICATION

INCL INCLM: 536/023.200
INCLS: 435/320.100; 435/325.000; 435/069.100
NCL NCLM: 536/023.200
NCLS: 435/320.100; 435/325.000; 435/069.100
IC [7]
ICM: C07H021-04
ICS: C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 326 OF 367 USPATFULL on STN
AN 2002:185265 USPATFULL
TI Modulators of amyloid aggregation
IN Findeis, Mark A., Cambridge, MA, UNITED STATES
Benjamin, Howard, Lexington, MA, UNITED STATES
Garnick, Marc B., Brookline, MA, UNITED STATES
Geffer, Malcolm L., Lincoln, MA, UNITED STATES
Hundal, Arvind, Brighton, MA, UNITED STATES
Kasman, Laura, Athens, GA, UNITED STATES
Musso, Gary, Hopkinton, MA, UNITED STATES
Signer, Ethan R., Cambridge, MA, UNITED STATES
Wakefield, James, Brookline, MA, UNITED STATES
Reed, Michael J., Marietta, GA, UNITED STATES
PA Praecis Pharmaceuticals, Inc. (U.S. corporation)
PI US 2002098173 A1 20020725
AI US 2001-972475 A1 20011004 (9)
RLI Continuation of Ser. No. US 1996-617267, filed on 14 Mar 1996, PATENTED
Continuation-in-part of Ser. No. US 1995-475579, filed on 7 Jun 1995,
PATENTED Continuation-in-part of Ser. No. US 1995-404831, filed on 14
Mar 1995, PATENTED Continuation-in-part of Ser. No. US 1995-548998,
filed on 27 Oct 1995, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 4009
INCL INCLM: 424/094.300
INCLS: 435/226.000
NCL NCLM: 424/094.300
NCLS: 435/226.000
IC [7]
ICM: A61K038-54
ICS: C12N009-64
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 327 OF 367 USPATFULL on STN
AN 2002:185242 USPATFULL
TI New macrocyclic chelants useful for metallopharmaceuticals
IN Liu, Shuang, Chelmsford, MA, UNITED STATES
PI US 2002098149 A1 20020725
US 6517814 B2 20030211
AI US 2001-33765 A1 20011227 (10)
PRAI US 2001-260500P 20010109 (60)
DT Utility
FS APPLICATION
LN.CNT 1855
INCL INCLM: 424/001.650
NCL NCLM: 424/009.360
NCLS: 424/001.110; 424/001.650; 424/009.100; 424/009.300; 424/009.361;
424/009.362; 424/009.400; 534/010.000; 534/014.000
IC [7]
ICM: A61K051-00
ICS: A61M036-14
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 328 OF 367 USPATFULL on STN
AN 2002:179167 USPATFULL
TI Peptide binding the KLVFF-sequence of ***amyloid*** - ***beta***
IN Nordstedt, Christer, Mulhouse, FRANCE
Naslund, Jan, Stockholm, SWEDEN
Thyberg, Johan, Stockholm, SWEDEN
Tjernberg, Lars O., Spanga, SWEDEN
Terenius, Lars, Uppsala, SWEDEN
PI US 2002094957 A1 20020718
AI US 2001-850061 A1 20010508 (9)
RLI Division of Ser. No. US 1998-95106, filed on 10 Jun 1998, PENDING
Continuation of Ser. No. WO 1996-SE1621, filed on 9 Dec 1996, UNKNOWN
PRAI SE 1995-4467 19951212

DT Utility
FS APPLICATION
LN.CNT 727
INCL INCLM: 514/015.000
INCLS: 514/016.000; 530/328.000; 530/329.000
NCL NCLM: 514/015.000
NCLS: 514/016.000; 530/328.000; 530/329.000
IC [7]
ICM: A61K038-10
ICS: A61K038-08

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 329 OF 367 USPATFULL on STN
AN 2002:178530 USPATFULL
TI Polypodal chelants for metallopharmaceuticals
IN Liu, Shuang, Chelmsford, MA, UNITED STATES
PI US 2002094316 A1 20020718
AI US 2001-33769 A1 20011227 (10)
PRAI US 2001-260618P 20010109 (60)
DT Utility
FS APPLICATION
LN.CNT 2716
INCL INCLM: 424/001.110
NCL NCLM: 424/001.110
IC [7]
ICM: A61K051-00
ICS: A61M036-14

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 330 OF 367 USPATFULL on STN
AN 2002:174955 USPATFULL
TI Methods of screening for agents that inhibit aggregation of polypeptides
IN Housman, David E., Newton, MA, United States
Preisinger, Elizabeth A., Roslindale, MA, United States
Kazantsev, Aleksey G., Boston, MA, United States
PA Massachusetts Institute of Technology, Boston, MA, United States (U.S. corporation)
PI US 6420122 B1 20020716
AI US 1999-405048 19990927 (9)
DT Utility
FS GRANTED
LN.CNT 1135
INCL INCLM: 435/007.100
INCLS: 435/004.000; 436/501.000; 530/300.000; 530/350.000
NCL NCLM: 435/007.100
NCLS: 435/004.000; 436/501.000; 530/300.000; 530/350.000
IC [7]
ICM: G01N033-53
EXF 436/86; 436/501; 536/23.4; 530/300; 530/350; 435/7.1; 435/4
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 331 OF 367 USPATFULL on STN
AN 2002:148656 USPATFULL
TI Compositions and methods for modulating TGF-beta signaling
IN Wang, Tongwen, Seattle, WA, UNITED STATES
PI US 2002076799 A1 20020620
AI US 2001-927738 A1 20010810 (9)
RLI Continuation-in-part of Ser. No. WO 2000-US3561, filed on 11 Feb 2000, UNKNOWN
PRAI US 1999-119786P 19990211 (60)
DT Utility
FS APPLICATION
LN.CNT 5961
INCL INCLM: 435/226.000
INCLS: 435/069.100; 435/325.000; 435/320.100; 435/183.000; 530/388.260; 536/023.200
NCL NCLM: 435/226.000
NCLS: 435/069.100; 435/325.000; 435/320.100; 435/183.000; 530/388.260; 536/023.200
IC [7]
ICM: C12N009-64
ICS: C12N009-00; C07H021-04; C12P021-02; C12N005-06; C07K016-40
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 332 OF 367 USPATFULL on STN

TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
IN Wu, Jing, San Mateo, CA, UNITED STATES
Tung, Jay S., Belmont, CA, UNITED STATES
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
Pleiss, Michael A., Sunnyvale, CA, UNITED STATES
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES
Neitz, Jeffrey, San Francisco, CA, UNITED STATES
Latimer, Lee H., Oakland, CA, UNITED STATES
John, Varghese, San Francisco, CA, UNITED STATES
Freedman, Stephen, Walnut Creek, CA, UNITED STATES
Britton, Thomas C., Carmel, IN, UNITED STATES
Audia, James E., Indianapolis, IN, UNITED STATES
Reel, Jon K., Carmel, IN, UNITED STATES
Mabry, Thomas E., Indianapolis, IN, UNITED STATES
Dressman, Bruce A., Indianapolis, IN, UNITED STATES
Cwi, Cynthia L., Indianapolis, IN, UNITED STATES
Droste, James J., Indianapolis, IN, UNITED STATES
Henry, Steven S., New Palestine, IN, UNITED STATES
McDaniel, Stacey L., Bloomington, IN, UNITED STATES
Scott, William Leonard, Indianapolis, IN, UNITED STATES
Stucky, Russell D., Indianapolis, IN, UNITED STATES
Porter, Warren J., Indianapolis, IN, UNITED STATES
PI US 2002068741 A1 20020606
AI US 2001-915263 A1 20010726 (9)
RLI Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING
PRAI US 1996-64851P 19961223 (60)
DT Utility
FS APPLICATION
LN.CNT 25726
INCL INCLM: 514/248.000
INCLS: 514/257.000; 514/258.000; 514/280.000; 514/290.000; 514/299.000;
514/410.000; 514/411.000
NCL NCLM: 514/248.000
NCLS: 514/257.000; 514/258.000; 514/280.000; 514/290.000; 514/299.000;
514/410.000; 514/411.000
IC [7]
ICM: A61K031-517
ICS: A61K031-502; A61K031-498; A61K031-473; A61K031-403
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 333 OF 367 USPATFULL on STN
AN 2002:119332 USPATFULL
TI Innate immune system-directed vaccines
IN Medzhitov, Ruslan, New Haven, CT, UNITED STATES
PI US 2002061312 A1 20020523
AI US 2001-752832 A1 20010103 (9)
PRAI US 2000-222042P 20000731 (60)
DT Utility
FS APPLICATION
LN.CNT 2414
INCL INCLM: 424/192.100
INCLS: 435/069.600; 435/325.000; 530/350.000; 536/023.400
NCL NCLM: 424/192.100
NCLS: 435/069.600; 435/325.000; 530/350.000; 536/023.400
IC [7]
ICM: A61K039-35
ICS: C12N005-10
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 334 OF 367 USPATFULL on STN
AN 2002:106291 USPATFULL
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting B-amyloid peptide release and/or its synthesis by use of such compounds
IN Wu, Jing, San Mateo, CA, UNITED STATES
Tung, Jay S., Belmont, CA, UNITED STATES
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
Pleiss, Michael A., Sunnyvale, CA, UNITED STATES
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES
Neitz, Jeffrey, San Francisco, CA, UNITED STATES
Latimer, Lee H., Oakland, CA, UNITED STATES
John, Varghese, San Francisco, CA, UNITED STATES
Freedman, Stephen, Walnut Creek, CA, UNITED STATES

Audia, James E., Indianapolis, IN, UNITED STATES
Reel, Jon K., Carmel, IN, UNITED STATES
Mabry, Thomas E., Indianapolis, IN, UNITED STATES
Dressman, Bruce A., Indianapolis, IN, UNITED STATES
Cwi, Cynthia L., Indianapolis, IN, UNITED STATES
Droste, James J., Indianapolis, IN, UNITED STATES
Henry, Steven S., New Palestine, IN, UNITED STATES
McDaniel, Stacey L., Bloomington, IN, UNITED STATES
Scott, William Leonard, Indianapolis, IN, UNITED STATES
Stucky, Russell D., Indianapolis, IN, UNITED STATES
Porter, Warren J., Indianapolis, IN, UNITED STATES

PI US 2002055500 A1 20020509
AI US 2001-916440 A1 20010730 (9)
RLI Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING
PRAI US 1996-64851P 19961223 (60)

DT Utility
FS APPLICATION

LN.CNT 25439

INCL INCLM: 514/212.030
INCLS: 514/327.000; 514/424.000; 514/659.000

NCL NCLM: 514/212.030
NCLS: 514/327.000; 514/424.000; 514/659.000

IC [7]
ICM: A61K031-55
ICS: A61K031-45; A61K031-4015; A61K031-13

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 335 OF 367 USPATFULL on STN

AN 2002:99458 USPATFULL

TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting B-amyloid peptide release and/or its synthesis by use of such compounds

IN Wu, Jing, San Mateo, CA, UNITED STATES
Tung, Jay S., Belmont, CA, UNITED STATES
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
Pleiss, Michael A., Sunnyvale, CA, UNITED STATES
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES
Neitz, R. Jeffrey, San Francisco, CA, UNITED STATES
Latimer, Lee H., Oakland, CA, UNITED STATES
John, Varghese, San Francisco, CA, UNITED STATES
Freedman, Stephen, Walnut Creek, CA, UNITED STATES
Britton, Thomas C., Carmel, IN, UNITED STATES
Audia, James E., Indianapolis, IN, UNITED STATES
Reel, Jon K., Carmel, IN, UNITED STATES
Mabry, Thomas E., Indianapolis, IN, UNITED STATES
Dressman, Bruce A., Indianapolis, IN, UNITED STATES
Cwi, Cynthia L., Indianapolis, IN, UNITED STATES
Droste, James J., Indianapolis, IN, UNITED STATES
Henry, Steven S., New Palestine, IN, UNITED STATES
McDaniel, Stacey L., Bloomington, IN, UNITED STATES
Scott, William Leonard, Indianapolis, IN, UNITED STATES
Stucky, Russell D., Indianapolis, IN, UNITED STATES
Porter, Warren J., Indianapolis, IN, UNITED STATES

PI US 2002052359 A1 20020502

US 6544978 B2 20030408

AI US 2001-915480 A1 20010727 (9)

RLI Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING

PRAI US 1996-64851P 19961223 (60)

DT Utility
FS APPLICATION

LN.CNT 25908

INCL INCLM: 514/212.010
INCLS: 514/327.000; 514/424.000; 514/519.000; 514/529.000; 514/683.000;
514/676.000

NCL NCLM: 514/211.060
NCLS: 514/211.070; 514/212.040; 514/212.060; 514/212.070; 514/212.080;
540/488.000; 540/521.000; 540/522.000; 540/523.000; 540/524.000;
540/527.000

IC [7]
ICM: A61K031-55
ICS: A61K031-445; A61K031-40; A61K031-215; A61K031-275

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 336 OF 367 USPATFULL on STN

AN 2002:85701 USPATFULL

compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds

IN Wu, Jing, San Mateo, CA, UNITED STATES
 Tung, Jay S., Belmont, CA, UNITED STATES
 Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
 Pleiss, Michael A., Sunnyvale, CA, UNITED STATES
 Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES
 Neitz, Jeffrey, San Francisco, CA, UNITED STATES
 Latimer, Lee H., Oakland, CA, UNITED STATES
 John, Varghese, San Francisco, CA, UNITED STATES
 Freedman, Stephen, Walnut Creek, CA, UNITED STATES
 Britton, Thomas C., Carmel, IN, UNITED STATES
 Audia, James A., Indianapolis, IN, UNITED STATES
 Reel, Jon K., Carmel, IN, UNITED STATES
 Mabry, Thomas E., Indianapolis, IN, UNITED STATES
 Dressman, Bruce A., Indianapolis, IN, UNITED STATES
 Cwi, Cynthia L., Indianapolis, IN, UNITED STATES
 Droste, James J., Indianapolis, IN, UNITED STATES
 Henry, Steven S., New Palestine, IN, UNITED STATES
 McDaniel, Stacey L., Indianapolis, IN, UNITED STATES
 Scott, William Leonard, Indianapolis, IN, UNITED STATES
 Stucky, Russell D., Indianapolis, IN, UNITED STATES
 Porter, Warren J., Indianapolis, IN, UNITED STATES

PI US 2002045747 A1 20020418
 AI US 2001-916282 A1 20010730 (9)
 RLI Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING
 PRAI US 1996-64851P 19961223 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 26053
 INCL INCLM: 540/450.000
 INCLS: 540/496.000; 540/504.000; 514/220.000; 514/221.000
 NCL NCLM: 540/450.000
 NCLS: 540/496.000; 540/504.000; 514/220.000; 514/221.000
 IC [7]
 ICM: A61K031-551
 ICS: C07D243-12

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 337 OF 367 USPATFULL on STN
 AN 2002:67195 USPATFULL
 TI Use of copolymer 1 and related peptides and polypeptides and T cells treated therewith for neuroprotective therapy
 IN Eisenbach-Schwartz, Michal, Rehovot, ISRAEL
 Yoles, Eti, Rehovot, ISRAEL
 Kipnis, Jonathan, Modiin, ISRAEL
 PI US 2002037848 A1 20020328
 AI US 2001-765301 A1 20010122 (9)
 RLI Continuation-in-part of Ser. No. US 2000-620216, filed on 20 Jul 2000, PENDING
 PRAI US 2000-209799P 20000607 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 2839
 INCL INCLM: 514/012.000
 NCL NCLM: 514/012.000
 IC [7]
 ICM: A61K038-16

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 338 OF 367 USPATFULL on STN
 AN 2002:37903 USPATFULL
 TI Compounds to treat alzheimer's disease
 IN Hom, Roy, San Francisco, CA, UNITED STATES
 Mamo, Shumeye, Oakland, CA, UNITED STATES
 Tung, Jay, Belmont, CA, UNITED STATES
 Gailunas, Andrea, San Francisco, CA, UNITED STATES
 John, Varghese, San Francisco, CA, UNITED STATES
 Fang, Lawrence Y., Foster City, CA, UNITED STATES
 PI US 2002022623 A1 20020221
 US 6737420 B2 20040518
 AI US 2001-815960 A1 20010323 (9)
 PRAI US 2000-191528P 20000323 (60)
 DT Utility
 FS APPLICATION

INCL INCLM: 514/227.800
INCLS: 544/060.000; 514/233.500; 514/417.000; 514/534.000; 544/144.000;
560/041.000; 548/473.000
NCL NCLM: 514/218.000
NCLS: 514/227.500; 514/231.200; 514/315.000; 514/317.000; 514/330.000;
514/331.000; 514/451.000; 514/461.000; 514/471.000; 514/618.000;
514/619.000; 540/492.000; 544/058.200; 544/059.000; 544/106.000;
544/358.000; 544/359.000; 546/192.000; 548/400.000; 548/561.000;
549/074.000; 549/426.000; 549/491.000; 549/497.000; 564/153.000;
564/156.000; 564/167.000

IC [7]
ICM: A61K031-541
ICS: A61K031-5377; A61K031-4035; A61K031-24; C07D417-02; C07D413-02;
C07D209-48

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 339 OF 367 USPATFULL on STN
AN 2002:32581 USPATFULL
TI Methods to treat alzheimer's disease
IN Hom, Roy, San Francisco, CA, UNITED STATES
Mamo, Shumeye S., Oakland, CA, UNITED STATES
Tung, Jay, Belmont, CA, UNITED STATES
Gailunas, Andrea, San Francisco, CA, UNITED STATES
John, Varghese, San Francisco, CA, UNITED STATES
Fang, Lawrence Y., Foster City, CA, UNITED STATES
PI US 2002019403 A1 20020214
AI US 2001-816876 A1 20010323 (9)
PRAI US 2000-191528P 20000323 (60)

DT Utility
FS APPLICATION

LN.CNT 8655

INCL INCLM: 514/256.000
INCLS: 514/519.000; 514/520.000; 514/534.000
NCL NCLM: 514/256.000
NCLS: 514/519.000; 514/520.000; 514/534.000

IC [7]
ICM: A61K031-505
ICS: A61K031-275; A61K031-277; A61K031-24
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 340 OF 367 USPATFULL on STN
AN 2002:21796 USPATFULL
TI Ternary ligand complexes useful as radiopharmaceuticals
IN Liu, Shuang, Chelmsford, MA, UNITED STATES
PI US 2002012631 A1 20020131
US 6534038 B2 20030318
AI US 2001-826449 A1 20010405 (9)
PRAI US 2000-195235P 20000407 (60)

DT Utility
FS APPLICATION

LN.CNT 2595

INCL INCLM: 424/009.360
INCLS: 546/022.000; 562/007.000; 562/406.000; 564/015.000; 562/008.000;
568/013.000
NCL NCLM: 424/009.100
NCLS: 424/001.110; 424/001.650; 424/001.730; 534/014.000; 568/017.000

IC [7]
ICM: C07F009-58
ICS: C07F009-28
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 341 OF 367 USPATFULL on STN
AN 2002:8035 USPATFULL
TI Macrocyclic chelants for metallopharmaceuticals
IN Liu, Shuang, Chelmsford, MA, UNITED STATES
PI US 2002004032 A1 20020110
US 6565828 B2 20030520
AI US 2001-826549 A1 20010405 (9)
PRAI US 2000-195234P 20000407 (60)

DT Utility
FS APPLICATION

LN.CNT 2981

INCL INCLM: 424/009.363
INCLS: 540/474.000
NCL NCLM: 424/001.530

IC [7]
ICM: A61K049-12
ICS: C07D257-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 342 OF 367 USPATFULL on STN
AN 2001:235319 USPATFULL
TI Kallikrein-binding "Kunitz domain" proteins and analogues thereof
IN Markland, William, Milford, MA, United States
Ladner, Robert Charles, Ijamsville, MD, United States
PA Dyax Corp., Cambridge, MA, United States (U.S. corporation)
PI US 6333402 B1 20011225
AI US 1999-421097 19991019 (9)
RLI Division of Ser. No. US 1994-208264, filed on 10 Mar 1994, now patented,
Pat. No. US 6057287 Continuation-in-part of Ser. No. US 1994-179964,
filed on 11 Jan 1994, now abandoned
DT Utility
FS GRANTED
LN.CNT 3154
INCL INCLM: 536/023.500
INCLS: 536/023.200; 435/007.000; 435/252.300; 435/320.100; 530/317.000
NCL NCLM: 536/023.500
NCLS: 435/007.100; 435/252.300; 435/254.230; 435/320.100; 435/325.000;
530/317.000; 536/023.200

IC [7]
ICM: C07H021-04
ICS: A61K038-12; C12N001-20; C12N015-00; G01N033-53
EXF 435/7; 435/252.3; 435/320.1; 514/2; 530/317; 536/23.1; 536/23.2;
536/23.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 343 OF 367 USPATFULL on STN
AN 2001:233130 USPATFULL
TI LIGAND BINDING SITE OF RAGE AND USES THEREOF
IN STERN, DAVID, GREAT NECK, NY, United States
YAN, SHI DU, NEW YORK, NY, United States
SCHMIDT, ANN MARIE, FRANKLIN LAKE, NJ, United States
LAMSTER, IRA, WYCKOFF, NJ, United States
PI US 2001053357 A1 20011220
US 6555651 B2 20030429
AI US 1997-948131 A1 19971009 (8)
DT Utility
FS APPLICATION
LN.CNT 2374
INCL INCLM: 424/130.100
INCLS: 530/350.000; 514/002.000; 514/012.000
NCL NCLM: 530/324.000
NCLS: 530/300.000

IC [7]
ICM: A61K038-04
ICS: A61K039-395; C07K014-705; C07K014-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 344 OF 367 USPATFULL on STN
AN 2001:231187 USPATFULL
TI Peptide binding the KLVFF-sequence of ***amyloid*** -. ***beta***
IN Nordstedt, Christer, Mulhouse, France
Naslund, Jan, New York, NY, United States
Thyberg, Johan, Stockholm, Sweden
Tjernberg, Lars O., Spanga, Sweden
Terenius, Lars, Uppsala, Sweden
PA Karolinska Innovations AB, Stockholm, Sweden (non-U.S. corporation)
PI US 6331440 B1 20011218
AI US 1998-95106 19980610 (9)
RLI Continuation of Ser. No. WO 1996-SE1621, filed on 9 Dec 1996
PRAI SE 1995-4467 19951212
US 1995-9386P 19951229 (60)
DT Utility
FS GRANTED
LN.CNT 541
INCL INCLM: 436/501.000
INCLS: 435/007.100; 514/002.000; 514/017.000; 514/018.000
NCL NCLM: 436/501.000
NCLS: 435/007.100; 514/002.000; 514/017.000; 514/018.000

ICM: G01N033-566
ICS: G01N033-53; A61K038-08
EXF 435/7.1; 435/7.2; 436/501; 514/17; 514/18
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 345 OF 367 USPATFULL on STN
AN 2001:121586 USPATFULL
TI Intracellular ***amyloid*** - ***beta*** peptide binding (ERAB)
polypeptide
IN Stern, David M., Great Neck, NY, United States
Yan, Shi Du, New York, NY, United States
PA The Trustees of Columbia University in the City of New York, New York,
NY, United States (U.S. corporation)
PI US 6268479 B1 20010731
AI US 1997-815225 19970312 (8)
DT Utility
FS GRANTED
LN.CNT 1529
INCL INCLM: 530/350.000
INCLS: 930/010.000
NCL NCLM: 530/350.000
NCLS: 930/010.000
IC [7]
ICM: C07K014-435
EXF 530/350; 930/10
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 346 OF 367 USPATFULL on STN
AN 2001:97417 USPATFULL
TI Epithelial cell targeting agent
IN Hein, Mich B., Fallbrook, CA, United States
Hiatt, Andrew C., San Diego, CA, United States
Fitchen, John H., La Jolla, CA, United States
PA Epicyte Pharmaceuticals, Inc., San Diego, CA, United States (U.S.
corporation)
PI US 6251392 B1 20010626
AI US 1997-954211 19971020 (8)
DT Utility
FS GRANTED
LN.CNT 2520
INCL INCLM: 424/134.100
INCLS: 435/188.000; 424/143.100; 424/172.100; 424/174.100; 424/182.100;
424/183.100; 530/861.000; 530/863.000; 530/387.100
NCL NCLM: 424/134.100
NCLS: 424/143.100; 424/172.100; 424/174.100; 424/182.100; 424/183.100;
435/188.000; 530/387.100; 530/861.000; 530/863.000
IC [7]
ICM: A61K039-395
ICS: C12N009-96; C07K016-00
EXF 530/861; 530/863; 530/864; 530/865; 530/866; 530/391.5; 530/391.7;
530/391.9; 530/387.1; 435/188; 435/188.5; 435/195; 435/219; 424/179.1;
424/180.1; 424/181.1; 424/183.1; 424/134.1; 424/138.1; 424/143.1;
424/182.1; 424/172.1; 424/174.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 347 OF 367 USPATFULL on STN
AN 2001:71330 USPATFULL
TI Recombinant helix modification recognition proteins and uses thereof
IN Kmiec, Eric B., Malvern, PA, United States
Holloman, William K., Yorktown Heights, NY, United States
Gerhold, David, Lansdale, PA, United States
PA Thomas Jefferson University, Philadelphia, PA, United States (U.S.
corporation)
PI US 6232095 B1 20010515
AI US 1995-563524 19951128 (8)
DT Utility
FS Granted
LN.CNT 1621
INCL INCLM: 435/069.100
INCLS: 435/320.100; 435/325.000; 435/069.700; 435/252.300; 536/023.400;
536/023.740; 530/350.000; 530/371.000
NCL NCLM: 435/069.100
NCLS: 435/069.700; 435/252.300; 435/320.100; 435/325.000; 530/350.000;
530/371.000; 536/023.400; 536/023.740
IC [7]

ICS: C12N015-63; C12N001-20; C12N015-85; C07H021-04; C07K014-00
EXF 435/6; 435/252.3; 435/69.1; 435/69.7; 435/325; 435/320.1; 530/350;
530/371; 530/387.1; 536/23.1; 536/23.4; 536/23.74; 424/130.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 348 OF 367 USPATFULL on STN
AN 2001:14622 USPATFULL
TI Peptide nucleic acid conjugates
IN Wickstrom, Eric, Philadelphia, PA, United States
Basu, Soumitra, New Haven, CT, United States
PA Thomas Jefferson University, Philadelphia, PA, United States (U.S.
corporation)
PI US 6180767 B1 20010130
AI US 1997-779072 19970107 (8)
PRAI US 1996-9747P 19960111 (60)
DT Utility
FS Granted
LN.CNT 1510
INCL INCLM: 536/022.100
INCLS: 435/006.000; 536/023.100; 536/025.300; 536/025.310; 536/025.320;
536/025.330; 536/025.340
NCL NCLM: 536/022.100
NCLS: 435/006.000; 536/023.100; 536/025.300; 536/025.310; 536/025.320;
536/025.330; 536/025.340
IC [7]
ICM: C07H019-00
ICS: C07H021-02; C07H021-00; C07H021-04
EXF 536/22.1; 536/23.1; 536/25.3; 536/25.31; 536/25.32; 536/25.33;
536/25.34; 435/6
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 349 OF 367 USPATFULL on STN
AN 2001:4934 USPATFULL
TI Polyamine analogues as therapeutic and diagnostic agents
IN Vermeulin, Nicolaas M. J., Woodinville, WA, United States
O'Day, Christine L., Mountlake Terrace, WA, United States
Webb, Heather K., Seattle, WA, United States
Burns, Mark R., Shoreline, WA, United States
Bergstrom, Donald E., West Lafayette, IN, United States
PA Oridigm Corporation, Seattle, WA, United States (U.S. corporation)
PI US 6172261 B1 20010109
WO 9903823 19990128
AI US 1999-341400 19990903 (9)
WO 1998-US14896 19980715
19990903 PCT 371 date
19990903 PCT 102(e) date
PRAI US 1997-52586P 19970715 (60)
US 1997-65728P 19971114 (60)
US 1998-85538P 19980515 (60)
DT Patent
FS Granted
LN.CNT 3638
INCL INCLM: 564/084.000
NCL NCLM: 564/084.000
IC [7]
ICM: C07C303-00
EXF 564/84
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 350 OF 367 USPATFULL on STN
AN 2000:54070 USPATFULL
TI Kallikrein-binding "Kunitz domain" proteins and analogues thereof
IN Markland, William, Milford, MA, United States
Ladner, Robert Charles, Ijamsville, MD, United States
PA Dyax Corp., Cambridge, MA, United States (U.S. corporation)
PI US 6057287 20000502
AI US 1994-208264 19940310 (8)
RLI Continuation-in-part of Ser. No. US 1994-179964, filed on 11 Jan 1994,
now abandoned
DT Utility
FS Granted
LN.CNT 3820
INCL INCLM: 514/002.000
INCLS: 514/012.000; 530/300.000; 530/317.000; 530/324.000; 435/004.000;
435/007.400; 435/007.720; 435/069.100

NCLS: 435/004.000; 435/007.400; 435/007.720; 435/069.100; 514/012.000;
530/300.000; 530/317.000; 530/324.000

IC [7]
ICM: A61K038-16
ICS: C07K014-00

EXF 530/317; 530/300; 530/324; 514/12; 514/2; 435/69.1; 435/4; 435/7.4;
435/7.72

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 351 OF 367 USPATFULL on STN

AN 2000:28107 USPATFULL

TI .beta.-sheet nucleating peptidomimetics

IN Kelly, Jeffery W., 213 Chimney Hill Cir., College Station, TX, United States 77840

PI US 6034211 20000307

AI US 1996-664379 19960614 (8)

PRAI US 1996-18925P 19960603 (60)

DT Utility

FS Granted

LN.CNT 1635

INCL INCLM: 530/317.000

INCLS: 546/101.000

NCL NCLM: 530/317.000

NCLS: 546/101.000

IC [7]
ICM: C07K005-00

EXF 548/427; 546/101; 514/323-328; 530/317

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 352 OF 367 USPATFULL on STN

AN 2000:15635 USPATFULL

TI Inhibitors of . ***beta*** .- ***amyloid*** toxicity

IN Kiessling, Laura L., Madison, WI, United States

Murphy, Regina M., Madison, WI, United States

PA Wisconsin Alumni Research Foundation, Madison, WI, United States (U.S. corporation)

PI US 6022859 20000208

AI US 1997-970833 19971114 (8)

PRAI US 1996-30840P 19961115 (60)

DT Utility

FS Granted

LN.CNT 891

INCL INCLM: 514/014.000

INCLS: 514/013.000; 514/015.000; 530/326.000; 530/327.000

NCL NCLM: 514/014.000

NCLS: 514/013.000; 514/015.000; 530/326.000; 530/327.000

IC [6]
ICM: A61K038-00

EXF 530/326-327; 514/13-15

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 353 OF 367 USPATFULL on STN

AN 1999:113631 USPATFULL

TI Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor

IN Holmes, Todd, Somerville, MA, United States

Zhang, Shuguang, Cambridge, MA, United States

Rich, Alexander, Cambridge, MA, United States

DiPersio, C. Michael, Norton, MA, United States

Lockshin, Curtis, Lexington, MA, United States

PA Massachusetts Institute of Technology, Cambridge, MA, United States (U.S. corporation)

PI US 5955343 19990921

AI US 1994-293284 19940822 (8)

RLI Continuation-in-part of Ser. No. US 1992-973326, filed on 28 Dec 1992, now abandoned

DT Utility

FS Granted

LN.CNT 2516

INCL INCLM: 435/240.100

INCLS: 435/240.200; 435/240.230; 435/240.241

NCL NCLM: 435/325.000

NCLS: 435/378.000; 435/395.000; 435/401.000

IC [6]
ICM: C12N005-02

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 354 OF 367 USPATFULL on STN
AN 1999:13026 USPATFULL
TI Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor
IN Morser, Michael John, San Francisco, CA, United States
Nagashima, Mariko, Belmont, CA, United States
PA Schering Aktiengesellschaft, Berlin, Germany, Federal Republic of (non-U.S. corporation)
PI US 5864018 19990126
AI US 1996-633148 19960416 (8)
DT Utility
FS Granted
LN.CNT 1960
INCL INCLM: 530/387.100
INCLS: 530/387.300; 530/388.100; 530/388.220; 530/391.300
NCL NCLM: 530/387.100
NCLS: 530/387.300; 530/388.100; 530/388.220; 530/391.300
IC [6]
ICM: C07K016-00
EXF 530/387.1; 530/387.3; 530/388.1; 530/388.225; 530/391.3
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 355 OF 367 USPATFULL on STN
AN 1998:162469 USPATFULL
TI A.beta. peptides that modulate . ***beta*** .- ***amyloid*** aggregation
IN Findeis, Mark A., Cambridge, MA, United States
Benjamin, Howard, Lexington, MA, United States
Garnick, Marc B., Brookline, MA, United States
Geffer, Malcolm L., Lincoln, MA, United States
Hundal, Arvind, Brighton, MA, United States
Kasman, Laura, Athens, GA, United States
Musso, Gary, Hopkinton, MA, United States
Signer, Ethan R., Cambridge, MA, United States
Wakefield, James, Brookline, MA, United States
Reed, Michael, Marietta, GA, United States
Molineaux, Susan, Brookline, MA, United States
Kubasek, William, Belmont, MA, United States
Chin, Joseph, Salem, MA, United States
Lee, Jung-Ja, Wayland, MA, United States
Kelley, Michael, Arlington, MA, United States
PA Praecis Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)
PI US 5854204 19981229
AI US 1996-612785 19960314 (8)
RLI Continuation-in-part of Ser. No. US 1995-404831, filed on 14 Mar 1995
And a continuation-in-part of Ser. No. US 1995-475579, filed on 7 Jun 1995
And a continuation-in-part of Ser. No. US 1995-548998, filed on 27 Oct 1995
DT Utility
FS Granted
LN.CNT 4304
INCL INCLM: 514/002.000
INCLS: 514/012.000; 514/014.000; 530/324.000; 530/326.000
NCL NCLM: 514/002.000
NCLS: 514/012.000; 514/014.000; 530/324.000; 530/326.000
IC [6]
ICM: C07K014-435
ICS: C07K007-08
EXF 514/14; 514/12; 514/2; 530/300; 530/324; 530/326; 930/10
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 356 OF 367 USPATFULL on STN
AN 1998:157595 USPATFULL
TI Transgenic non-human mice expressing Flag-APP-C100 protein develop alzheimer's disease brain morphology and behavior
IN Neve, Rachael L., Belmont, MA, United States
Berger-Sweeney, Joanne, Natick, MA, United States
PA The McLean Hospital Corporation, Belmont, MA, United States (U.S. corporation)
Wellesley College, Wellesley, MA, United States (U.S. corporation)
PI US 5849999 19981215
AI US 1996-729345 19961016 (8)

FS Granted
LN.CNT 899
INCL INCLM: 800/002.000
INCLS: 800/DIG.001; 424/009.100; 435/172.300; 935/060.000
NCL NCLM: 800/003.000
NCLS: 424/009.100; 800/012.000; 800/025.000
IC [6]
ICM: C12N005-00
ICS: C12N015-00; A61K049-00
EXF 800/2; 800/DIG.1; 935/60; 435/172.3; 435/320.1; 536/23.1; 424/9.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 357 OF 367 USPATFULL on STN
AN 1998:150712 USPATFULL
TI Method for decomposing amyloid protein precursor and ***amyloid***
beta -protein
IN Miyazaki, Kaoru, Kanagawa-ken, Japan
PA Oriental Yeast Co., Ltd., Tokyo, Japan (non-U.S. corporation)
PI US 5843695 19981201
AI US 1996-641774 19960430 (8)
RLI Division of Ser. No. US 1994-232474, filed on 25 Apr 1994, now abandoned
PRAI JP 1993-122207 19930427
JP 1994-51133 19940225
DT Utility
FS Granted
LN.CNT 262
INCL INCLM: 435/023.000
INCLS: 435/004.000
NCL NCLM: 435/023.000
NCLS: 435/004.000
IC [6]
ICM: C12Q001-37
EXF 424/94.6; 424/94.2; 424/94.67; 424/94.63; 435/4; 435/7.2; 435/7.4;
435/23; 514/879; 514/2; 514/12; 514/21
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 358 OF 367 USPATFULL on STN
AN 1998:143904 USPATFULL
TI Directed evolution of novel binding proteins
IN Ladner, Robert Charles, Ijamsville, MD, United States
Guttermann, Sonia Kosow, Belmont, MA, United States
Roberts, Bruce Lindsay, Milford, MA, United States
Markland, William, Milford, MA, United States
Ley, Arthur Charles, Newton, MA, United States
Kent, Rachel Baribault, Boxborough, MA, United States
PA Dyax, Corp., Cambridge, MA, United States (U.S. corporation)
PI US 5837500 19981117
AI US 1995-415922 19950403 (8)
RLI Continuation of Ser. No. US 1993-9319, filed on 26 Jan 1993, now
patented, Pat. No. US 5403484 which is a division of Ser. No. US
1991-664989, filed on 1 Mar 1991, now patented, Pat. No. US 5223409
which is a continuation-in-part of Ser. No. US 1990-487063, filed on 2
Mar 1990, now abandoned which is a continuation-in-part of Ser. No. US
1988-240160, filed on 2 Sep 1988, now abandoned
DT Utility
FS Granted
LN.CNT 15973
INCL INCLM: 435/069.700
INCLS: 435/172.300; 530/350.000; 530/412.000; 536/023.400
NCL NCLM: 435/069.700
NCLS: 435/091.100; 435/091.200; 435/471.000; 530/350.000; 530/412.000;
536/023.400
IC [6]
ICM: C12N015-62
ICS: C07K019-00
EXF 435/69.7; 435/172.3; 530/350; 530/412; 536/23.4
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 359 OF 367 USPATFULL on STN
AN 97:86591 USPATFULL
TI Stable macroscopic membranes formed by self-assembly of amphiphilic
peptides and uses therefor
IN Zhang, Shuguang, Cambridge, MA, United States
Lockshin, Curtis, Lexington, MA, United States
Rich, Alexander, Cambridge, MA, United States

PA Massachusetts Insititute of Technology, Cambridge, MA, United States
(U.S. corporation)
PI US 5670483 19970923
AI US 1994-346849 19941130 (8)
RLI Continuation of Ser. No. US 1992-973326, filed on 28 Dec 1992, now
abandoned
DT Utility
FS Granted
LN.CNT 2210
INCL INCLM: 514/014.000
INCLS: 514/012.000; 514/013.000; 530/300.000; 530/324.000; 530/325.000;
530/326.000; 530/327.000; 530/350.000
NCL NCLM: 514/014.000
NCLS: 514/012.000; 514/013.000; 530/300.000; 530/324.000; 530/325.000;
530/326.000; 530/327.000; 530/350.000
IC [6]
ICM: A61K007-08
ICS: A61K014-00; C07K038-10; C07K038-16
EXF 530/300; 530/350; 514/12; 514/13; 514/14
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 360 OF 367 USPATFULL on STN
AN 96:108822 USPATFULL
TI Methods and systems for screening potential alzheimer's disease
therapeutics
IN Nishimoto, Ikuo, Brookline, MA, United States
PA The General Hospital Corporation, Boston, MA, United States (U.S.
corporation)
PI US 5578451 19961126
AI US 1995-371930 19950112 (8)
RLI Continuation of Ser. No. US 1993-19208, filed on 18 Feb 1993, now
abandoned
DT Utility
FS Granted
LN.CNT 1339
INCL INCLM: 435/007.100
INCLS: 435/007.200; 435/007.210; 435/975.000
NCL NCLM: 435/007.100
NCLS: 435/007.200; 435/007.210; 435/975.000
IC [6]
ICM: G01N033-53
ICS: G01N033-567
EXF 435/6; 435/7.2; 435/7.21; 435/7.1; 436/518; 436/536
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 361 OF 367 USPATFULL on STN
AN 96:101466 USPATFULL
TI Directed evolution of novel binding proteins
IN Ladner, Robert C., Ijamsville, MD, United States
Guterman, Sonia K., Belmont, MA, United States
Roberts, Bruce L., Milford, MA, United States
Markland, William, Milford, MA, United States
Ley, Arthur C., Newton, MA, United States
Kent, Rachel B., Boxborough, MA, United States
PA Protein Engineering Corporation, Cambridge, MA, United States (U.S.
corporation)
PI US 5571698 19961105
AI US 1993-57667 19930618 (8)
RLI Continuation of Ser. No. US 1991-664989, filed on 1 Mar 1991, now
patented, Pat. No. US 5223409 which is a continuation-in-part of Ser.
No. US 1990-487063, filed on 2 Mar 1990, now abandoned which is a
continuation-in-part of Ser. No. US 1988-240160, filed on 2 Sep 1988,
now abandoned
DT Utility
FS Granted
LN.CNT 15323
INCL INCLM: 435/069.700
INCLS: 435/006.000; 435/064.100; 435/172.300; 435/252.300; 435/320.100
NCL NCLM: 435/069.700
NCLS: 435/006.000; 435/069.100; 435/252.300; 435/320.100; 435/477.000
IC [6]
ICM: C12N025-62
EXF 435/6; 435/64.1; 435/64.7; 435/172.3; 435/252.3; 435/320.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 96:77867 USPATFULL
 TI Gelatinase A inhibitor, and analytical reagent thereof for the
 determination of gelatinase A
 IN Miyazaki, Kaoru, Kanagawa-ken, Japan
 PA Oriental Yeast Co., Ltd., Tokyo, Japan (non-U.S. corporation)
 PI US 5550216 19960827
 AI US 1994-231940 19940425 (8)
 PRAI JP 1993-120457 19930426
 JP 1994-62129 19940308
 DT Utility
 FS Granted
 LN.CNT 367
 INCL INCLM: 530/395.000
 INCLS: 530/324.000; 530/354.000; 530/355.000; 530/828.000; 436/064.000;
 436/086.000; 436/087.000
 NCL NCLM: 530/395.000
 NCLS: 436/064.000; 436/086.000; 436/087.000; 530/324.000; 530/354.000;
 530/355.000; 530/828.000
 IC [6]
 ICM: C07K017-00
 ICS: A61K038-00; G01N033-00
 EXF 530/395; 530/324; 530/354; 530/355; 530/828; 514/12; 514/21; 435/39;
 436/64; 436/86; 436/87
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 363 OF 367 USPATFULL on STN
 AN 93:52487 USPATFULL
 TI Directed evolution of novel binding proteins
 IN Ladner, Robert C., Ijamsville, MD, United States
 Guterman, Sonia K., Belmont, MA, United States
 Roberts, Bruce L., Milford, MA, United States
 Markland, William, Milford, MA, United States
 Ley, Arthur C., Newton, MA, United States
 Kent, Rachel B., Boxborough, MA, United States
 PA Protein Engineering Corp., Cambridge, MA, United States (U.S.
 corporation)
 PI US 5223409 19930629
 AI US 1991-664989 19910301 (7)
 RLI Continuation-in-part of Ser. No. US 1990-487063, filed on 2 Mar 1990,
 now abandoned And a continuation-in-part of Ser. No. US 1988-240160,
 filed on 2 Sep 1988, now abandoned
 DT Utility
 FS Granted
 LN.CNT 15410
 INCL INCLM: 435/069.700
 INCLS: 435/069.100; 435/172.300; 435/252.300; 435/320.100; 530/380.300;
 530/387.500
 NCL NCLM: 435/069.700
 NCLS: 435/005.000; 435/069.100; 435/252.300; 435/320.100; 435/472.000;
 530/387.300; 530/387.500
 IC [5]
 ICM: C12N015-09
 ICS: C12N015-62; C12N015-63
 EXF 435/69.1; 435/172.3; 435/252.3; 435/320.1; 530/350
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 364 OF 367 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN
 AN 2003-804023 [75] WPIDS
 CR 2003-876973 [81]
 DNC C2003-221996
 TI Controlling self-assembly of peptide-based structures (e.g. nanotubes)
 comprises providing a controlled environment and placing segments of
 beta - ***amyloids*** in the controlled environment to generate
 a self-assembling structure.
 DC A89 B04 D16
 IN LI, X; LYNN, D; CONTICELLO, V; DONG, J; MORGAN, D A
 PA (LIXX-I) LI X; (LYNN-I) LYNN D; (UYEM-N) UNIV EMORY
 CYC 103
 PI WO 2003082900 A2 20031009 (200375)* EN 46 C07K000-00
 RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS
 LU MC MW NZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW
 W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK
 DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR
 KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL
 PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA

US 2003215853 A1 20031120 (200377) C12Q001-68
 AU 2003226007 A1 20031013 (200435) C07K000-00
 ADT WO 2003082900 A2 WO 2003-US9229 20030324; US 2003215853 A1 Provisional US
 2002-366870P 20020322, Provisional US 2002-420533P 20021023, Provisional
 US 2003-456641P 20030321, US 2003-396001 20030324; AU 2003226007 A1 AU
 2003-226007 20030324
 FDT AU 2003226007 A1 Based on WO 2003082900
 PRAI US 2003-456641P 20030321; US 2002-366826P 20020322;
 US 2002-420746P 20021023; US 2002-366870P 20020322;
 US 2002-420533P 20021023; US 2003-396001 20030324
 IC ICM C07K000-00; C12Q001-68
 ICS C07H021-04; C08G063-48

 L5 ANSWER 365 OF 367 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN
 AN 2003-712557 [67] WPIDS
 DNC C2003-195932
 TI New helical peptidomimetic compounds, useful for preparing medicaments for
 treating subject having or at risk of having a ***Beta*** -
 amyloid -associated disease, e.g. Alzheimer's disease or Down's
 syndrome.
 DC B04
 IN WOLFE, M S
 PA (BGHM) BRIGHAM & WOMENS HOSPITAL INC
 CYC 29
 PI WO 2003068168 A2 20030821 (200367)* EN 44 A61K000-00
 RW: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE
 SI SK TR
 W: AU CA JP
 US 2003186877 A1 20031002 (200372) A61K038-16
 AU 2003217543 A1 20030904 (200428) A61K000-00
 ADT WO 2003068168 A2 WO 2003-US4683 20030214; US 2003186877 A1 Provisional US
 2002-357023P 20020214, US 2003-367599 20030214; AU 2003217543 A1 AU
 2003-217543 20030214
 FDT AU 2003217543 A1 Based on WO 2003068168
 PRAI US 2002-357023P 20020214; US 2003-367599 20030214
 IC ICM A61K000-00; A61K038-16
 ICS A61K038-04; A61K038-06; A61K038-08; A61K038-10; C07K005-04;
 C07K005-06; C07K007-06; C07K007-08

 L5 ANSWER 366 OF 367 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN
 AN 2003-342445 [32] WPIDS
 DNC C2003-089818
 TI Chemical compound for use in diagnosing or treating Alzheimer's disease,
 comprises multiple copies of a plaque-recognition peptide and is capable
 of crossing blood brain-barrier.
 DC B04 D16 K08
 IN STEIN, S
 PA (STEI-I) STEIN S
 CYC 101
 PI WO 2003018609 A2 20030306 (200332)* EN 37 C07K000-00
 RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR IE IT KE LS LU
 MC MW MZ NL OA PT SD SE SK SL SZ TR TZ UG ZM ZW
 W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK
 DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR
 KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT
 RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA
 ZM ZW
 AU 2002327514 A1 20030310 (200452) C07K000-00
 ADT WO 2003018609 A2 WO 2002-US26889 20020823; AU 2002327514 A1 AU 2002-327514
 20020823
 FDT AU 2002327514 A1 Based on WO 2003018609
 PRAI US 2001-314382P 20010823
 IC ICM C07K000-00

 L5 ANSWER 367 OF 367 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN
 AN 1991-295576 [40] WPIDS
 DNC C1991-127779
 TI New chymotrypsin-like serine protease(s) - and their inhibitors are used
 to treat Alzheimer's disease.
 DC B04 D16
 IN KAUER, J C; NELSON, R B N; POTTER, H; SIMAN, R; NELSON, R B; KAUER, J
 PA (CEPH-N) CEPHALON INC
 CYC 35
 PI WO 9113904 A 19910919 (199140)*
 RW: AT BE CH DE DK ES FR GB GR IT LU NL OA SE

AU 9174654	A	19911010	(199201)		
ZA 9101607	A	19911224	(199205)		
FI 9203983	A	19920904	(199249)		C12N000-00
EP 518955	A1	19921223	(199252)	EN 86	C07K003-00
R: AT BE CH DE DK ES FR GB GR IT LI LU NL SE					
NO 9203469	A	19921104	(199306)		C12N009-00
HU 62312	T	19930428	(199322)		C07K003-00
JP 05506777	W	19931007	(199345)		C12N009-64
EP 518955	A4	19930922	(199527)		
AU 661270	B	19950720	(199537)		C12N009-64
EP 732399	A2	19960918	(199642)	EN 54	C12N009-64
R: AT BE CH DE DK ES FR GB GR IT LI LU NL SE					
EP 732399	A3	19970312	(199722)		
ADT	ZA 9101607 A ZA 1991-1607 19910705; FI 9203983 A WO 1991-US1474 19910304,				
	FI 1992-3983 19920904; EP 518955 A1 EP 1991-905743 19910304, WO				
	1991-US1474 19910304; NO 9203469 A WO 1991-US1474 19910304, NO 1992-3469				
	19920904; HU 62312 T WO 1991-US1474 19910304, HU 1992-2842 19910304; JP				
	05506777 W JP 1991-506146 19910304, WO 1991-US1474 19910304; EP 518955 A4				
	EP 1991-905743 ; AU 661270 B AU 1991-74654 19910304; EP 732399 A2				
	Div ex EP 1991-905743 19910304, EP 1996-103933 19910304; EP 732399 A3 Div				
	ex EP 1991-905743 19910304, EP 1996-103933 19910304				
FDT	EP 518955 A1 Based on WO 9113904; HU 62312 T Based on WO 9113904; JP				
	05506777 W Based on WO 9113904; AU 661270 B Previous Publ. AU 9174654,				
	Based on WO 9113904				
PRAI	US 1990-489290 19900305				
IC	ICM C07K003-00; C12N000-00; C12N009-00; C12N009-64				
	ICS A23J001-00; A61K037-64; A61K038-04; C07K005-00; C07K005-06;				
	C07K005-08; C07K005-10; C07K007-00; C07K007-06; C07K017-00;				
	C07K017-02; C12Q001-37; G01N033-564				
STN	INTERNATIONAL LOGOFF AT 12:25:25 ON 30 AUG 2004				